WO2001055085A1 - Propionic acid derivatives and their use in the treatment of diabetes and obesity - Google Patents

Propionic acid derivatives and their use in the treatment of diabetes and obesity Download PDF

Info

Publication number
WO2001055085A1
WO2001055085A1 PCT/DK2001/000058 DK0100058W WO0155085A1 WO 2001055085 A1 WO2001055085 A1 WO 2001055085A1 DK 0100058 W DK0100058 W DK 0100058W WO 0155085 A1 WO0155085 A1 WO 0155085A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
ethoxy
propionic acid
enyloxy
biphenyl
Prior art date
Application number
PCT/DK2001/000058
Other languages
French (fr)
Inventor
John Patrick Mogensen
Per Sauerberg
Paul Stanley Bury
Lone Jeppesen
Ingrid Pettersson
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL15026001A priority Critical patent/IL150260A0/en
Priority to PL01357010A priority patent/PL357010A1/en
Priority to BR0107901-8A priority patent/BR0107901A/en
Priority to HU0204574A priority patent/HUP0204574A3/en
Priority to MXPA02007286A priority patent/MXPA02007286A/en
Priority to AU28319/01A priority patent/AU2831901A/en
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to EP01946844A priority patent/EP1254101A1/en
Priority to KR1020027009463A priority patent/KR20020070508A/en
Priority to CA002395298A priority patent/CA2395298A1/en
Priority to JP2001555028A priority patent/JP2003520838A/en
Publication of WO2001055085A1 publication Critical patent/WO2001055085A1/en
Priority to NO20023566A priority patent/NO20023566L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Definitions

  • the present invention relates to novel compounds, pharmaceutical compositions containing them, methods for preparing the compounds and their use as medicaments. More specifically, compounds of the invention can be utilised in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Re- ceptors (PPAR).
  • PPAR Peroxisome Proliferator-Activated Re- ceptors
  • Coronary artery disease is the major cause of death in Type 2 diabetic and metabolic syndrome patients (i.e. patients that fall within the 'deadly quartet' category of impaired glucose tolerance, insulin resistance, hypertriglycehdaemia and/or obesity).
  • hypolipidaemic fibrates and antidiabetic thiazolidinediones separately display moderately effective triglyceride-lowering activities although they are neither potent nor efficacious enough to be a single therapy of choice for the dyslipidaemia often observed in Type 2 diabetic or metabolic syndrome patients.
  • the thiazolidinediones also potently lower circulating glucose levels of Type 2 diabetic animal models and humans.
  • the fibrate class of compounds are without beneficial effects on glycaemia.
  • thiazolidinediones and fibrates exert their action by activating distinct transcription factors of the peroxisome proliferator activated receptor (PPAR) family, resulting in increased and decreased expression of specific enzymes and apolipoproteins respectively, both key-players in regulation of plasma triglyceride content.
  • Fibrates on the one hand, are PPAR ⁇ activators, acting primarily in the liver.
  • Thiazolidinediones on the other hand, are high affinity ligands for PPAR ⁇ acting primarily on adipose tissue.
  • Adipose tissue plays a central role in lipid homeostasis and the maintenance of energy balance in vertebrates.
  • Adipocytes store energy in the form of triglycerides during periods of nutritional affluence and release it in the form of free fatty acids at times of nutritional deprivation.
  • white adipose tissue is the result of a continuous differentiation process throughout life.
  • Much evidence points to the central role of PPAR ⁇ activation in initiating and regulating this cell differentiation.
  • Several highly specialised proteins are induced during adipocyte differentiation, most of them being involved in lipid storage and metabolism. The exact link from activation of PPAR ⁇ to changes in glucose metabolism, most notably a decrease in insulin resistance in muscle, has not yet been clarified.
  • a possible link is via free fatty acids such that activation of PPAR ⁇ induces Lipoprotein Lipase (LPL), Fatty Acid Transport Protein (FATP) and Acyl-CoA Synthetase (ACS) in adipose tissue but not in muscle tissue.
  • LPL Lipoprotein Lipase
  • FATP Fatty Acid Transport Protein
  • ACS Acyl-CoA Synthetase
  • PPAR ⁇ is involved in stimulating ⁇ -oxidation of fatty acids.
  • a PPAR ⁇ -mediated change in the expression of genes involved in fatty acid metabolism lies at the basis of the phenomenon of peroxisome proliferation, a pleiotropic cellular response, mainly limited to liver and kidney and which can lead to hepatocarcinogenesis in rodents.
  • the phenomenon of peroxisome proliferation is not seen in man.
  • PPAR ⁇ is also involved in the control of HDL cholesterol levels in rodents and humans.
  • Glucose lowering as a single approach does not overcome the macrovascular complications associated with Type 2 diabetes and metabolic syndrome.
  • Novel treatments of Type 2 diabetes and metabolic syndrome must therefore aim at lowering both the overt hypertriglyceri- daemia associated with these syndromes as well as alleviation of hyperglycaemia.
  • A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from hydroxy, halogen, perhalomethyl, perhalomethoxy, acyl, cyano, amino, C 1-6 -alkylamino, C 1-6 -dialkylamino, methylenedioxy, aralkenyl, aralkynyl, heteroary- loxy, heteroaralkoxy, aralkyl, heteroaralkyl, arylamino, or A is optionally substituted with C 1-6 -alkyl, C 2-6 -alkenyl or C 2-6 -alkynyl each of which is optionally substituted with one or more substituents selected from C 1-6 -alkoxycarbonyl or carboxy, or
  • A is optionally substituted with C 1-6 -alkoxy, C 1-6 -alkylthio or C 2-6 -alkenyloxy each of which is optionally substituted with one or more halogens, or A is optionally substituted with aryloxy, arylthio or aralkoxy each of which is optionally substituted with one or more substituents selected from C 1-6 -alkoxy, nitro, carboxy or C 1-6 - alkoxycarbonyl; and X-i and X 2 independently are hydrogen, aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C 1-6 -alkoxy, C 1-6 - alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino
  • A is selected from the ring systems consisting of
  • FIG. 1 wherein the attachment point of A to the remaining part of the structure of formula (I) is as indicated on the chemical structures in Figure 1 , and wherein A is optionally substituted with one or more substituents selected from C 1-6 -aIkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C 1-6 -alkoxy, C 1-6 -alkyIthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C 1-6 -alkylamino, C 1-6 - dialkylamino, arylamino or methylenedioxy; and wherein X ⁇ and X 2 are hydrogen; and
  • R 5 is hydrogen or C 1-6 -aIkyl
  • Y is hydrogen, or Y is C 1-12 -alkyl, C 2- i 2 -alkenyl, C 2- ⁇ 2 -alkynyl, C 4-12 -alkenynyl, aralkyl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, C 1-6 - alkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
  • Z is hydrogen, halogen, hydroxy, or Z is C 1-6 -alkyl or C -6 -alkoxy each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C 1-6 -alkoxy; and Q is O, S or NR 6 , wherein R 6 is hydrogen, C 1-6 -alkyI, C 2-6 -alkenyl, C 2- 6-alkynyl, C 4-6 -alkenynyl, aralkyl, heteroaralkyl and wherein R 6 is optionally substituted with one or more substituents selected from halogen, hydroxy, C 1-6 -alkoxy, amino or carboxy; and
  • Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C 1-6 -alkyl, aryl or C 1-6 -alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
  • Ri is hydrogen, hydroxy or halogen; or R ⁇ forms a bond together with R 2 ;
  • R is hydrogen or C 1-6 -alkyl; or R 2 forms a bond together with R-i;
  • R 3 is hydrogen, or
  • R 3 is C 1-6 -alkyl, C 2- 6-alkenyl, C 2-6 -alkynyl, C ⁇ e-alkenynyl, aryl, aralkyl, C 1-6 -alkoxyC 1-6 alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
  • R 4 is hydrogen, C -6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C -6 -alkenynyl or aryl;
  • n is an integer ranging from 0 to 3;
  • n is an integer ranging from 0 to 1 ;
  • A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from hydroxy, halogen, perhalomethyl, perhalomethoxy, acyl, cyano, amino, C 1-6 -alkylamino, C 1-6 -dialkylamino, methylenedioxy, aralkenyl, aralkynyl, heteroary- loxy, heteroaralkoxy, aralkyl, heteroaralkyl, arylamino, or
  • A is optionally substituted with C 1-6 -alkyl, C 2-6 -alkenyl or C 2-6 -alkynyl each of which is optionally substituted with one or more substituents selected from C 1-6 -alkoxycarbonyl or carboxy, or A is optionally substituted with C 1-6 -alkoxy, C 1-6 -alkylthio or C 2-6 -alkenyloxy each of which is optionally substituted with one or more halogens, or
  • A is optionally substituted with aryloxy, arylthio or aralkoxy each of which is optionally substituted with one or more substituents selected from C 1-6 -alkoxy, nitro, carboxy or C 1-6 - alkoxycarbonyl; and Xi and X 2 independently are hydrogen, aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C 1-6 -alkoxy, C 1-6 - alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaral- kyl, cyano, amino, C 1-6 -alkylamino, C ⁇ -6 -dialkylamino, arylamino or methylenedioxy, or aryl or heteroaryl each of which is optionally substituted with one
  • attachment point of A to the remaining part of the structure of formula (I) is as indicated on the chemical structures in Figure 1 , and wherein A is optionally substituted with one or more substituents selected from C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C 1-6 -alkoxy, C 1-6 -alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C 1-6 -alky!amino, C 1-6 - dialkylamino, arylamino or methylenedioxy; and wherein Xi and X 2 are hydrogen; and
  • R 5 is hydrogen or C 1-6 -aIkyl
  • Y is hydrogen, or
  • Y is d- 12 -alkyl, C 2- ⁇ 2 -alkenyl, C 2 - ⁇ 2 -alkynyl, C 4-12 -alkenynyl, aralkyl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, C h alky!, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and Z is hydrogen, halogen, hydroxy, or
  • Z is C 1-6 -alkyI or C 1-6 -alkoxy each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C 1-6 -alkoxy;
  • Q is O, S or NR 6 , wherein R 6 is hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 4-6 -alkenynyl, aralkyl, heteroaralkyl and wherein R 6 is optionally substituted with one or more substituents selected from halogen, hydroxy, C 1-6 -alkoxy, amino or carboxy; and
  • Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C 1-6 -alkyl, aryl or C 1-6 -alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
  • Ri is hydrogen, hydroxy or halogen; or R 1 forms a bond together with R ;
  • R 2 is hydrogen or C 1-6 -alkyl; or R 2 forms a bond together with R ⁇ and
  • R 3 is hydrogen, or
  • R 3 is C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C ⁇ e-alkenynyl, aryl, aralkyl, C 1-6 -alkoxyC 1-6 alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
  • R 4 is hydrogen, C 1-6 -alkyl, C 2 - 6 -alkenyl, C 2-6 -alkynyl, C ⁇ e-alkenynyl or aryl;
  • n is an integer ranging from 1 to 3;
  • m 1 ;
  • A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C 1-6 -alkoxy, C 1-6 -alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C 1-6 -alkylamino, C ⁇ - dialkylamino, arylamino or methylenedioxy, and
  • X-i and X independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from C ⁇ -6 -alkyl, C 2- 6-alkenyl, C 2-6 -aIkyny(, hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C 1-6 -alkoxy, C 1-6 -alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino, C 1-6 -alkylamino, d-e-dialkylamino, arylamino or methylenedioxy; or
  • A is selected from the ring systems consisting of
  • attachment point of A to the remaining part of the structure of formula (I) is as indicated on the chemical structures in Figure 1 , and wherein A is optionally substituted with one or more substituents selected from C 1-6 -alkyl, C 2 . 6-alkenyl, C 2-6 -alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C -6 -alkoxy, C ⁇ -6 -alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C 1-6 -alkylamino, C 1-6 -dialkylamino, arylamino or methylenedioxy, and wherein X.
  • R 5 is hydrogen or C 1-6 -alkyl
  • Y is hydrogen, C 1-12 -alkyl, C 2- ⁇ 2 -alkenyl, C 2-12 -alkynyl, C ⁇ -alkenynyl, aralkyl or heteroaralkyl optionally substituted with one or more substituents selected from halogen, C 1-6 -aIkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
  • Z is hydrogen, halogen, hydroxy, C 1-6 -alkyl or C 1-6 -alkoxy optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C 1-6 -alkoxy; and Q is O, S or NR 6 , wherein R 6 is hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2- 6-alkynyl, C 4-6 -alkenynyl, aralkyl, heteroaralkyl and wherein R 6 is optionally substituted with one or more substituents selected from halogen, hydroxy, C ⁇ -6 -alkoxy, amino or carboxy; and
  • Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C-i-e-alkyl, aryl or C 1-6 -alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
  • Ri is hydrogen, hydroxy or halogen; or R forms a bond together with R 2 ;
  • R 2 is hydrogen or C 1-6 -alkyl; or R 2 forms a bond together with R ⁇ and
  • R 3 is hydrogen, C 1-6 -alkyI, C 2-6 -alkenyl, C 2-6 -alkynyl, C 4-6 -alkenynyl, aryl, aralkyl, C 1-6 - alkoxyC 1-6 alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
  • R 4 is hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 4-6 -alkenynyl or aryl;
  • n is an integer ranging from 0 to 3;
  • n is an integer ranging from 0 to 1.
  • the present invention is concerned with compounds of formula (I)
  • A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from C 1-6 -alkyl, C 2 .6-alkenyl, C 2-6 -alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C 1-6 -alkoxy, C 1-6 -alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C 1-6 -alkylamino, C 1-6 - dialkylamino, arylamino or methylenedioxy; or
  • Xi and X 2 is hydrogen
  • A is selected from the ring systems consisting of
  • A is optionally substituted with one or more substituents selected from C 1-6 -alkyl, C 2- 6-alkenyl, C 2 . 6 -alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C 1-6 -alkoxy, C 1-6 -alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C ⁇ -6 -alkylamino, C 1-6 -dialkylamino, arylamino or methylenedioxy; and
  • R 5 is hydrogen or C 1-6 -alkyl
  • Xi and X 2 independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C 1-6 -alkoxy, d- ⁇ -alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino, d ⁇ -alkylamino, C 1-6 -dialkylamino, arylamino or methylenedioxy; and
  • Y is hydrogen, d_ ⁇ 2 -alkyl, C 2-12 -alkenyl, C 2-12 -alkynyl, C ⁇ -alkenynyl, aralkyl or heteroaralkyl optionally substituted with one or more substituents selected from halogen, C 1-6 -alkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
  • Z is hydrogen, halogen, hydroxy, C 1-6 -alkyl or d -6 -alkoxy optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C 1-6 -alkoxy; and Q is O, S or NR 6 , wherein R 6 is hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 4 . 6 -alkenynyl, aralkyl, heteroaralkyl and wherein R 6 is optionally substituted with one or more substituents selected from halogen, hydroxy, C 1-6 -alkoxy, amino or carboxy; and
  • Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C 1-6 -alkyl, aryl or C 1-6 -alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
  • Ri is hydrogen, hydroxy or halogen; or R forms a bond together with R 2 ;
  • R is hydrogen or C 1-6 -alkyl; or R 2 forms a bond together with R ⁇ and
  • R 3 is hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 4-6 -alkenynyl, aryl, aralkyl, C 1-6 - alkoxyC 1-6 alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
  • n is an integer ranging from 0 to 3;
  • n is an integer ranging from 0 to 1.
  • the present invention is concerned with compounds of formula I wherein A is aryl or heteroaryl optionally substituted with one or more substituents selected from from C 1-6 -alkyI, C 2-6 -alkenyI each of which is optionally substituted with one or more substituents selected from C 1-6 -alkoxycarbonyl or carboxy, or A is optionally substituted with aryloxy optionally substituted with one or more C 1-6 -alkoxy, or A is optionally substituted with aralkoxy optionally substituted with one or more substituents selected from C 1-6 -alkoxy, nitro, carboxy or C 1-6 -aIkoxycarbonyl, or A is optionally substituted with C 1-6 -alkoxy optionally substituted with one or more halogens, or
  • A is optionally substituted with aralkenyl, C 2-6 -alkenyloxy, aralkynyl, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl or methylenedioxy.
  • the present invention is concerned with compounds of formula I wherein A is aryl, heteroaryl or
  • aryloxy optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, d-e-alkoxy, C 1-6 -aIkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
  • the present invention is concerned with compounds of formula I wherein A is aryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, C 1-6 -alkoxy, d- ⁇ -alkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
  • the present invention is concerned with compounds of formula I wherein A is aryl optionally substituted with one or more substituents selected from from C 1-6 -alkyl, C 2-6 -alkenyl each of which is optionally substituted with one or more substituents selected from C 1-6 -alkoxycarbonyl or carboxy, or A is optionally substituted with aryloxy optionally substituted with one or more C 1-6 -alkoxy, or A is optionally substituted with aralkoxy optionally substituted with one or more substituents selected from C 1-6 -alkoxy, nitro, carboxy or C 1-6 -alkoxycarbonyl, or A is optionally substituted with C 1-6 -alkoxy optionally substituted with one or more halogens, or A is optionally substituted with aralkenyl, C 2-6 -alkenyloxy, aralkynyl, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl
  • the present invention is concerned with compounds of formula I wherein A is aryl optionally substituted with one or more substituents selected from from C 1-6 -alkyl, or
  • A is optionally substituted with aryloxy optionally substituted with one or more C 1-6 -aIkoxy, A is optionally substituted with aralkoxy optionally substituted with one or more substituents selected from C 1-6 -alkoxy, or
  • A is optionally substituted with C 1-6 -alkoxy optionally substituted with one or more halogens, or
  • A is optionally substituted with aralkenyl, aralkynyl, halogen, perhalomethyl, perhalomethoxy or aralkyl.
  • the present invention is concerned with compounds of formula I wherein A is heteroaryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, C 1-6 -alkoxy, C 1-6 -alkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
  • the present invention is concerned with compounds of formula I wherein A is heteroaryl.
  • the present invention is concerned with compounds of formula I wherein A is
  • the present invention is concerned with compounds of formula I wherein A is
  • the present invention is concerned with compounds of formula I wherein X ⁇ and X 2 independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, halogen, perha- lomethyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
  • the present invention is concerned with compounds of formula I wherein Xi and X 2 independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from halogen, acyl, aryl, or aryl or heteroaryl optionally substituted with one or more substituents selected from C h alky!, C 2-6 -alkynyl each of which is optionally substituted with hydroxy.
  • the present invention is concerned with compounds of formula I wherein X 1 and X 2 independently are hydrogen, or aryl or heteroaryl optionally substituted with one or more substituents selected from halogen.
  • the present invention is concerned with compounds of formula I wherein X ⁇ and X 2 independently are hydrogen or aryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, halogen, perhalomethyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
  • the present invention is concerned with compounds of formula I wherein X ⁇ and X 2 independently are hydrogen, aryl optionally substituted with one or more substituents selected from halogen, acyl, aryl, or aryl optionally substituted with one or more substituents selected from C 1-6 -alkyl, C 2-6 -alkynyl each of which is optionally substituted with hydroxy.
  • the present invention is concerned with compounds of formula I wherein X and X 2 independently are hydrogen, or phenyl optionally substituted with one or more substituents selected from halogen.
  • the present invention is concerned with compounds of formula I wherein X ! and X 2 independently are hydrogen or heteroaryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, halogen, perhalomethyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
  • the present invention is concerned with compounds of formula I wherein Xi and X 2 independently are hydrogen or heteroaryl.
  • the present invention is concerned with compounds of formula I wherein X ⁇ and X 2 is hydrogen.
  • the present invention is concerned with compounds of for- mula I wherein Y is hydrogen or C 1-12 -alkyl.
  • the present invention is concerned with compounds of formula I wherein Y is hydrogen or methyl.
  • the present invention is concerned with compounds of formula I wherein Z is hydrogen or C 1-6 -aIkoxy.
  • the present invention is concerned with compounds of formula I wherein Z is hydrogen or C 1-6 -alkyl.
  • the present invention is concerned with compounds of formula I wherein Z is hydrogen.
  • the present invention is concerned with compounds of for- mula I wherein Q is O.
  • the present invention is concerned with compounds of formula I wherein Ar is arylene optionally substituted with one or more substituents selected from d-e-alkyl or C 1-6 -alkoxy each of which can be optionally substituted with carboxy.
  • the present invention is concerned with compounds of formula I wherein Ar is arylene.
  • the present invention is concerned with compounds of formula I wherein Ri is hydrogen or Ri forms a bond together with R 2 .
  • the present invention is concerned with compounds of formula I wherein Ri is hydrogen.
  • the present invention is concerned with compounds of formula I wherein R 2 is hydrogen or R 2 forms a bond together with R-i.
  • the present invention is concerned with compounds of for- mula I wherein R 2 is hydrogen.
  • the present invention is concerned with compounds of formula I wherein R 3 is C 1-6 -alkyl or aralkyl.
  • the present invention is concerned with compounds of formula I wherein R 3 is C -6 -alkyl.
  • the present invention is concerned with compounds of formula I wherein R is hydrogen, C 1-3 -alkyl.
  • the present invention is concerned with compounds of formula I wherein R* is hydrogen.
  • the present invention is concerned with compounds of for- mula I wherein n is 1.
  • the present invention is concerned with compounds of formula I wherein m is 1.
  • the present invention is concerned with compounds of formula I wherein alkyl is methyl, ethyl, n-propyl, iso-propyl, butyl, tert-butyl, pentyl, hexyl, cyclopropyl or cyclopentyl.
  • the present invention is concerned with compounds of formula I wherein alkenyl is vinyl or 1-propenyl.
  • the present invention is concerned with compounds of formula I wherein alkynyl is ethynyl, 1-propynyl and 2-propynyI.
  • the present invention is concerned with compounds of formula I wherein alkoxy is methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, isopropoxy or cyclopentyloxy.
  • the present invention is concerned with compounds of formula I wherein alkylthio is methylthio, ethylthio, propylthio or cyclopentylthio.
  • the present invention is concerned with compounds of formula I wherein aryl is phenyl optionally substituted with halogen.
  • the present invention is concerned with compounds of formula I wherein arylene is phenylene optionally substituted with halogen.
  • the present invention is concerned with compounds of formula I wherein halogen is fluorine or chlorine.
  • the present invention is concerned with compounds of formula I wherein perhalomethyl is trifluoromethyl.
  • the present invention is concerned with compounds of formula I wherein acyl is acetyl.
  • the present invention is concerned with compounds of formula I wherein heteroaryl is furan, thiophene, pyrrole, imidazole, pyrazole, pyridine, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole or benzofuran.
  • the present invention is concerned with compounds of formula I wherein heteroaryl is furan, pyrrole, indole or benzofuran.
  • the present invention is concerned with compounds of formula I wherein heteroarylene is furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine or pyridazine.
  • the present invention is concerned with compounds of formula I wherein aralkyl is benzyl or phenethyl.
  • the present invention is concerned with compounds of formula I wherein aryloxy is phenoxy.
  • the present invention is concerned with compounds of formula I wherein aralkoxy is benzyloxy.
  • the present invention is concerned with compounds of formula I wherein n is an integer ranging from 1 to 3 and m is 1.
  • the present invention is concerned with compounds of formula I wherein the substituents Z and Y are arranged in a trans-configuration.
  • the present invention is concerned with compounds of formula I wherein the substituents Z and Y are arranged in a cis-configuration.
  • Preferred compounds of the invention are:
  • any optical isomer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
  • any optical isomer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
  • any optical isomer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
  • C ⁇ -12 -alkyl as used herein, alone or in combination is intended to include those alkyl groups of the designated length in either a linear or branched or cyclic configuration represents e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl and the like.
  • Typical C 1-12 -alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, hexyl, iso-hexyl, cyclopropyl, cyclob- utyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl and the like, especially preferred is methyl, ethyl, n-propyl, iso-propyl, butyl, tert-butyl, pentyl, hexyl, cyclopropyl and cyclopentyl.
  • C 2-12 -alkenyl represents an olefinically unsaturated branched or straight group having from 2 to the specified number of carbon atoms and at least one double bond.
  • groups include, but are not limited to, vinyl, 1-propenyI, 2- propenyl, allyl, iso-propenyl, 1,3-butadienyl, 1-butenyl, hexenyl, pentenyl and the like, especially preferred is vinyl and 1-propenyI.
  • C 2-12 -alkynyl represent an unsaturated branched or straight group having from 2 to the specified number of carbon atoms and at least one triple bond.
  • groups include, but are not limited to ethynyl, 1-propynyl, 2-propynyl, 1- butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl and the like, especially preferred is ethynyl, 1- propynyl and 2-propynyl.
  • C 4-12 -alkenynyl represent an unsaturated branched or straight hydrocarbon group having from 4 to the specified number of carbon atoms and both at least one double bond and at least one triple bond. Examples of such groups include, but are not, limited to, 1-penten-4-yne, 3-penten-1-yne, 1 ,3-hexadiene-5-yne and the like.
  • C 1-6 -alkoxy as used herein, alone or in combination is intended to include those d_g- alkyl groups of the designated length in either a linear or branched or cyclic configuration linked thorugh an ether oxygen having its free valence bond from the ether oxygen.
  • linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy and the like, especially preferred is methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy.
  • Examples of branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy and the like, especially preferred is isopropoxy.
  • cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like, especially preferred is cyclopentyloxy.
  • C 1-6 -alkylthio refers to a straight or branched or cyclic monovalent substituent comprising a C 1-6 -alkyl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom and having 1 to 6 carbon atoms e.g. methylthio, ethylthio, propylthio, butylthio, pentylthio and the like, especially preferred is methylthio, ethylthio and propylthio.
  • Examples of cyclic alkylthio are cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio and the like, especially preferred is cyclopentylthio.
  • d-e-alkylamino refers to a straight or branched or cyclic monovalent substituent comprising a C 1-6 -alkyl group linked through amino having a free valence bond from the nitrogen atom e.g. methylamino, ethylamino, propylamino, butylamino, pentylamino and the like.
  • cyclic alkylamino are cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino and the like.
  • arylamino refers to an aryl as defined herein linked through amino having a free valence bond from the nitrogen atom e.g. phenylamino, naphthylamino and the like.
  • C 1-6 -alkoxyC ⁇ -6 -alkyl refers to a C 1-6 -alkyl as defined herein whereto is attached a C 1-6 -alkoxy as defined herein, e.g. methoxy methyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like.
  • aryl is intended to include a bicyclic aromatic ring, such as carbocyclic aromatic rings selected from the group consisting of phenyl and naphthyl, (1-naphthyl or 2-naphthyl), optionally substituted with halogen, amino, hydroxy, C 1-6 -alkyl, C 1-6 -alkoxy, carboxy or C 1-6 -alkylester and the like, especially preferred is halogen.
  • arylene is intended to include divalent aromatic rings, such as carbocyclic aromatic rings selected from the group consisting of phenylene, naphthylene and the like optionally substituted with halogen, amino, hydroxy, C ⁇ -alkyl, C 1-6 -alkoxy, carboxy or C 1-6 -alkylester and the like.
  • halogen means fluorine, chlorine, bromine or iodine, especially preferred is fluorine and chlorine.
  • perhalomethyl means trifluoromethyl, trichloromethyl, tribromomethyl or triiodomethyl, especially preferred is trifluoromethyl.
  • C 1-6 -dialkylamino refers to an amino group wherein the two hydrogen atoms independently are substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms; such as dimethylamino, N- ethyl-N-methylamino, diethylamino, dipropylamino, N-(n-butyl)-N-methylamino, di(n- pentyl)amino and the like.
  • acyl refers to a monovalent substituent comprising a C 1-6 -alkyl group linked through a carbonyl group; such as e.g. acetyl, propionyl, butyryl, isobutyryl, pivaloyl, valeryl and the like, especially preferred is acetyl.
  • heteroaryl refers to a monovalent substituent comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g.
  • heteroarylene refers to a divalent group comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g.
  • heteroaryloxy refers to a heteroaryl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom e.g. pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine linked to oxygen, and the like.
  • oxygen atom e.g. pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline
  • aralkyl refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic carbohydride; such as benzyl, phenethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-(1-naphthyl)ethyl and the like, especially preferred is benzyl and phenethyl.
  • aryloxy refers to phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like, especially preferred is phenoxy.
  • aralkoxy refers to a C 1-6 -aIkoxy group substituted with an aromatic carbohydride, such as benzyloxy, phenethoxy, 3-phenylpropoxy, 1-naphthylmethoxy, 2-(1- naphthyl)ethoxy and the like, especially preferred is benzyloxy.
  • heteroarylkyl refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with a heteroaryl group; such as (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl- 1-(2-pyrimidyl)ethyl and the like.
  • heteroaralkoxy refers to a heteroaralkyl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom, e.g. (2-furyl)methyl, (3- furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyI-1-(2- pyrimidyl)ethyl linked to oxygen, and the like.
  • arylthio refers to an aryl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom, the aryl group optionally being mono- or polysubstituted with C 1-6 -alkyl, halogen, hydroxy or C ⁇ -alkoxy; e.g. phenylthio, (4-methylphenyl)-thio, (2-chlorophenyl)thio and the like.
  • heterocyclyl means a monovalent saturated or unsaturated non aromatic group being monocyclic and containing one or more, such as from one to four carbon atom(s), and from one to four N, O or S atom(s) or a combination thereof.
  • heterocyclyl includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. pyrrolidine, pyrroline and the like); 5-membered heterocycles having two heteroatoms in 1,2 or 1,3 positions (e.g.
  • pyrazoline pyrazolidine, 1 ,2-oxathiolane, imidazolidine, imi- dazoline, 4-oxazolone and the like
  • 5-membered heterocycles having three heteroatoms e.g. tetrahydrofurazan and the like
  • 5-membered heterocycles having four heteroatoms 6- membered heterocycles with one heteroatom (e.g. piperidine and the like); 6-membered heterocycles with two heteroatoms (e.g. piperazine, morpholine and the like); 6-membered heterocycles with three heteroatoms; and 6-membered heterocycles with four heteroatoms, and the like.
  • a divalent heterocyclic group means a divalent saturated or unsaturated system being monocyclic and containing one or more, such as from one to four carbon atom(s), and one to four N, O or S atom(s) or a combination thereof.
  • the phrase a divalent heterocyclic group includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. pyrrolidine, pyrroline and the like); 5-membered heterocycles having two heteroatoms in 1 ,2 or 1,3 positions (e.g.
  • 5-membered heterocycles having three heteroatoms e.g. tetrahydrofurazan and the like
  • 5-membered heterocycles having four heteroatoms 6-membered heterocycles with one heteroatom (e.g. piperidine and the like); 6- membered heterocycles with two heteroatoms (e.g. piperazine
  • treatment includes treatment, prevention and management of such condition.
  • the present invention also encompasses pharmaceutically acceptable salts of the present compounds.
  • Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.
  • Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hy- drobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaphtho- ates, g
  • compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
  • Exam- pies of metal salts include lithium, sodium, potassium, magnesium salts and the like.
  • ammonium and alkylated ammonium salts include ammonium, methylammonium, di- methylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethyl- ammonium, butylammonium, tetramethylammonium salts and the like.
  • organic bases include lysine, arginine, guanidine, diethanolamine, choline and the like.
  • the pharmaceutically acceptable salts are prepared by reacting the compound of formula I with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of sol- vents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guandine and their derivatives etc. may also be used.
  • acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, DimmerDeD acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, pal- mitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.
  • acids such as hydrochloric acid, hydrobromic acid, nitric acid, DimmerDeD acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic
  • stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods.
  • Some of the preferred methods include use of microbial resolution, enzymatic resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lac- tic acid, and the like wherever applicable or chiral bases such as brucine, (R)- or (S)- phenylethylamine, cinchona alkaloids and their derivatives and the like.
  • the compound of formula I may be converted to a 1 :1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the dia-stereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula I may be prepared by hydro- lysing the pure diastereomeric amide.
  • polymorphs of compound of general formula I forming part of this invention may be prepared by crystallization of compound of formula I under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cool- ing during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
  • the invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances.
  • prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the formula (I).
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • the invention also encompasses active metabolites of the present compounds.
  • the present compounds of formula I can be utilised in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Prolifera- tor-Activated Receptors (PPAR).
  • PPAR Peroxisome Prolifera- tor-Activated Receptors
  • the present invention relates to a method of treating and/or preventing Type I or Type II diabetes.
  • the present invention relates to the use of one or more compounds of the general formula I or pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment and/or prevention of Type I or Type II diabetes.
  • the present compounds are useful for the treatment and/or prevention of IGT.
  • the present compounds are useful for the treatment and/or prevention of Type 2 diabetes.
  • the present compounds are useful for the delaying or prevention of the progression from IGT to Type 2 diabetes.
  • the present compounds are useful for the delaying or prevention of the progression from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes.
  • the present compounds reduce blood glucose and triglyceride levels and are accordingly useful for the treatment and/or prevention of ailments and disorders such as diabetes and/or obesity.
  • the present compounds are useful for the treatment and/or prophylaxis of insulin resistance (Type 2 diabetes), impaired glucose tolerance, dyslipidemia, disorders related to Syndrome X such as hypertension, obesity, insulin resistance, hyperglycaemia, atherosclerosis, hyperlipidemia, coronary artery disease, myocardial ischemia and other cardiovascular disorders.
  • Type 2 diabetes Type 2 diabetes
  • disorders related to Syndrome X such as hypertension, obesity, insulin resistance, hyperglycaemia, atherosclerosis, hyperlipidemia, coronary artery disease, myocardial ischemia and other cardiovascular disorders.
  • the present compounds are effective in decreasing apoptosis in mammalian cells such as beta cells of Islets of Langerhans.
  • the present compounds are useful for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis.
  • the present compounds may also be useful for improving cognitive functions in dementia, treating diabetic complications, psoriasis, polycystic ovarian syndrome (PCOS) and prevention and treatment of bone loss, e.g. osteoporosis.
  • PCOS polycystic ovarian syndrome
  • the invention also relates to pharmaceutical compositions comprising, as an active ingredi- ent, at least one compound of the formula I or any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or diluents.
  • the invention relates to the use of compounds of the general formula I or their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof for the preparation of a pharmaceutical composition for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR) such as the conditions mentioned above.
  • PPAR Peroxisome Proliferator-Activated Receptors
  • the present invention also relates to a process for the preparation of the above said novel compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates.
  • the method comprises: a)
  • L is a leaving group such as p-toluenesulfonate, methanesulfonate, halogen , triflate and the like and wherein A, X ⁇ X 2 , Y, Z and t are defined as above with a compound of formula V
  • A, X ⁇ and X 2 are defined as above, through a Friedel-Crafts acylation with in example CIOCCHZ(CH 2 ) n R7 (wherein n and Z is defined as above and R 7 are halogen or OH), in the presence of a Friedel-Crafts catalysts such as aluminium trichloride and the like, to give a compound of formula VIII
  • A, Xi, X 2 , Y, Z, Q, Ar, R ⁇ R 2 , R 3 , R 4 , n and m are defined as above, except that R is not H, to obtain a compound of formula I, wherein A, X 1? X 2 , Y, Z, Q, Ar, Ri, R 2 , Rs, R ⁇ n and m are defined as above, except that R 4 is H.
  • the PPAR gene transcription activation assays were based on transient transfection into human HEK293 cells of two plasmids encoding a chimeric test protein and a reporter protein respectively.
  • the chimeric test protein was a fusion of the DNA binding domain (DBD) from the yeast GAL4 transcription factor to the ligand binding domain (LBD) of the human PPAR proteins.
  • the GAL4 DBD will force the fusion protein to bind only to Gal4 enhancers (of which none existed in HEK293 cells).
  • the reporter plasmid contained a Gal4 enhancer driving the expression of the firefly luciferase protein.
  • HEK293 cells expressed the GAL4-DBD-PPAR-LBD fusion protein.
  • the fusion protein will in turn bind to the Gal4 enhancer controlling the luciferase expression, and do nothing in the absence of ligand.
  • luciferase protein Upon addition to the cells of a PPAR ligand, luciferase protein will be produced in amounts corresponding to the activation of the PPAR protein. The amount of luciferase protein is measured by light emission after addition of the appropriate substrate.
  • HEK293 cells were grown in DMEM + 10% FCS. Cells were seeded in 96-well plates the day before transfection to give a confluency of 50-80 % at transfection. A total of 0,8 ⁇ g DNA containing 0,64 ⁇ g pM1 ⁇ / ⁇ LBD, 0,1 ⁇ g pCMV ⁇ Gal, 0,08 ⁇ g pGL2Gal4DBD and 0,02 ⁇ g pADVANTAGE was transfected per well using FuGene transfection reagent according to the manufacturers instructions (Roche). Cells were allowed to express protein for 48 h followed by addition of compound.
  • Plasmids Human PPAR ⁇ and ⁇ was obtained by PCR amplification using cDNA synthesized by reverse transcription of mRNA from liver and adipose tissue respectively. Amplified cDNAs were cloned into pCR2.1 and sequenced. The ligand binding domain (LBD) of each PPAR isoform was generated by PCR (PPAR ⁇ : aa 167 - C-terminus; PPAR ⁇ : aa 165 - C- terminus) and fused to the DNA binding domain (DBD) of the yeast transcription factor GAL4 by subcloning fragments in frame into the vector pM1 generating the plasmids pMl ⁇ LBD and pMl ⁇ LBD.
  • LBD ligand binding domain
  • the reporter was constructed by inserting an oligonucleotide encoding five repeats of the GAL4 recognition sequence (5 x CGGAGTACTGTCCTCCG(AG)) into the vector pGL2 promotor (Promega) generating the plasmid pGL2(GAL4) 5 .
  • pCMV ⁇ Gal was purchased from Clontech and pADVANTAGE was purchased from Promega.
  • Luciferase assay Medium including test compound was aspirated and 100 ⁇ l PBS incl. 1mM Mg++ and Ca++ was added to each well. The luciferase assay was performed using the Lu- cLite kit according to the manufacturers instructions (Packard Instruments). Light emission was quantified by counting SPC mode on a Packard Instruments top-counter. To measure ⁇ - galactosidase activity 25 ⁇ l supernatant from each transfection lysate was transferred to a new microplate. ⁇ -galactosidase assays were performed in the microwell plates, using a kit from Promega and read in a microplate reader. The ⁇ -galactosidase data were used to nor- malize (transfection efficiency, cell growth etc.) the luciferase data.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
  • the present compounds may also be administered in combination with one or more further pharmacologically active substances eg., selected from antiobesity agents, antidiabetics, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents.
  • Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, uro- cortin agonists, ⁇ 3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing
  • the antiobesity agent is leptin.
  • the antiobesity agent is dexamphetamine or amphetamine.
  • the antiobesity agent is fenfluramine or dexfenfluramine.
  • the antiobesity agent is sibutramine.
  • the antiobesity agent is orlistat.
  • the antiobesity agent is mazindol or phentermine.
  • Suitable antidiabetics comprise insulin, GLP-1 (glucagons like peptide-1) derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents.
  • the orally active hypoglycaemic agents preferably comprise sulphonylureas, biguanides, meglitinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc., GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as HMG CoA inhibitors (statins), compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potas- sium channel of the ⁇ -cells.
  • the present compounds are administered in combination with insulin.
  • the present compounds are administered in combination with a sul- phonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide.
  • a sul- phonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide.
  • the present compounds are administered in combination with a bi- guanide eg. metformin.
  • the present compounds are administered in combination with a meglitinide eg. repaglinide or senaglinide.
  • the present compounds are administered in combination with an ⁇ -glucosidase inhibitor eg. miglitol or acarbose.
  • an ⁇ -glucosidase inhibitor eg. miglitol or acarbose.
  • the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the ⁇ -cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • an agent acting on the ATP-dependent potassium channel of the ⁇ -cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • the present compounds may be administered in combination with nateglinide.
  • the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
  • an antihyperlipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
  • the present compounds are administered in combination with more than one of the above-mentioned compounds eg. In combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
  • the present compounds may be administered in combination with one or more antihypertensive agents.
  • antihypertensive agents are ⁇ -blockers such as alpre- nolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, ni- modipine, diltiazem and verapamil, and ⁇ -blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19 th Edition, Gennaro, Ed.,
  • compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 19 th Ed., 1995.
  • the compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
  • compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
  • the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container for example in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl dtstearate, alone or mixed with a wax.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
  • the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring sub- stances and the like, which do not deleteriously react with the active compounds.
  • the route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, trarisdermal orparenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, in- tranasal,. ophthalmic solution or an ointment, the oral route being preferred.
  • oral nasal, pulmonary, trarisdermal orparenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, in- tranasal,. ophthalmic solution or an ointment, the oral route being preferred.
  • the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • the preparation may contain a compound of formula I dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
  • a liquid carrier in particular an aqueous carrier
  • the carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or cap- sules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain:
  • the compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of diseases related to the regulation of blood sugar.
  • Such mammals include also animals, both domestic animals, e.g. household pets, and non- domestic animals such as wildlife.
  • the compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 100 mg, preferably from about 0.1 to about 100 mg, per day may be used. A most preferable dosage is about 0.1 mg to about 70 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a dosage of from about 2 to about 70 mg per day and when the condition is under control to reduce the dosage as low as from about 0.1 to about 10 mg per day. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
  • the compounds of the present invention are dispensed in unit dosage form comprising from about 0.1 to about 100 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
  • dosage forms suitable for oral, nasal, pulmonary or transdermal administration comprise from about 0.001 mg to about 100 mg, preferably from about 0.01 mg to about 50 mg of the compounds of formula I admixed with a pharmaceutically acceptable carrier or diluent.
  • DIBAL-H diisobutylaluminum hydride
  • CDCI 3 deuterated chloroform
  • Diethyl azodicarboxylate (0.346 ml, 2.2 mmol) was added at 0°C to a stirred solution of triphenyl- phosphine (0.656 g, 2.2 mmol) and (£J-3-biphenyl-4-yl-but-2-en-1-ol (0.270 g, 1.2 mmol) in dry THF (20 ml) and the mixture stirred for 5 min.
  • a solution of (S -ethyl 2-ethoxy-3- (4-hydroxy-phenyl)-propionate (0.238 g, 1.0 mmol) in dry THF (10 ml) was added, the mixture allowed to warm to room temperature, and stirring continued for 48 h.
  • the title compound was prepared from (£)-3-(4'-bromo-biphenyl-4-yl)-but-2-en-1-ol (0.364 g, 1.2 mmol), triphenylphosphine (0.328 g, 1.3 mmol), diethyl azodicarboxylate (0.173 ml, 1.1 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxy-phenyl)-propionate (0.238 g, 1.0 mmol) by a pro- 0 cedure analogous to that described in example 1c, yielding 0.180 g (34%) of (£)-(S)-3- ⁇ 4-[3- (4'-bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl ⁇ -2-ethoxy-propionic acid ethyl ester.
  • the title compound was prepared from (£J-(S)-3- ⁇ 4-[3-(4'-bromo-biphenyl-4-yl)-but-2- enyloxy]-phenyl ⁇ -2-ethoxy-propionic acid ethyl ester (example 3) (0.150 g, 0.29 mmol) and 5 sodium hydroxide (1 M, 0.45 ml, 0.45 mmol) by a procedure analogous to that described in example 2 yielding 0.180 g (34%) of (£)-(S)-3- ⁇ 4-[3-(4'-bromo-biphenyl-4-yl)-but-2-enyloxy]- phenyl ⁇ -2-ethoxy-propionic acid ethyl ester.
  • the title compound was prepared from 4-phenoxyacetophenone (12.0 g, 0.056 mol) by a sequence analogous to that described in example 3, yielding 0.190 g (41%) of (£ -(S)-2-ethoxy- 3- ⁇ 4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl ⁇ -propionic acid ethyl ester.
  • the title compound was prepared from (£)-(S)-2-ethoxy-3- ⁇ 4-[3-(4-phenoxy-phenyl)-but-2- enyloxy]-phenyl ⁇ -propionic acid ethyl ester (example 5) (0.170 g, 0.37 mmol) and sodium hydroxide (1 M, 0.74 ml, 0.74 mmol) by a procedure analogous to that described in example 2 yielding 0.136 g (85%) of (£ (S)-2-ethoxy-3- ⁇ 4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]- phenyl ⁇ -propionic acid.
  • the title compound was prepared from 4-(4-methoxyphenoxy)acetophenone (2.63 g, 0.01.1 mol) by a sequence analogous to that described in example 3 yielding 0.200 g (41%) of (£)- (S)-2-ethoxy-3-(4- ⁇ 3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy ⁇ -phenyl)-propionic acid ethyl ester.
  • the title compound was prepared from (£ -(S)-2-ethoxy-3- ⁇ 4-[3-(9H-fluoren-2-yl)-but-2- enyloxy]-phenyl ⁇ -propionic acid ethyl ester (example 9) (0.230 g, 0.504 mol) and sodium hydroxide (1 M, 1.008 ml, 1.008 mmol) by a procedure analogous to that described in example 2 yielding 0.140 g (84%) of (£)-(S)-2-ethoxy-3- ⁇ 4-[3-(9H-fluoren-2-yl)-but-2-enyloxy]-phenyl ⁇ - propionic acid.
  • the title compound was prepared from 3,4-dimethoxyacetophenone (10.00 g, 0.055 mol) by a sequence analogous to that described in example 3 yielding 0.160 g (31%) of (£)-(S)-3- ⁇ 4- [3-(3,4-dimethoxy-phenyl)-but-2-enyloxy]-phenyl ⁇ -2-ethoxy-propionic acid ethyl ester.
  • the title compound was prepared from (£)-(S)-3- ⁇ 4-[3-(3,4-dimethoxy-phenyl)-but-2-enyloxy]- phenyl ⁇ -2-ethoxy-propionic acid ethyl ester (example 11) (0.150 g, 0.350 mmol) and sodium hydroxide (1M, 1.05 ml, 1.05 mmol) by a procedure analogous to that described in example 2 yielding 0.120 g (86%) of (£)-(S)-3- ⁇ 4-[3-(3,4-dimethoxy-phenyl)-but-2-enyloxy]-phenyl ⁇ -2- ethoxy-propionic acid.
  • the title compound was prepared from 3,5-bis(trifluoromethyl)acetophenone (5.12 g, 0.02 mol) by a sequence analogous to that described in example 3 yielding 0.370 g (73%) of (£)- (S)-3- ⁇ 4-[3-(3,5-bis-trifluoromethyl-phenyI)-but-2-enyloxy]-phenyl ⁇ -2-ethoxy-propionic acid ethyl ester.
  • the title compound was prepared from (£)-(S)-3-[4-(3-biphenyl-4-yl-allyloxy)-phenyl]-2- ethoxy-propionic acid ethyl ester (example 15) (0.200 g, 0.464 mmol) and sodium hydroxide (1 M, 0.928 ml, 0.928 mmol) by a procedure analogous to that described in example 2 yield- ing 0.043 g (23%) of (£)-(S)-3-[4-(3-biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid.
  • the title compound was prepared from 2-acetonaphthone (10.0 g, 0.06 mol) by a sequence analogous to that described in example 3 yielding 0.190 g (38%) of (£)-(S)-2 ⁇ ethoxy-3-[4-(3- naphthalen-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester.
  • the title compound was prepared from (£)-(S)-2-ethoxy-3-[4-(3-naphthalen-2-yl-but-2- enyloxy)-phenyl]-propionic acid ethyl ester (example 17) (0.165 g, 0.394 mmol) and sodium hydroxide (1 M, 0.789 ml, 0.789 mmol) by a procedure analogous to that described in exam- pie 2 yielding 0.030 g (19%) of (£)-(S)-2-ethoxy-3-[4-(3-naphthalen-2-yl-but-2-enyloxy)- phenylj-propionic acid.
  • the title compound was prepared from (£)-(S)-2-ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)- phenylj-propionic acid ethyl ester (example 19) (0.220 g, 0.595 mmol) and sodium hydroxide (1 M, 1.19 ml, 1.19 mmol) by a procedure analogous to that described in example 2 yielding 0.200 g (98%) of (£)-(S)-2-ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid.
  • the title compound was prepared from 3,5-dibenzyloxyacetophenone (6.64 g, 0.02 mol) by a sequence analogous to that described in example.3 yielding 0.460 g (53%) of (£)-(S)-3- ⁇ 4-[3- (3,5-bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyl ⁇ -2-ethoxy-propionic acid ethyl ester.
  • the title compound was prepared from (£)-(S)-3- ⁇ 4-[3-(3,5-bis-benzyloxy-phenyl)-but-2- enyloxy]-phenyl ⁇ -2-ethoxy-propionic acid ethyl ester (example 21) (0.430 g, 0.741 mmol) and sodium hydroxide (1 M, 1.5 ml, 1.5 mmol) by a procedure analogous to that described in example 2 yielding 0.300 g (73%) of (£)-(S)-3- ⁇ 4-[3-(3,5-bis-benzyloxy-phenyl)-but-2-enyloxy]- phenyl ⁇ -2-ethoxy-propionic acid.
  • Triethyl phosphonoacetate (8.9 g, 40.0 mmol) was added at 0°C over a period of 10 min. to a stirred suspension of sodium hydride (60% in oil, 1.44 g, 36.0 mmol) in dry THF (145 mL). After stirring at 0°C for 15 min. a solution of 2-naphthaldehyde (3.12 g, 20.0 mmol) in dry THF (15 mL) was added, the mixture slowly warmed to room temperature, and stirring con- tinued for 16h. The reaction mixture was quenched with water (100 mL) and acidified to pH 6 with 1N hydrochloric acid.
  • the title compound was prepared from 3-phenoxybenzaldehyde (4.0 g, 20.0 mmol) by a sequence analogous to that described in example 23.
  • the title compound was prepared from 4-benzyloxybenzaldehyde (21.2 g, 0.1 mol) by a sequence analogous to that described in example 23.
  • the title compound was purified on HPLC, using ethyl acetate/heptane (20:80) as eluent.
  • the title compound was prepared from piperonal (3.0 g, 20 mmol) by a sequence analogous to that described in example 23.
  • the title compound was purified on HPLC, using ethyl acetate/heptane (10:90) as eluent.
  • the title compound was prepared from benzofuran-7-carboxaldehyde (1.46 g, 10 mmol) by a sequence analogous to that described in example 23.
  • the title compound was prepared from 2,3-methylenedioxybenzaldehyde (1.5 g, 10 mmol) by a sequence analogous to that described in example 23.
  • the title compound was prepared from fluorene-2-carboxaldehyde (9.7 g, 50 mmol) by a sequence analogous to that described in example 23.
  • the title compound was prepared from phenanthrene-9-carboxaldehyde (4.1 g, 20.0 mmol) by a sequence analogous to that described in example 23.
  • Azodicarboxylic dipiperidide (0.756 g, 3.0 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (0.74 ml, 0.61 g, 3.0 mmol), (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (0.500 g, 2.10 mmol) and (£)-3-(4-bromophenyl)-but-2-en-1-ol (0.454 g, 2.0 mmol) in dry benzene (20 ml), the mixture warmed to room temperature, and stirred for 2.5 days.
  • Tetrakis(triphenylphoshine)palladium(0) (0.26 g, 0.22 mmol, 4 mol%) was added, under nitrogen, to a stirred solution of (£)-ethyl 3-(4-bromophenyl)-but-2-enoate (1.5 g, 5.57 mmol) ⁇ prepared as detailed in example 50 a ⁇ in DME (70 ml), and the resulting orange coloured solution stirred at room temperature for 10 min.
  • Azodicarboxylic dipiperidide (0.731 g, 2.9 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (0.71 ml, 0.58 g, 2.9 mmol), (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (0.483 g, 2.03 mmol) and (£)-3-(4'-chloro-biphenyl-4-yl)-but-2-en-1-ol (0.500 g, 1.93 mmol) in dry benzene (15 ml), the mixture warmed to room temperature, and stirred for 3 h.
  • Tetrakis(triphenylphoshine)palladium(0) (0.20 g, 0.18 mmol, 4 mol%) was added, under nitrogen, to a stirred solution of (£)-3-(4-bromophenyl)-but-2-en-1-ol (1.0 g, 4.40 mmol) ⁇ prepared as detailed in example 50 b ⁇ in DME (55 ml), and the resulting orange coloured solution stirred at room temperature for 10 min.
  • Azodicarboxylic dipiperidide (0.756 g, 3.0 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (0.74 ml, 0.61 g, 3.0 mmol), (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (0.50 g, 2.10 mmol) and 3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2-en-1-oI (0.593 g, 2.0 mmol) in dry benzene (15 ml), the mixture warmed to room temperature, and stirred for 4 h.
  • the resulting mixture was diluted with water (100 ml) and ethyl acetate (50 ml), the aqueous layer collected and further extracted with ethyl acetate (50 ml). The organic layers were combined, washed with brine, dried (MgSO 4 ) and evaporated.
  • the title compound (0.54 g, 61% yield) was prepared from (£)-3-(5'-chloro-2'-methoxy- biphenyl-4-yl)-but-2-en-1-ol (0.50 g, 1.73 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (0.433 g, 1.82 mmol) by a procedure analogous to that described in example 52 c.
  • the title compound (0.41 g, 80% yield) was prepared from (£)-3-(2',3'-dichloro-biphenyl-4- yl)-but-2-en-1-ol (0.293 g, 1.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.25 g, 1.05 mmol) by a procedure analogous to that described in example 52 c.
  • the title compound (0.41 g, 80% yield) was prepared from (£)-3-(2',6'-dimethoxy-biphenyl-4- yl)-but-2-en-1-ol (0.50 g, 1.76 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.44 g, 1.85 mmol) by a procedure analogous to that described in example 52 c.
  • the title compound (0.83 g, 87% yield) was prepared from (£)-3-(4-bromophenyl)-2-methyl- but-2-en-1-ol (0.50 g, 2.07 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.519 g, 2.18 mmol) by a procedure analogous to that described in example 52c.
  • the title compound (0.91 g, 95% yield) was prepared from (Z)-3-(4-bromophenyl)-2-methyI- but-2-en-1-ol (0.50 g, 2.07 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.519 g, 2.18 mmol) by a procedure analogous to that described in example 52 c.
  • the title compound (0.41 g, 80% yield) was prepared from (£)-3-[1 ,1';3',1"]terphenyl-4"-yl- but-2-en-1-ol (0.30 g, 1.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.25 g, 1.05 mmol) by a procedure analogous to that described in example 52 c.
  • the title compound was prepared from (£)-(S)-2-ethoxy-3- ⁇ 4-[3-(3'-methyl-biphenyl-4-yl)-but- 2-enyloxy]-phenyl ⁇ -propionate (example 68) (0.225 g, 0.49 mmol) and sodium hydroxide (1 M, 0.98 ml, 0.98 mmol) by a procedure analogous to that described in example 51 ; giving (£)- (S)-2-ethoxy-3- ⁇ 4-[3-(3'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl ⁇ -propionic acid as a gum; 0.20 g (95%).
  • This solid was recrystallised from aqueous ethanol to give a first crop of very pure (£)-3-(3'-acetyl- biphenyl-4-yl)-but-2-en-1-ol as colourless platelets; 2.78 g (41%) and a second crop of (£)-3- (3'-acetyl-biphenyl-4-yl)-but-2-en-1-ol as an amorphous off-white solid; 2.53 g (37%).
  • the title compound (0.16 g, 65% yield) was prepared from (£)-3-(3'-acetyl-biphenyl-4-yl)-but- 2-en-1-ol (0.133 g, 0.50 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-pr ⁇ pionate (0.125 g, 0.525 mmol) by a procedure analogous to that described in example 52 c.
  • the title compound was prepared from (£)-3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-prop-2- en-1-ol by a procedure analogous to that described in 52 c.
  • Bu 4 NBr 2.0 g, 6.3 mmol
  • K 2 CO 3 7.8 g, 56.7 mmol
  • Pd(Oac) 2 250 mg, 1.1 mmol
  • styrene 20 mL, 175 mmol
  • 3,5- dibromobenzaldehyde 5.0 g, 18.9 mmol
  • dry DMF 5.0 mL
  • the reaction mixture was diluted with ethyl acetate (20 mL) and the solution filtered. The filtrate was diluted with water and extracted with ethyl acetate (3 x 50 mL).
  • the title compound was prepared from 3-(3,5-bis-phenylethynyl-phenyl)-acrylic acid ethyl ester by a sequence analogous to that described in example 23b-c.
  • the title compound was prepared from 3,5-diphenethyl-benzaldehyde by a sequence analo- gous to that described in example 23.
  • Tetrakis(triphenylphoshine)palIadium(0) (0.69 g, 0.60 mmol, 6 mol%) was added, under nitrogen, to a stirred solution of (£)-ethyl 3-(4-iodophenyI)-but-2-enoate (3.16 g, 10.0 mmol) in DME (100 ml), and the resulting orange coloured solution stirred at room temperature for 10 min.
  • Aqueous 2M sodium carbonate (30.0 ml, 60.0 mmol) was then added, the mixture stirred for 10 min, then furan-2-boronic acid (2.25 g, 20.11 mmol) was added, and the reaction mixture heated to 80°C for 20 h, under reflux.
  • the title compound (678 mg, 77%) was prepared from (£)-3-(4-furan-2-yl-phenyl)-but-2-en-1- ol (430 mg, 2.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (526 mg, 2.21 mmol) by a procedure analogous to that described in example 52c.
  • the title compound (1.80 g, 78%) was prepared as a colourless oil from (£)-3-(2'-methyl- biphenyl-4-yl)-but-2-en-1-ol (1.19 g, 4.99 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (1.31 g, 6.48 mmol) by a procedure analogous to that described in example 52c.
  • the colourless gum (£)-3-(2',5'-dimethoxy-biphenyl-4-yl)-but-2-en-1-oI was prepared by DIBAL-H reduction of (£)-ethyl 3-(2',5'-dimethoxy-biphenyl-4-yl)-but-2-enoate by a procedure analogous to that described in example 52b.
  • the title compound (0.765 g, 61%) was prepared as a colourless gum from (£)-3-(2',5'- dimethoxy-biphenyI-4-yl)-but-2-en-1-ol (0.711 g, 2.50 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (0.655 g, 2.75 mmol) by a procedure analogous to that described in example 52c.
  • the title compound (843 mg, 89%) was prepared from (£)-3-(4-bromophenyl)-2-ethyl-but-2- en-1-ol (510 mg, 2.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (500 mg, 2.10 mmol) by a procedure analogous to that described in example 52c.
  • the title compound was prepared from (£)-(S)-ethyl 3- ⁇ 4-[3-(4-bromophenyl)-2-ethyI-but-2- enyloxy]-phenyl ⁇ -2-ethoxy-propionate (Example 96) (0.78 g, 1.64 mmol) and sodium hydroxide (1M, 3.3 ml, 3.3 mmol) by a procedure analogous to that described in example 51, yielding (£)-(S)-3- ⁇ 4-[3-(4-bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl ⁇ -2-ethoxy-propionic acid (0.703 g, 96%) as a pale yellow oil, which contained a small amount of dichloromethane; 0.703 g (96%).
  • the title compound (535 mg, 81%) was prepared from (Z)-3-(4-bromophenyl)-2-ethyl-but-2- en-1-ol (prepared as described in example 96b) (355 mg, 1.39 mmol) and (S)-ethyl 2-ethoxy- 3-(4-hydroxyphenyl)-propionate (348 mg, 1.46 mmol) by a procedure analogous to that described in example 52c.

Abstract

The present invention relates to compounds of general formula (I). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Description

NEW COMPOUNDS, THEIR PREPARATION AND USE
FIELD OF INVENTION
The present invention relates to novel compounds, pharmaceutical compositions containing them, methods for preparing the compounds and their use as medicaments. More specifically, compounds of the invention can be utilised in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Re- ceptors (PPAR).
BACKGROUND OF THE INVENTION
Coronary artery disease (CAD) is the major cause of death in Type 2 diabetic and metabolic syndrome patients (i.e. patients that fall within the 'deadly quartet' category of impaired glucose tolerance, insulin resistance, hypertriglycehdaemia and/or obesity).
The hypolipidaemic fibrates and antidiabetic thiazolidinediones separately display moderately effective triglyceride-lowering activities although they are neither potent nor efficacious enough to be a single therapy of choice for the dyslipidaemia often observed in Type 2 diabetic or metabolic syndrome patients. The thiazolidinediones also potently lower circulating glucose levels of Type 2 diabetic animal models and humans. However, the fibrate class of compounds are without beneficial effects on glycaemia. Studies on the molecular actions of these compounds indicate that thiazolidinediones and fibrates exert their action by activating distinct transcription factors of the peroxisome proliferator activated receptor (PPAR) family, resulting in increased and decreased expression of specific enzymes and apolipoproteins respectively, both key-players in regulation of plasma triglyceride content. Fibrates, on the one hand, are PPARα activators, acting primarily in the liver. Thiazolidinediones, on the other hand, are high affinity ligands for PPARγ acting primarily on adipose tissue.
Adipose tissue plays a central role in lipid homeostasis and the maintenance of energy balance in vertebrates. Adipocytes store energy in the form of triglycerides during periods of nutritional affluence and release it in the form of free fatty acids at times of nutritional deprivation. The development of white adipose tissue is the result of a continuous differentiation process throughout life. Much evidence points to the central role of PPARγ activation in initiating and regulating this cell differentiation. Several highly specialised proteins are induced during adipocyte differentiation, most of them being involved in lipid storage and metabolism. The exact link from activation of PPARγ to changes in glucose metabolism, most notably a decrease in insulin resistance in muscle, has not yet been clarified. A possible link is via free fatty acids such that activation of PPARγ induces Lipoprotein Lipase (LPL), Fatty Acid Transport Protein (FATP) and Acyl-CoA Synthetase (ACS) in adipose tissue but not in muscle tissue. This, in turn, reduces the concentration of free fatty acids in plasma dramatically, and due to substrate competition at the cellular level, skeletal muscle and other tissues with high metabolic rates eventually switch from fatty acid oxidation to glucose oxidation with decreased insulin resistance as a consequence.
PPARα is involved in stimulating β-oxidation of fatty acids. In rodents, a PPARα-mediated change in the expression of genes involved in fatty acid metabolism lies at the basis of the phenomenon of peroxisome proliferation, a pleiotropic cellular response, mainly limited to liver and kidney and which can lead to hepatocarcinogenesis in rodents. The phenomenon of peroxisome proliferation is not seen in man. In addition to its role in peroxisome proliferation in rodents, PPARα is also involved in the control of HDL cholesterol levels in rodents and humans. This effect is, at least partially, based on a PPARα-mediated transcrip- tional regulation of the major HDL apolipoproteins, apo A-l and apo A-ll. The hypotriglyceridemic action of fibrates and fatty acids also involves PPARα and can be summarised as follows: (I) an increased lipolysis and clearance of remnant particles, due to changes in lipoprotein lipase and apo C-lll levels, (II) a stimulation of cellular fatty acid uptake and their subsequent conversion to acyl-CoA derivatives by the induction of fatty acid binding protein and acyl-CoA synthase, (III) an induction of fatty acid ?-oxidation pathways, (IV) a reduction in fatty acid and triglyceride synthesis, and finally (V) a decrease in VLDL production. Hence, both enhanced catabolism of triglyceride-rich particles as well as reduced secretion of VLDL particles constitutes mechanisms that contribute to the hypolipidemic effect of fibrates.
A number of compounds have been reported to be useful in the treatment of hyperglycemia, hyperlipidemia and hypercholesterolemia (U.S. Pat. 5,306,726, PCT Publications nos. W091/19702, WO 95/03038, WO 96/04260, WO 94/13650, WO 94/01420, WO 97/36579, WO 97/25042, WO 95/17394, WO 99/08501 , WO 99/19313 and WO 99/16758).
SUMMARY OF THE INVENTION
Glucose lowering as a single approach does not overcome the macrovascular complications associated with Type 2 diabetes and metabolic syndrome. Novel treatments of Type 2 diabetes and metabolic syndrome must therefore aim at lowering both the overt hypertriglyceri- daemia associated with these syndromes as well as alleviation of hyperglycaemia.
The clinical activity of fibrates and thiazolidinediones indicates that research for compounds displaying combined PPARα and PPARγ activation should lead to the discovery of efficacious glucose and triglyceride lowering drugs that have great potential in the treatment of Type 2 diabetes and the metabolic syndrome (i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity).
DETAILED DESCRIPTION OF THE INVENTION
Accordingly, the present invention relates to compounds of the general formula (I):
Figure imgf000004_0001
wherein A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from hydroxy, halogen, perhalomethyl, perhalomethoxy, acyl, cyano, amino, C1-6-alkylamino, C1-6-dialkylamino, methylenedioxy, aralkenyl, aralkynyl, heteroary- loxy, heteroaralkoxy, aralkyl, heteroaralkyl, arylamino, or A is optionally substituted with C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl each of which is optionally substituted with one or more substituents selected from C1-6-alkoxycarbonyl or carboxy, or
A is optionally substituted with C1-6-alkoxy, C1-6-alkylthio or C2-6-alkenyloxy each of which is optionally substituted with one or more halogens, or A is optionally substituted with aryloxy, arylthio or aralkoxy each of which is optionally substituted with one or more substituents selected from C1-6-alkoxy, nitro, carboxy or C1-6- alkoxycarbonyl; and X-i and X2 independently are hydrogen, aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C1-6-alkoxy, C1-6- alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6-dialkylamino, arylamino or methylenedioxy, or aryl or heteroaryl each of which is optionally substituted with one or more substituents se- lected from C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl each of which is optionally substituted with hydroxy; or
A is selected from the ring systems consisting of
Figure imgf000006_0001
Figure 1 wherein the attachment point of A to the remaining part of the structure of formula (I) is as indicated on the chemical structures in Figure 1 , and wherein A is optionally substituted with one or more substituents selected from C1-6-aIkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkyIthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6- dialkylamino, arylamino or methylenedioxy; and wherein X^ and X2 are hydrogen; and
R5 is hydrogen or C1-6-aIkyl; and
Y is hydrogen, or Y is C1-12-alkyl, C2-i2-alkenyl, C2-ι2-alkynyl, C4-12-alkenynyl, aralkyl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, C1-6- alkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
Z is hydrogen, halogen, hydroxy, or Z is C1-6-alkyl or C -6-alkoxy each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C1-6-alkoxy; and Q is O, S or NR6, wherein R6 is hydrogen, C1-6-alkyI, C2-6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl, aralkyl, heteroaralkyl and wherein R6 is optionally substituted with one or more substituents selected from halogen, hydroxy, C1-6-alkoxy, amino or carboxy; and
Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C1-6-alkyl, aryl or C1-6-alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
Ri is hydrogen, hydroxy or halogen; or R^ forms a bond together with R2; and
R is hydrogen or C1-6-alkyl; or R2 forms a bond together with R-i; and
R3 is hydrogen, or
R3 is C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C^e-alkenynyl, aryl, aralkyl, C1-6-alkoxyC1-6alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
R4 is hydrogen, C -6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C -6-alkenynyl or aryl; and
n is an integer ranging from 0 to 3; and
m is an integer ranging from 0 to 1 ;
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs.
In a preferred embodiment, the present invention is concerned with compounds of formula (I)
Figure imgf000008_0001
wherein A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from hydroxy, halogen, perhalomethyl, perhalomethoxy, acyl, cyano, amino, C1-6-alkylamino, C1-6-dialkylamino, methylenedioxy, aralkenyl, aralkynyl, heteroary- loxy, heteroaralkoxy, aralkyl, heteroaralkyl, arylamino, or
A is optionally substituted with C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl each of which is optionally substituted with one or more substituents selected from C1-6-alkoxycarbonyl or carboxy, or A is optionally substituted with C1-6-alkoxy, C1-6-alkylthio or C2-6-alkenyloxy each of which is optionally substituted with one or more halogens, or
A is optionally substituted with aryloxy, arylthio or aralkoxy each of which is optionally substituted with one or more substituents selected from C1-6-alkoxy, nitro, carboxy or C1-6- alkoxycarbonyl; and Xi and X2 independently are hydrogen, aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C1-6-alkoxy, C1-6- alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaral- kyl, cyano, amino, C1-6-alkylamino, Cι-6-dialkylamino, arylamino or methylenedioxy, or aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from C1-6-alkyl, C2.6-alkenyl or C2-6-alkynyl each of which is optionally substituted with hydroxy; or A is selected from the ring systems consisting of
Figure imgf000009_0001
Figure 1
wherein the attachment point of A to the remaining part of the structure of formula (I) is as indicated on the chemical structures in Figure 1 , and wherein A is optionally substituted with one or more substituents selected from C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alky!amino, C1-6- dialkylamino, arylamino or methylenedioxy; and wherein Xi and X2 are hydrogen; and
R5 is hydrogen or C1-6-aIkyl; and
Y is hydrogen, or
Y is d-12-alkyl, C2-ι2-alkenyl, C2-ι2-alkynyl, C4-12-alkenynyl, aralkyl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, Chalky!, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and Z is hydrogen, halogen, hydroxy, or
Z is C1-6-alkyI or C1-6-alkoxy each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C1-6-alkoxy; and
Q is O, S or NR6, wherein R6 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl, aralkyl, heteroaralkyl and wherein R6 is optionally substituted with one or more substituents selected from halogen, hydroxy, C1-6-alkoxy, amino or carboxy; and
Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C1-6-alkyl, aryl or C1-6-alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
Ri is hydrogen, hydroxy or halogen; or R1 forms a bond together with R ; and
R2 is hydrogen or C1-6-alkyl; or R2 forms a bond together with R^ and
R3 is hydrogen, or
R3 is C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C^e-alkenynyl, aryl, aralkyl, C1-6-alkoxyC1-6alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
R4 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C^e-alkenynyl or aryl; and
n is an integer ranging from 1 to 3; and
m is 1 ;
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs. In another preferred embodiment, the present invention is concerned with compounds of formula (I)
Figure imgf000011_0001
wherein A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C^- dialkylamino, arylamino or methylenedioxy, and
X-i and X independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from Cι-6-alkyl, C2-6-alkenyl, C2-6-aIkyny(, hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, d-e-dialkylamino, arylamino or methylenedioxy; or
wherein A is selected from the ring systems consisting of
Figure imgf000012_0001
Figure imgf000012_0003
Figure imgf000012_0002
Figure 1
wherein the attachment point of A to the remaining part of the structure of formula (I) is as indicated on the chemical structures in Figure 1 , and wherein A is optionally substituted with one or more substituents selected from C1-6-alkyl, C2. 6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C -6-alkoxy, Cι-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6-dialkylamino, arylamino or methylenedioxy, and wherein X.| and X2 are hydrogen; and
R5 is hydrogen or C1-6-alkyl; and
Y is hydrogen, C1-12-alkyl, C2-ι2-alkenyl, C2-12-alkynyl, C^-alkenynyl, aralkyl or heteroaralkyl optionally substituted with one or more substituents selected from halogen, C1-6-aIkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
Z is hydrogen, halogen, hydroxy, C1-6-alkyl or C1-6-alkoxy optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C1-6-alkoxy; and Q is O, S or NR6, wherein R6 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl, aralkyl, heteroaralkyl and wherein R6 is optionally substituted with one or more substituents selected from halogen, hydroxy, Cι-6-alkoxy, amino or carboxy; and
Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C-i-e-alkyl, aryl or C1-6-alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
Ri is hydrogen, hydroxy or halogen; or R forms a bond together with R2; and
R2 is hydrogen or C1-6-alkyl; or R2 forms a bond together with R^ and
R3 is hydrogen, C1-6-alkyI, C2-6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl, aryl, aralkyl, C1-6- alkoxyC1-6alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
R4 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl or aryl; and
n is an integer ranging from 0 to 3; and
m is an integer ranging from 0 to 1.
In another preferred embodiment, the present invention is concerned with compounds of formula (I)
Figure imgf000014_0001
wherein A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from C1-6-alkyl, C2.6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6- dialkylamino, arylamino or methylenedioxy; or
provided Xi and X2 is hydrogen, A is selected from the ring systems consisting of
Figure imgf000015_0001
wherein A is optionally substituted with one or more substituents selected from C1-6-alkyl, C2- 6-alkenyl, C2.6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, Cι-6-alkylamino, C1-6-dialkylamino, arylamino or methylenedioxy; and
R5 is hydrogen or C1-6-alkyl; and
Xi and X2 independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C1-6-alkoxy, d-β-alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino, d^-alkylamino, C1-6-dialkylamino, arylamino or methylenedioxy; and
Y is hydrogen, d_ι2-alkyl, C2-12-alkenyl, C2-12-alkynyl, C^^-alkenynyl, aralkyl or heteroaralkyl optionally substituted with one or more substituents selected from halogen, C1-6-alkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
Z is hydrogen, halogen, hydroxy, C1-6-alkyl or d-6-alkoxy optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C1-6-alkoxy; and Q is O, S or NR6, wherein R6 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C4.6-alkenynyl, aralkyl, heteroaralkyl and wherein R6 is optionally substituted with one or more substituents selected from halogen, hydroxy, C1-6-alkoxy, amino or carboxy; and
Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C1-6-alkyl, aryl or C1-6-alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
Ri is hydrogen, hydroxy or halogen; or R forms a bond together with R2; and
R is hydrogen or C1-6-alkyl; or R2 forms a bond together with R^ and
R3 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl, aryl, aralkyl, C1-6- alkoxyC1-6alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
* is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-s-alkynyl, C4-6-alkenynyl or aryl; and
n is an integer ranging from 0 to 3; and
m is an integer ranging from 0 to 1.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A is aryl or heteroaryl optionally substituted with one or more substituents selected from from C1-6-alkyI, C2-6-alkenyI each of which is optionally substituted with one or more substituents selected from C1-6-alkoxycarbonyl or carboxy, or A is optionally substituted with aryloxy optionally substituted with one or more C1-6-alkoxy, or A is optionally substituted with aralkoxy optionally substituted with one or more substituents selected from C1-6-alkoxy, nitro, carboxy or C1-6-aIkoxycarbonyl, or A is optionally substituted with C1-6-alkoxy optionally substituted with one or more halogens, or
A is optionally substituted with aralkenyl, C2-6-alkenyloxy, aralkynyl, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl or methylenedioxy. In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A is aryl, heteroaryl or
Figure imgf000017_0001
optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, d-e-alkoxy, C1-6-aIkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A is aryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, C1-6-alkoxy, d-β-alkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A is aryl optionally substituted with one or more substituents selected from from C1-6-alkyl, C2-6-alkenyl each of which is optionally substituted with one or more substituents selected from C1-6-alkoxycarbonyl or carboxy, or A is optionally substituted with aryloxy optionally substituted with one or more C1-6-alkoxy, or A is optionally substituted with aralkoxy optionally substituted with one or more substituents selected from C1-6-alkoxy, nitro, carboxy or C1-6-alkoxycarbonyl, or A is optionally substituted with C1-6-alkoxy optionally substituted with one or more halogens, or A is optionally substituted with aralkenyl, C2-6-alkenyloxy, aralkynyl, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl or methylenedioxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A is aryl optionally substituted with one or more substituents selected from from C1-6-alkyl, or
A is optionally substituted with aryloxy optionally substituted with one or more C1-6-aIkoxy, A is optionally substituted with aralkoxy optionally substituted with one or more substituents selected from C1-6-alkoxy, or
A is optionally substituted with C1-6-alkoxy optionally substituted with one or more halogens, or
A is optionally substituted with aralkenyl, aralkynyl, halogen, perhalomethyl, perhalomethoxy or aralkyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A is heteroaryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A is heteroaryl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A is
Figure imgf000018_0001
optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkyIthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A is
Figure imgf000018_0002
optionally substituted with one or more substituents selected from C1-6-alkyl, and wherein R5 is hydrogen or C1-6-alkyl. In another preferred embodiment, the present invention is concerned with compounds of formula I wherein X^ and X2 independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, halogen, perha- lomethyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Xi and X2 independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from halogen, acyl, aryl, or aryl or heteroaryl optionally substituted with one or more substituents selected from Chalky!, C2-6-alkynyl each of which is optionally substituted with hydroxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein X1 and X2 independently are hydrogen, or aryl or heteroaryl optionally substituted with one or more substituents selected from halogen.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein X^ and X2 independently are hydrogen or aryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, halogen, perhalomethyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein X^ and X2 independently are hydrogen, aryl optionally substituted with one or more substituents selected from halogen, acyl, aryl, or aryl optionally substituted with one or more substituents selected from C1-6-alkyl, C2-6-alkynyl each of which is optionally substituted with hydroxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein X and X2 independently are hydrogen, or phenyl optionally substituted with one or more substituents selected from halogen.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein X! and X2 independently are hydrogen or heteroaryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, halogen, perhalomethyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Xi and X2 independently are hydrogen or heteroaryl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein X^ and X2 is hydrogen.
In another preferred embodiment, the present invention is concerned with compounds of for- mula I wherein Y is hydrogen or C1-12-alkyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Y is hydrogen or methyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Z is hydrogen or C1-6-aIkoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Z is hydrogen or C1-6-alkyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Z is hydrogen.
In another preferred embodiment, the present invention is concerned with compounds of for- mula I wherein Q is O.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Ar is arylene optionally substituted with one or more substituents selected from d-e-alkyl or C1-6-alkoxy each of which can be optionally substituted with carboxy. In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Ar is arylene.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Ri is hydrogen or Ri forms a bond together with R2.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Ri is hydrogen.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R2 is hydrogen or R2 forms a bond together with R-i.
In another preferred embodiment, the present invention is concerned with compounds of for- mula I wherein R2 is hydrogen.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R3 is C1-6-alkyl or aralkyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R3 is C -6-alkyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R is hydrogen, C1-3-alkyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R* is hydrogen.
In another preferred embodiment, the present invention is concerned with compounds of for- mula I wherein n is 1.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein m is 1. In another preferred embodiment, the present invention is concerned with compounds of formula I wherein alkyl is methyl, ethyl, n-propyl, iso-propyl, butyl, tert-butyl, pentyl, hexyl, cyclopropyl or cyclopentyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein alkenyl is vinyl or 1-propenyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein alkynyl is ethynyl, 1-propynyl and 2-propynyI.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein alkoxy is methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, isopropoxy or cyclopentyloxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein alkylthio is methylthio, ethylthio, propylthio or cyclopentylthio.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein aryl is phenyl optionally substituted with halogen.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein arylene is phenylene optionally substituted with halogen.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein halogen is fluorine or chlorine.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein perhalomethyl is trifluoromethyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein acyl is acetyl. In another preferred embodiment, the present invention is concerned with compounds of formula I wherein heteroaryl is furan, thiophene, pyrrole, imidazole, pyrazole, pyridine, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole or benzofuran. In another preferred embodiment, the present invention is concerned with compounds of formula I wherein heteroaryl is furan, pyrrole, indole or benzofuran.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein heteroarylene is furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine or pyridazine.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein aralkyl is benzyl or phenethyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein aryloxy is phenoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein aralkoxy is benzyloxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein n is an integer ranging from 1 to 3 and m is 1.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein the substituents Z and Y are arranged in a trans-configuration.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein the substituents Z and Y are arranged in a cis-configuration.
Preferred compounds of the invention are:
(£)-(S)-Ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-ethoxy-propionate, (E)-(S)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-ethoxy-propionic acid,
(E)-(S)-3-{4-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester,
CE)-(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl}-propionic acid, (£)-(S)-2-Ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy}-phenyI)-propionic acid ethyl ester,
(E)-(S)-2-Ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy}-phenyl)-propionic acid,
(£)-(S)-2-Ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester,
(E)-(S)-2-Ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid, (E)-(S)-3-{4-[3-(3,4-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(3,4-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (E)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionicacid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£J-(S)-3-[4-(3-Biphenyl-4-yI-alIyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (E)-(S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (E)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yI-but-2-enyloxy)-phenyl]-propionic acid ethyl ester, (E)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-but-2-enyloxy)-phenyl]-propionic acid,
(£)-(S)-2-Ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid, (E)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyI}-2-ethoxy-propionic acid, (E)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-allyloxy)-phenyl]-propionic acid ethyl ester, (E)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-allyloxy)-phenyl]-propionic acid, (£)-(S)-2-Ethoxy-3-{4-[3-(3-phenoxy-phenyl)-allyloxy]-phenyl}-propionic acid ethyl ester, (E)-(S)-2-Ethoxy-3-{4-[3-(3-phenoxy-phenyl)-allyloxy]-phenyl}-propionic acid, (S)-3-[4-(2-Benzofuran-3-yl-alIyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (S)-3-[4-(2-Benzofuran-3-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms. Also preferred compounds of the invention are:
E)-(S)-3-{4-[3-(4-Benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, £)-(S)-3-{4-[3-(4-Benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, E)-(S)-3-[4-(3-Benzo[1 ,3]dioxol-5-yl~allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, E)-(S)-3-[4-(3-Benzo[1 ,3]dioxol-5-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, E)-(S)-3-{4-[3-(4-Allyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, E)-(S)-3-{4-[3-(4-Allyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, £)-(S)-3-[4-(3-Benzofuran-7-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, £)-(S)-3-[4-(3-Benzofuran-7-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, S)-3-[4-(3-Benzo[1 ,3]dioxol-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, S)-3-[4-(3-Benzo[1 ,3]dioxol-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, £)-(S)-2-Ethoxy-3-(4-[3-(9H-fluoren-2-yl)-allyloxy]-phenyl)-propionic acid ethyl ester, E)-(S)-2-Ethoxy-3-(4-[3-(9H-fluoren-2-yl)-allyloxy]-phenyl)-propionic acid, S)-2-Ethoxy-3-[4-(3-quinolin-2-yl-allyloxy)-phenyl]-propionic acid ethyl ester, S)-2-Ethoxy-3-[4-(3-quinolin-2-yl-allyloxy)-phenyl]-propionic acid, £)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-alIyloxy]-phenyl}-2-ethoxy-propionic acid ethyl es-
:er,
E)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, E)-(S)-3-{4-[3-(3,5-Dimethoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, E)-(S)-3-{4-[3-(3,5-Dimethoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, £)-(S)-2-Ethoxy-3-[4-(3-phenanthren-9-yl-allyloxy)-phenyl]-propionic acid ethyl ester, £)-(S)-2-Ethoxy-3-{4-[3-(2-methoxy-naphthalen-1 -yl)-allyloxy]-phenyl}-propionic acid ethyl ester,
E)-(S)-2-Ethoxy-3-{4-[3-(2-methoxy-naphthalen-1-yl)-allyloxy]-phenyl}-propionic acid, £)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, E)-(S)-3-{4-[3-(4-Bromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, £)-(S)-Ethyl 3-{4-[3-(4'-Chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, E)-(S)-3-{4-[3-(4'-Chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, E)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}- propionate,
(E)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}- propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(5'-chloro-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}- propionate,
(E)-(S)-3-{4-[3-(5'-Chloro-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid, (£)-(S)-Ethyl 3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(2',3'-DichIoro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(E)-(S)-Ethyl 3-{4-[3-(2',6'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate, (E)-(S)-3-{4-[3-(2',6'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(Z)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (Z)-(S)-3-{4-[3-(4-Bromophenyl)-2-methyI-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(E)-(S)-Ethyl 2-Ethoxy-3-[4-(3-[1 ,1 ';3',1 "]terphenyl-4"-yl-but-2-enyloxy)-phenyl]-propionate,
(£)-(S)-2-Ethoxy-3-[4-(3-[1 , 1 ';3', 1 "]terphenyl-4"-yl-but-2-enyloxy)-phenyl]-propionic acid,
(E)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(3'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(3'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid, (£)-(S)-3-{4-[3-(3'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-allyloxy]-phenyl}-propionic acid ethyl ester,
(£ -(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-allyloxy]-phenyl}-propionic acid, (£)-(S)-3-{4-[3-(3,5-Distyryl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£T)-(S)-3-{4-[3-(3,5-Distyryl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
Also preferred compounds of the invention are:
(E)-(S)-3-{4-[3-(3,5-Diisopropoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(3,5-Diisopropoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (S)-3-{4-[3-(3-Bromo-5-styryl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(S)-3-{4-[3-(3-Bromo-5-styryl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(E)-(S)-2-Ethoxy-3-[4-(3-phenyl-allyloxy)-phenyl]-propionic acid ethyl ester,
(E)-(S)-2-Ethoxy-3-[4-(3-phenyl-allyIoxy)-phenyl]-propionic acid, (E)-(S)-3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (E)-(S)-3-{4-[3-(3,5-Bis-phenylethynyl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(3,5-Bis-phenylethynyl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (E)-(S)-3-{4-[3-(3,5-Diphenethyl-phenyI)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (E)-(S)-3-{4-[3-(3,5-Diphenethyl-phenyI)-aIlyloxy]-phenyl}-2-ethoxy-propionic acid,
3-{4-[3-(3,5-Bis-cyclopentyloxy-phenyl)-aIlyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(3,5-Bis-cyclopentyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, ,
(E)-(S)-3-(4-{3-[3,5-Bis-(2,2,2-trifluoro-ethoxy)-phenyl]-allyloxy}-phenyl)-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-(4-{3-[3,5-Bis-(2,2,2-trifluoro-ethoxy)-phenyl]-alIyloxy}-phenyl)-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4-furan-2-yI-phenyl)-but-2-enyloxy]-phenyl}-propionate,
(E)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(2'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate,
(E)-(S)-2-Ethoxy-3-{4-[3-(2'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid, (E)-(S)-Ethyl 3-{4-[3-(2',5'-Dimethoxy-biphenyl-4-yl)-but-2-enyIoxy]-phenyl}-2-ethoxy- propionate,
(E)-(S)-3-{4-[3-(2',5'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (Z)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (Z)-(S)-3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(E)-(S)-Ethyl 3-{4-[3-(4'-terf-Butyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(E)-(S)-Ethyl 3-{4-[3-(3',5'-Bis-trifluoromethyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(3',5'-Bis-trifluoromethyI-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid,
(£)-(S)-EthyI 2-Ethoxy-3-{4-[3-(4'-isopropyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(4'-isopropyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid,
(E)-(S)- 3-{4-[3-(3,5-Dimethoxy-phenyl)-but-2-enyIoxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(3'-Acetyl-biphenyl-4-yI)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(4'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-3-{4-[3-(4'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-[4-(3-[1 , 1 ';3\ 1 "]terphenyl-5'-yl-allyloxy)-phenyl]-propionate,
(£)-(S)-2-Ethoxy-3-[4-(3-[1 ,1 ';3',1 "]terphenyl-5'-yI-allyloxy)-phenyl]-propionic acid,
(£,E)-(S)-Ethyl 3-(4'-{3-[4-(2-Ethoxy-2-ethoxycarbonyl-ethyl)-phenoxy]-1-methyl-propenyl}- biphenyl-3-yl)-but-2-enoate,
(£,E)-(S)- 3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-1-methyl-propenyl}-biphenyl-3-yl)- but-2-enoic acid, (£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(3'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(3'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid,
(£)-(S,S )-Ethyl 2-Ethoxy-3-(4-{3-[3'-(1-hydroxy-ethyl)-biphenyl-4-yl]-but-2-enyloxy}-phenyl)- propionate,
(£)-(S,S )-2-Ethoxy-3-(4-{3-[3'-(1-hydroxy-ethyl)-biphenyI-4-yl]-but-2-enyloxy}-phenyl)- propionic acid, (£)-(S)-Ethyl 3-{4-[3-(3,5-Dibromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-3-{4-[3-(3,5-Dibromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3,5-Dibromophenyl)-allyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-3-{4-[3-(3,5-Dibromophenyl)-alIyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-Ethyl 3-{4-[3-(4,4"-Di-ferf-butyl-[1 ,1 ';3',1 "]terphenyl-5'-yl)-allyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(4,4"-Di-fe/f-butyl-[1 , 1 ';3', 1 "]terphenyl-5'-yl)-allyloxy]-phenyl}-2-ethoxy- propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3',5'-Dibromo-biphenyl-4-yI)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(3',5'-Dibromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3',5'-DichIoro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(3',5'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-Ethyl 3-{4-[3-(3',5'-Dichloro-biphenyl-4-yl)-allyIoxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-3-{4-[3-(3,,5'-Dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3',5'-di-.erf-butyl-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-3-{4-[3-(3',5'-Di-terf-butyl-biphenyI-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3',5'-Di-.ert-butyl-biphenyl-4-yI)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(3',5'-Di-tert-butyl-biphenyl-4-yi)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S/ )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-isopropoxy-propionate,
(£)-(S/?)-3-[4-(3-BiphenyI-4-yl-but-2-enyloxy)-phenyl]-2-isopropoxy-propionic acid,
(£)-(S )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-butoxy-propionate,
(£)-(S/j )-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-butoxy-propionic acid, (£)-(S )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-hexyloxy-propionate,
(£)-(S )-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-hexyloxy-propionic acid,
(£)-(S )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-(3-phenyl-propoxy)-propionate,
(£)-(S )-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-(3-phenyl-propoxy)-propionic acid,
(£)-(S )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-(4-phenyl-butoxy)-propionate, (£)-(S/R)-3-[4-(3-Biphenyl-4-yl-but-2-enyIoxy)-phenyl]-2-(4-phenyl-butoxy)-propionic acid, (£)-(S//?)-Propyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-propoxy-propionate, (£)-(S/f?)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-propoxy-propionic acid,
(£)-(S)-3-{4-[3-(3,5-Diethoxyoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Diethoxyoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-3-{4-[3-(3)5-Bis-trifluoromethyl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-allyIoxy]-phenyl}-2-ethoxy-propionic acid, (E)-(R, S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£)-(f?,S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (£)-(S)- 4-(3-{3-[4-(2-Ethoxy-2-ethoxycarbonyl-ethyl)-phenoxy]-propenyl}-phenoxymethyl)- benzoic acid methyl ester, (£)-(S)- 4-(3-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propenyl}-phenoxymethyl)-benzoic acid;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
Also preferred compounds of the invention are:
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4'-fluoro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate, (£)-(S)-2-Ethoxy-3-{4-[3-(4'-fluoro-biphenyI-4-yl)-but-2-enyloxy]-phenyl}-propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4-lodophenyl)-but-2-enyloxy]-phenyl}-propionate;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
In the above structural formulas and throughout the present specification, the following terms have the indicated meaning:
The term "Cι-12-alkyl" as used herein, alone or in combination is intended to include those alkyl groups of the designated length in either a linear or branched or cyclic configuration represents e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl and the like. Typical C1-12-alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, hexyl, iso-hexyl, cyclopropyl, cyclob- utyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl and the like, especially preferred is methyl, ethyl, n-propyl, iso-propyl, butyl, tert-butyl, pentyl, hexyl, cyclopropyl and cyclopentyl.
The term "C2-12-alkenyl" as used herein, represents an olefinically unsaturated branched or straight group having from 2 to the specified number of carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, vinyl, 1-propenyI, 2- propenyl, allyl, iso-propenyl, 1,3-butadienyl, 1-butenyl, hexenyl, pentenyl and the like, especially preferred is vinyl and 1-propenyI.
The term "C2-12-alkynyl", as used herein, represent an unsaturated branched or straight group having from 2 to the specified number of carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to ethynyl, 1-propynyl, 2-propynyl, 1- butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl and the like, especially preferred is ethynyl, 1- propynyl and 2-propynyl.
The term "C4-12-alkenynyl" as used herein, represent an unsaturated branched or straight hydrocarbon group having from 4 to the specified number of carbon atoms and both at least one double bond and at least one triple bond. Examples of such groups include, but are not, limited to, 1-penten-4-yne, 3-penten-1-yne, 1 ,3-hexadiene-5-yne and the like.
The term "C1-6-alkoxy" as used herein, alone or in combination is intended to include those d_g- alkyl groups of the designated length in either a linear or branched or cyclic configuration linked thorugh an ether oxygen having its free valence bond from the ether oxygen. Examples of linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy and the like, especially preferred is methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy. Examples of branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy and the like, especially preferred is isopropoxy. Examples of cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like, especially preferred is cyclopentyloxy.
The term "C1-6-alkylthio" as used herein, alone or in combination, refers to a straight or branched or cyclic monovalent substituent comprising a C1-6-alkyl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom and having 1 to 6 carbon atoms e.g. methylthio, ethylthio, propylthio, butylthio, pentylthio and the like, especially preferred is methylthio, ethylthio and propylthio. Examples of cyclic alkylthio are cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio and the like, especially preferred is cyclopentylthio.
The term "d-e-alkylamino" as used herein, alone or in combination, refers to a straight or branched or cyclic monovalent substituent comprising a C1-6-alkyl group linked through amino having a free valence bond from the nitrogen atom e.g. methylamino, ethylamino, propylamino, butylamino, pentylamino and the like. Examples of cyclic alkylamino are cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino and the like.
The term "arylamino" as used herein, alone or in combination, refers to an aryl as defined herein linked through amino having a free valence bond from the nitrogen atom e.g. phenylamino, naphthylamino and the like.
The term "C1-6-alkoxyCι-6-alkyl" as used herein, alone or in combination, refers to a C1-6-alkyl as defined herein whereto is attached a C1-6-alkoxy as defined herein, e.g. methoxy methyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like.
The term "aryl" is intended to include a bicyclic aromatic ring, such as carbocyclic aromatic rings selected from the group consisting of phenyl and naphthyl, (1-naphthyl or 2-naphthyl), optionally substituted with halogen, amino, hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy or C1-6-alkylester and the like, especially preferred is halogen.
The term "arylene" is intended to include divalent aromatic rings, such as carbocyclic aromatic rings selected from the group consisting of phenylene, naphthylene and the like optionally substituted with halogen, amino, hydroxy, C^-alkyl, C1-6-alkoxy, carboxy or C1-6-alkylester and the like.
The term "halogen" means fluorine, chlorine, bromine or iodine, especially preferred is fluorine and chlorine.
The term "perhalomethyl" means trifluoromethyl, trichloromethyl, tribromomethyl or triiodomethyl, especially preferred is trifluoromethyl. The term "C1-6-dialkylamino" as used herein refers to an amino group wherein the two hydrogen atoms independently are substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms; such as dimethylamino, N- ethyl-N-methylamino, diethylamino, dipropylamino, N-(n-butyl)-N-methylamino, di(n- pentyl)amino and the like.
The term "acyl" as used herein refers to a monovalent substituent comprising a C1-6-alkyl group linked through a carbonyl group; such as e.g. acetyl, propionyl, butyryl, isobutyryl, pivaloyl, valeryl and the like, especially preferred is acetyl.
The term "heteroaryl" as used herein, alone or in combination, refers to a monovalent substituent comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g. furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine and the like, preferred is furan, thiophene, pyrrole, imidazole, pyrazole, pyridine, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole, benzofuran, especially preferred is furan, pyrrole, indole and benzofuran.
The term "heteroarylene" as used herein, alone or in combination, refers to a divalent group comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g. furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine and the like, especially preferred is furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine.
The term "heteroaryloxy" as used herein, alone or in combination, refers to a heteroaryl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom e.g. pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine linked to oxygen, and the like.
The term "aralkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic carbohydride; such as benzyl, phenethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-(1-naphthyl)ethyl and the like, especially preferred is benzyl and phenethyl.
The term "aryloxy" as used herein refers to phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like, especially preferred is phenoxy.
The term "aralkoxy" as used herein refers to a C1-6-aIkoxy group substituted with an aromatic carbohydride, such as benzyloxy, phenethoxy, 3-phenylpropoxy, 1-naphthylmethoxy, 2-(1- naphthyl)ethoxy and the like, especially preferred is benzyloxy.
The term "heteroaralkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with a heteroaryl group; such as (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl- 1-(2-pyrimidyl)ethyl and the like.
The term "heteroaralkoxy" as used herein refers to a heteroaralkyl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom, e.g. (2-furyl)methyl, (3- furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyI-1-(2- pyrimidyl)ethyl linked to oxygen, and the like.
The term "arylthio" as used herein, alone or in combination, refers to an aryl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom, the aryl group optionally being mono- or polysubstituted with C1-6-alkyl, halogen, hydroxy or C^-alkoxy; e.g. phenylthio, (4-methylphenyl)-thio, (2-chlorophenyl)thio and the like.
As used herein, the phrase "heterocyclyl" means a monovalent saturated or unsaturated non aromatic group being monocyclic and containing one or more, such as from one to four carbon atom(s), and from one to four N, O or S atom(s) or a combination thereof. The phrase "heterocyclyl" includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. pyrrolidine, pyrroline and the like); 5-membered heterocycles having two heteroatoms in 1,2 or 1,3 positions (e.g. pyrazoline, pyrazolidine, 1 ,2-oxathiolane, imidazolidine, imi- dazoline, 4-oxazolone and the like); 5-membered heterocycles having three heteroatoms (e.g. tetrahydrofurazan and the like); 5-membered heterocycles having four heteroatoms; 6- membered heterocycles with one heteroatom (e.g. piperidine and the like); 6-membered heterocycles with two heteroatoms (e.g. piperazine, morpholine and the like); 6-membered heterocycles with three heteroatoms; and 6-membered heterocycles with four heteroatoms, and the like.
As used herein, the phrase "a divalent heterocyclic group" means a divalent saturated or unsaturated system being monocyclic and containing one or more, such as from one to four carbon atom(s), and one to four N, O or S atom(s) or a combination thereof. The phrase a divalent heterocyclic group includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. pyrrolidine, pyrroline and the like); 5-membered heterocycles having two heteroatoms in 1 ,2 or 1,3 positions (e.g. pyrazoline, pyrazolidine, 1 ,2-oxathiolane, imidazolidine, imidazoline, 4-oxazolone and the like); 5-membered heterocycles having three heteroatoms (e.g. tetrahydrofurazan and the like); 5-membered heterocycles having four heteroatoms; 6-membered heterocycles with one heteroatom (e.g. piperidine and the like); 6- membered heterocycles with two heteroatoms (e.g. piperazine, morpholine and the like); 6- membered heterocycles with three heteroatoms; and 6-membered heterocycles with four heteroatoms, and the like.
As used herein the term "treatment" includes treatment, prevention and management of such condition.
Certain of the above defined terms may occur more than once in the above formula (I), and upon such occurrence each term shall be defined independently of the other.
The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hy- drobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative exam- pies of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaphtho- ates, glycerophosphates, ketoglutarates and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Exam- pies of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, di- methylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethyl- ammonium, butylammonium, tetramethylammonium salts and the like. Examples of organic bases include lysine, arginine, guanidine, diethanolamine, choline and the like.
The pharmaceutically acceptable salts are prepared by reacting the compound of formula I with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of sol- vents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guandine and their derivatives etc. may also be used. Alternatively, acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, DimmerDeD acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, pal- mitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.
The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, enzymatic resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lac- tic acid, and the like wherever applicable or chiral bases such as brucine, (R)- or (S)- phenylethylamine, cinchona alkaloids and their derivatives and the like. Commonly used methods are compiled by Jaques et al in "Enantiomers, Racemates and Resolution" (Wiley Interscience, 1981). More specifically the compound of formula I may be converted to a 1 :1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the dia-stereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula I may be prepared by hydro- lysing the pure diastereomeric amide.
Various polymorphs of compound of general formula I forming part of this invention may be prepared by crystallization of compound of formula I under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cool- ing during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
The invention also encompasses active metabolites of the present compounds.
Furthermore, the present compounds of formula I can be utilised in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Prolifera- tor-Activated Receptors (PPAR). In a further aspect, the present invention relates to a method of treating and/or preventing Type I or Type II diabetes.
In a still further aspect, the present invention relates to the use of one or more compounds of the general formula I or pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment and/or prevention of Type I or Type II diabetes.
In a still further aspect, the present compounds are useful for the treatment and/or prevention of IGT.
In a still further aspect, the present compounds are useful for the treatment and/or prevention of Type 2 diabetes.
In a still further aspect, the present compounds are useful for the delaying or prevention of the progression from IGT to Type 2 diabetes.
In a still further aspect, the present compounds are useful for the delaying or prevention of the progression from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes.
In another aspect, the present compounds reduce blood glucose and triglyceride levels and are accordingly useful for the treatment and/or prevention of ailments and disorders such as diabetes and/or obesity.
In still another aspect, the present compounds are useful for the treatment and/or prophylaxis of insulin resistance (Type 2 diabetes), impaired glucose tolerance, dyslipidemia, disorders related to Syndrome X such as hypertension, obesity, insulin resistance, hyperglycaemia, atherosclerosis, hyperlipidemia, coronary artery disease, myocardial ischemia and other cardiovascular disorders.
In still another aspect, the present compounds are effective in decreasing apoptosis in mammalian cells such as beta cells of Islets of Langerhans. In still another aspect, the present compounds are useful for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis.
In still another aspect, the present compounds may also be useful for improving cognitive functions in dementia, treating diabetic complications, psoriasis, polycystic ovarian syndrome (PCOS) and prevention and treatment of bone loss, e.g. osteoporosis.
The invention also relates to pharmaceutical compositions comprising, as an active ingredi- ent, at least one compound of the formula I or any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or diluents.
Furthermore, the invention relates to the use of compounds of the general formula I or their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof for the preparation of a pharmaceutical composition for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR) such as the conditions mentioned above.
The present invention also relates to a process for the preparation of the above said novel compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates.
The method comprises: a)
Reacting a compound of formula II
Figure imgf000039_0001
(II) wherein A, X-i, X2 and Y are defined as above, through a Wittig process with e.g. (EtO)2PO(CHZ)(CH2)tCOOR6 (wherein R6 is an alkyl group), in the presence of a base such as sodium hydride, EtONa and the like to give a compound of formula III.
Figure imgf000040_0001
(III)
wherein A, Xι, X2, Y, Z and R6 are defined as above, and wherein t is 0-2, and
b) reducing a compound of formula III, wherein A, X^ X2, Y, Z, R6 and t are defined as above with a suitable reagent such a diisobutylaluminum hydride, to give a compound of formula IV.
Figure imgf000040_0002
(IV) wherein A, X^ X2, Y, Z and t are defined as above, and
c) reacting a compound of IV, wherein A, X^ X2, Y, Z and t are defined as above, with a compound of formula V
Figure imgf000041_0001
(V)
wherein Q, Ar, R^ R2, R3, R* and m are defined as above, under Mitsunobu conditions, using a reagent such as triphenylphosphine/diethylazodicarboxylate and the like to obtain a compound of formula I, wherein A, X^ X2, Y, Z, Q, Ar, R1? R2, R3, R4, n and m are defined as above, except that R4 is not H, n and m are not 0, and
d)
converting the -OH functionality in a compound of formula IV wherein A, X^ X2, Y, Z and t are defined as above to an appropriate leaving group (L) such as p-toluenesulfonate, methane- sulfonate, halogen (in examples by methods according to: Houben-Weyl, Methoden der or- ganischen Chemie, Alkohole III, 6/1 b, Thieme Verlag 1984, 4th Ed., pp. 927-939; Comprehensive Organic Transformations. A guide to functional group preparations, VCH Publishers 1989, 1st Ed., pp. 353-363), triflate and the like, to give a compound of formula VI
Figure imgf000042_0001
(VI)
e)
reacting a compound of formula VI
Figure imgf000042_0002
(VI)
wherein L is a leaving group such as p-toluenesulfonate, methanesulfonate, halogen , triflate and the like and wherein A, X^ X2, Y, Z and t are defined as above with a compound of formula V
Figure imgf000042_0003
(V)
wherein Q, Ar, R1 ; R2, R3, R and m are defined as above, to give a compound of formula I wherein A, X^ X2, Y, Z, Q, Ar, R^ R2, Rs, R , n and m are defined as above except that R4 is not H, n and m are not 0, or
e) reacting a compound of formula VII
Figure imgf000043_0001
(VII)
wherein A, X^ and X2 are defined as above, through a Friedel-Crafts acylation with in example CIOCCHZ(CH2)nR7 (wherein n and Z is defined as above and R7 are halogen or OH), in the presence of a Friedel-Crafts catalysts such as aluminium trichloride and the like, to give a compound of formula VIII
Figure imgf000043_0002
(VIII) wherein A, X^ X2, Z, R7 and n are defined as above, and
f) reacting a compound of formula VIII, wherein A, X^ X2, Z and R7 are defined as above with a Grignard reagents such a MgBrY or a lithium reagent such as LiY or organozinc reagent such as ZnY, wherein Y is defined as above, followed by a acidic workup to give a compound of formula IX
Figure imgf000044_0001
(IX)
wherein A, Xi, X2, Z, Y, R7 and n are defined as above, and
9) reacting a compound of IX, wherein A, X-i, X2, Z, Y, R7 and n are defined as above, with a compound of formula V
Figure imgf000044_0002
(V) wherein Q, Ar, Ri, R2, Rs, R and m are defined as above except that m is not 0, under either basic condition e.g. potassium carbonate/acetone (if R7 is halogen) or Mitsunobu conditions ( if R7 is OH) using a reagent such as triphenylphosphine/diethylazodicarboxylate and the like to obtain a compound of formula I, wherein A, X-i, X2, Y, Z, Q, Ar, R^ R2, R3, R4, n and m are defined as above, except that R is not H, n and m arenot 0, or
h)
by chemical or enzymatic saponification of a compound of formula I
Figure imgf000045_0001
(I)
wherein A, Xi, X2, Y, Z, Q, Ar, R^ R2, R3, R4, n and m are defined as above, except that R is not H, to obtain a compound of formula I, wherein A, X1? X2, Y, Z, Q, Ar, Ri, R2, Rs, R^ n and m are defined as above, except that R4 is H.
i)
Trans-cis or cis-trans isomerization of compounds I, III, IV, VI, and IX (Arai et al., Chem. Rev., 93, pp 23-39, 1993; J. March, Advanced Organic Chemistry, 4th Ed., J. Wiley & Sons, New York 1992, pp. 218, 245, 745).
PHARMACOLOGICAL METHODS In vitro PPAR alpha and PPAR gamma activation activity.
Principle
The PPAR gene transcription activation assays were based on transient transfection into human HEK293 cells of two plasmids encoding a chimeric test protein and a reporter protein respectively. The chimeric test protein was a fusion of the DNA binding domain (DBD) from the yeast GAL4 transcription factor to the ligand binding domain (LBD) of the human PPAR proteins. The PPAR LBD harbored in addition to the ligand binding pocket also the native activation domain (activating function 2 = AF2) allowing the fusion protein to function as a PPAR ligand dependent transcription factor. The GAL4 DBD will force the fusion protein to bind only to Gal4 enhancers (of which none existed in HEK293 cells). The reporter plasmid contained a Gal4 enhancer driving the expression of the firefly luciferase protein. After trans- fection, HEK293 cells expressed the GAL4-DBD-PPAR-LBD fusion protein. The fusion protein will in turn bind to the Gal4 enhancer controlling the luciferase expression, and do nothing in the absence of ligand. Upon addition to the cells of a PPAR ligand, luciferase protein will be produced in amounts corresponding to the activation of the PPAR protein. The amount of luciferase protein is measured by light emission after addition of the appropriate substrate.
Methods
In vitro transactivation assays.
Cell culture and transfection: HEK293 cells were grown in DMEM + 10% FCS. Cells were seeded in 96-well plates the day before transfection to give a confluency of 50-80 % at transfection. A total of 0,8 μg DNA containing 0,64 μg pM1α/γLBD, 0,1 μg pCMVβGal, 0,08 μg pGL2Gal4DBD and 0,02 μg pADVANTAGE was transfected per well using FuGene transfection reagent according to the manufacturers instructions (Roche). Cells were allowed to express protein for 48 h followed by addition of compound. Plasmids: Human PPAR α and γ was obtained by PCR amplification using cDNA synthesized by reverse transcription of mRNA from liver and adipose tissue respectively. Amplified cDNAs were cloned into pCR2.1 and sequenced. The ligand binding domain (LBD) of each PPAR isoform was generated by PCR (PPARα: aa 167 - C-terminus; PPARγ: aa 165 - C- terminus) and fused to the DNA binding domain (DBD) of the yeast transcription factor GAL4 by subcloning fragments in frame into the vector pM1 generating the plasmids pMlαLBD and pMlγLBD. Ensuing fusions were verified by sequencing. The reporter was constructed by inserting an oligonucleotide encoding five repeats of the GAL4 recognition sequence (5 x CGGAGTACTGTCCTCCG(AG)) into the vector pGL2 promotor (Promega) generating the plasmid pGL2(GAL4)5. pCMVβGal was purchased from Clontech and pADVANTAGE was purchased from Promega.
Luciferase assay: Medium including test compound was aspirated and 100 μl PBS incl. 1mM Mg++ and Ca++ was added to each well. The luciferase assay was performed using the Lu- cLite kit according to the manufacturers instructions (Packard Instruments). Light emission was quantified by counting SPC mode on a Packard Instruments top-counter. To measure β- galactosidase activity 25 μl supernatant from each transfection lysate was transferred to a new microplate. β-galactosidase assays were performed in the microwell plates, using a kit from Promega and read in a microplate reader. The β-galactosidase data were used to nor- malize (transfection efficiency, cell growth etc.) the luciferase data.
Compounds: All compounds were dissolved in DMSO and diluted 1 :1000 upon addition to the cells. Compounds were tested in quadruple in five concentrations ranging form 0.01 to 30 μM. Cells were treated with compound for 24 h followed by luciferase assay. Each compound was tested in three separate experiments. EC50 values were calculated via non-linear regression using GraphPad PRISM 3.02 (GraphPad Software, San Diego, CA).The results were expressed as means. Table 1. In vitro PPAR alpha and PPAR gamma activation of examples according to the present invention.
In vitro activation
PPAR α PPAR γ
Example no EC-50, μM % max3 EC50, μM % max0
4 3.1 212 0.72 156
9 0.038 234 0.35 125
27 0.10 185 0.11 99
57 0.38 178 0.70 110
124 0.35 102 0.30 83
134 2.90 122 0.89 155
Compounds were tested in at least three separate experiments in five concentrations ranging from 0.01 to 30 μM. EC50's were not calculated for compounds producing transactivation lower than 25% at 30 μM. aFold activation relative to maximum activation obtained with Wy14643 (approx. 20 fold corresponded to 100%) and with Drosiglitazone (approx. 120 fold corresponded to 100%).
PHARMACEUTICAL COMPOSITIONS
In another aspect, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
The present compounds may also be administered in combination with one or more further pharmacologically active substances eg., selected from antiobesity agents, antidiabetics, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity. Thus, in a further aspect of the invention the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents.
Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, uro- cortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, RXR (retinoid X receptor) modulators or TR β agonists.
In one embodiment of the invention the antiobesity agent is leptin.
In another embodiment the antiobesity agent is dexamphetamine or amphetamine.
In another embodiment the antiobesity agent is fenfluramine or dexfenfluramine.
In still another embodiment the antiobesity agent is sibutramine.
In a further embodiment the antiobesity agent is orlistat.
In another embodiment the antiobesity agent is mazindol or phentermine.
Suitable antidiabetics comprise insulin, GLP-1 (glucagons like peptide-1) derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents. The orally active hypoglycaemic agents preferably comprise sulphonylureas, biguanides, meglitinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc., GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as HMG CoA inhibitors (statins), compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potas- sium channel of the β-cells.
In one embodiment of the invention the present compounds are administered in combination with insulin.
In a further embodiment the present compounds are administered in combination with a sul- phonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide.
In another embodiment the present compounds are administered in combination with a bi- guanide eg. metformin.
In yet another embodiment the present compounds are administered in combination with a meglitinide eg. repaglinide or senaglinide.
In a further embodiment the present compounds are administered in combination with an α-glucosidase inhibitor eg. miglitol or acarbose.
In another embodiment the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the β-cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
Furthermore, the present compounds may be administered in combination with nateglinide. In still another embodiment the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
In a further embodiment the present compounds are administered in combination with more than one of the above-mentioned compounds eg. In combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
Furthermore, the present compounds may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are β-blockers such as alpre- nolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, ni- modipine, diltiazem and verapamil, and α-blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
It should be understood that any suitable combination of the compounds according to the in- vention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.
Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 19th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
Typical compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl dtstearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The pharmaceutical compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring sub- stances and the like, which do not deleteriously react with the active compounds.
The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, trarisdermal orparenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, in- tranasal,. ophthalmic solution or an ointment, the oral route being preferred.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
For nasal administration, the preparation may contain a compound of formula I dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or cap- sules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
A typical tablet which may be prepared by conventional tabletting techniques may contain:
Core:
Active compound (as free compound or salt thereof) 5 mg
Colloidal silicon dioxide (Aerosil) 1.5 mg
Cellulose, microcryst. (Avicel) 70 mg
Modified cellulose gum (Ac-Di-Sol) 7.5 mg Magnesium stearate Ad.
Coating:
HPMC approx. 9 mg
*Mywacett 9-40 T approx. 0.9 mg
*Acylated monoglyceride used as plasticizer for film coating.
The compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of diseases related to the regulation of blood sugar.
Such mammals include also animals, both domestic animals, e.g. household pets, and non- domestic animals such as wildlife. The compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 100 mg, preferably from about 0.1 to about 100 mg, per day may be used. A most preferable dosage is about 0.1 mg to about 70 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a dosage of from about 2 to about 70 mg per day and when the condition is under control to reduce the dosage as low as from about 0.1 to about 10 mg per day. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
Generally, the compounds of the present invention are dispensed in unit dosage form comprising from about 0.1 to about 100 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
Usually, dosage forms suitable for oral, nasal, pulmonary or transdermal administration comprise from about 0.001 mg to about 100 mg, preferably from about 0.01 mg to about 50 mg of the compounds of formula I admixed with a pharmaceutically acceptable carrier or diluent.
Any novel feature or combination of features described herein is considered essential to this invention.
EXAMPLES
The process for preparing compounds of formula I, and preparations containing them, is further illustrated in the following examples, which however, are not to be construed as limiting.
The structures of the compounds are confirmed by either elemental analysis (MA) nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR shifts (δ) are given in parts per million (ppm) and only selected peaks are given. Mp is melting point and is given in °C. Col- umn chromatography was carried out using the technique described by W.C. Still et al, J. Org. Chem. 1978, 43, 2923-2925 on Merck silica gel 60 (Art 9385). Compounds used as starting materials are either known compounds or compounds which can readily be prepared by methods known per se. Abbrevations:
THF: tetrahydrofuran
DIBAL-H: diisobutylaluminum hydride
Na2SO4: sodium sulfate
MgSO4: magnesium sulfate
DMSO: dimethylsulfoxide
CDCI3: deuterated chloroform
DMF: N.N-dimethylformamide
HCl: hydrochloric acid
DME: 1 ,2-dimethoxyethane min: minutes h: hours
EXAMPLE 1
Figure imgf000055_0001
(£)-(S)-Ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-ethoxy-propionate
a)
Sodium (1.75 g, 73.4 mmol) was added to ethanol (45 ml) at 20°C and the mixture stirred until the metal had fully reacted. Triethyl phosphonoacetate (14.69 g, 73.4 mmol) was added, the mixture stirred for 5 min., then 4-acetylbiphenyl (12.00 g, 61.1 mmol) was added to the stirred solution. The mixture was stirred at room temperature for 24h, the resulting suspension filtered, and the filter-cake collected and recrystallised from ethanol to give (E)-3- biphenyl-4-yl-but-2-enoic acid ethyl ester as white crystals; 5.73 g (36%) 1H NMR (300 MHz, CDCI3) δ: 1.32 (3H, t), 2.62 (3H, d), 4.21 (2H, q), 6.2 (1H, d), 7.31-7.65 (9H, m). MS: 267 (M+), 266(100%), 221 , 194, 178. Microanalysis Calculated % C: 81.00, H: 7.0. Found C: 80.86, H: 6.90. b)
A 1 M solution of DIBAL-H in toluene (40 ml, 40 mmol) was added dropwise at -70°C over 20 min. to a stirred solution of 3-biphenyI-4-yl-but-2-enoic acid ethyl ester (2.66 g, 10.0 mmol) in dry THF (100 ml) and the mixture stirred for 30 min. Methanol (2 ml) was added, followed by saturated aqueous Rochelle's salt (100 ml), and the resulting mixture extracted with ethyl acetate (200 ml), separated and the organic phase washed with brine, dried (Na2SO4), evaporated and dried in vacuo yielding (£)-3-biphenyl-4-yl-but-2-en-1-ol as colorless crystals: 1.94 g (86%)
1H NMR (300 MHz, CDCI3) δ: 1.40 (1H, br s), 2.12 (3H, d), 4.45 (2H, dd), 6.05 (1 H, dt), 7.35- 7.7 (9H, m). MS: 225 (M+), 224(100%), 209, 181 ,165.
Microanalysis Calculated % C: 86.00, H: 7.00. Found C: 85.67, H: 7.29
c)
Diethyl azodicarboxylate (0.346 ml, 2.2 mmol) was added at 0°C to a stirred solution of triphenyl- phosphine (0.656 g, 2.2 mmol) and (£J-3-biphenyl-4-yl-but-2-en-1-ol (0.270 g, 1.2 mmol) in dry THF (20 ml) and the mixture stirred for 5 min. A solution of (S -ethyl 2-ethoxy-3- (4-hydroxy-phenyl)-propionate (0.238 g, 1.0 mmol) in dry THF (10 ml) was added, the mixture allowed to warm to room temperature, and stirring continued for 48 h. The resulting mixture was evaporated in vacuo and the residue purified by column chromatography on silica gel (20% ethyl acetate in n-heptane) to give (£)-(S)-ethyl 3-[4-(3-biphenyl-4-yl-but-2- enyloxy)-phenyl]-2-ethoxy-propionate as an oil; 0.288 g (65%).
1H NMR (300 MHz, CDCI3) δ: 1.13-1.25 (6H, m), 2.13 (3H, d), 2.94 (2H, d), 3.29-3.37 (1 H, m), 3.54-3.61 (1 H, m), 3.97 (1 H, t), 4.1 (2H, q), 4.70 (2H, d), 6.11 (1 H, dt), 6.86 (2H, d), 7.16 (2H, d), 7.25-7.63 (9H, m).
EXAMPLE 2
Figure imgf000056_0001
(£)-(S)-3-[4-(3-BiphenyI-4-yl-but-2-enyloxy)-phenyl]-2-ethoxy-propionic acid Sodium hydroxide (1 M, 0.45 ml, 0.45 mmol) was added to a solution of (£)-(S)-ethyl 3-[4-(3- biphenyl-4-yl-but-2-enyloxy)-phenyI]-2-ethoxy-propionate (example 1) (0.100 g, 0.225 mmol) in ethanol (20 ml) and the mixture stirred at 70°C for 2.5 h. After cooling to room temperature the resulting mixture was partitioned between water (50 ml) and ethyl acetate and the aqueous phase collected. The aqueous phase was acidified with 1N hydrochloric acid (5 ml) and extracted with ethyl acetate (100 ml), and the organic phase collected, washed with brine, dried (Na2SO4) and evaporated to give (£J-(S)-3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyl]-2- ethoxy-propionic acid as a white solid; 0.014 g (15%). 1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 2.63 (3H, d), 2.93 (1 H, dd), 3.1 (1H, dd), 3.4-3.65 (2H, m), 4.1 (2H, q), 4.72 (2H, d), 6.1 (1H, dt), 6.9 (2H, d), 7.2 (2H, d), 7.35-7.60 (9H, m).
EXAMPLE 3
Figure imgf000057_0001
(E)-(S)-3-{4-[3-(4'-Bromo-biphenyl-4-yI)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
a)
(£)-3-(4'-Bromo-biphenyl-4-yl)-but-2-enoic acid ethyl ester was prepared from 4-(4- bromophenyl)acetophenone (12.0 g, 0.044 mol), sodium (1.25 g, 0.052 mol) and triethyl phosphonoacetate (11.73 g, 0.052 mol) by a procedure analogous to that described in ex- ample 1a yielding 11.97 g (80%).
1H NMR (300 MHz, CDCI3) δ: 1.32 (3H, t), 2.61 (3H, d), 4.23 (2H, q), 6.19 (1 H, d), 7.40-7.58 (8H, m).
b) (£)-3-(4'-bromo-biphenyl-4-yI)-but-2-en-1-ol was prepared from (£)-3-(4'-bromo-biphenyl-4- yl)-but-2-enoic acid ethyl ester (3.45 g, 10.0 mmol) and DIBAL-H (1M in toluene, 40 ml, 40 mmol) by a procedure analogous to that described in example 1 b, yielding 1.68 g (55%). 1H NMR (300MHz, CDCI3) δ: 2.14 (3H, d), 4.4 (2H, t), 6.05 (1H, dt), 7.45-7.55 (8H, m), 5 c)
The title compound was prepared from (£)-3-(4'-bromo-biphenyl-4-yl)-but-2-en-1-ol (0.364 g, 1.2 mmol), triphenylphosphine (0.328 g, 1.3 mmol), diethyl azodicarboxylate (0.173 ml, 1.1 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxy-phenyl)-propionate (0.238 g, 1.0 mmol) by a pro- 0 cedure analogous to that described in example 1c, yielding 0.180 g (34%) of (£)-(S)-3-{4-[3- (4'-bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester. 1H NMR (300 MHz, CDCI3) δ: 1.15-1.25 (6H, m), 2.15 (3H, d), 2.95 (2H, d) 3.29-3.4 (1 H, m), 3.5-3.65 (1 H, m), 3.96 (1H, t), 4.15 (2H, q), 4.75 (2H, dd), 6.11 (1 H, dt), 6.85 (2H, d), 7.14 (2H, d), 7.4-7.55 (8H, m). 5
EXAMPLE 4
Figure imgf000058_0001
0 N (£ (S)-3-{4-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£J-(S)-3-{4-[3-(4'-bromo-biphenyl-4-yl)-but-2- enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 3) (0.150 g, 0.29 mmol) and 5 sodium hydroxide (1 M, 0.45 ml, 0.45 mmol) by a procedure analogous to that described in example 2 yielding 0.180 g (34%) of (£)-(S)-3-{4-[3-(4'-bromo-biphenyl-4-yl)-but-2-enyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester.
1H NMR (300 MHz, CDCI3) δ: 1.14 (3H, t), 2.13 (3H, d), 2.86-3.10 (2H, m), 3.37-3.45 (1 H, m), 3.55-3.65 (1 H, m), 4.05 (2H, q), 4.70 (2H, dd), 6.12 (1H, dt), 6.9 (2H, d), 7.18 (2H, d), 7.4- 0 7.60 (8H, m). EXAMPLE 5
Figure imgf000059_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester
The title compound was prepared from 4-phenoxyacetophenone (12.0 g, 0.056 mol) by a sequence analogous to that described in example 3, yielding 0.190 g (41%) of (£ -(S)-2-ethoxy- 3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester.
1H NMR (300 MHz, CDCI3) δ: 1.2 (6H, m), 2.12 (3H, s), 2.97 (2H, d), 3.30-3.42 (1H, m), 3.59- 3.70 (1 H, m), 3.98 (1 H, t), 4.15 (2H, q), 4.73 (2H, dd), 6.05 (1 H, dt), 6.85-7.45 (13H, m).
EXAMPLE 6
Figure imgf000059_0002
(£J-(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl}-propionic acid
The title compound was prepared from (£)-(S)-2-ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2- enyloxy]-phenyl}-propionic acid ethyl ester (example 5) (0.170 g, 0.37 mmol) and sodium hydroxide (1 M, 0.74 ml, 0.74 mmol) by a procedure analogous to that described in example 2 yielding 0.136 g (85%) of (£ (S)-2-ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]- phenyl}-propionic acid.
1H NMR (300 MHz, CDCI3) δ: 1.14 (3H, t), 2.13 (3H, d), 2.86-3.10 (2H, m), 3.38-3.45 (1 H, m), 3.55-3.65(1H, m), 4.05 (2H, q), 4.70 (2H, dd), 6.12 (1H, dt), 6.9 (2H, d), 7.18 (2H, d), 7.4- 7.60 (8H, m). EXAMPLE 7
Figure imgf000060_0001
(£)-(S)-2-Ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy}-phenyl)-propionic acid ethyl ester
The title compound was prepared from 4-(4-methoxyphenoxy)acetophenone (2.63 g, 0.01.1 mol) by a sequence analogous to that described in example 3 yielding 0.200 g (41%) of (£)- (S)-2-ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy}-phenyl)-propionic acid ethyl ester.
1H NMR (300 MHz, CDCI3) δ: 1.15-1.23 (6H, m), 2.12 (3H, s), 2.97 (2H, d), 3.30-3.40 (1 H, m), 3.57-3.65 (1H, m), 3.80 (3H, s), 3.98 (1H, t), 4.18 (2H, q), 4.63 (2H, dd), 5.97-6.05 (1H, m), 6.85-6.96 (8H, m), 7.15 (2H, d), 7.35 (2H, d). MS 490 (M+), 417, 359 (100%), 269.
EXAMPLE 8
Figure imgf000060_0002
(£)-(S -2-Ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy}-phenyl)-propionic acid The title compound was prepared from (£)-(S)-2-ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)- phenyl]-but-2-enyloxy}-phenyI)-propionic acid ethyl ester (example 7) (0.176 g, 0.36 mmol) and sodium hydroxide (1 M, 0.74 ml, 0.74 mmol) by a procedure analogous to that described in example 2 yielding 0.140 g (84%) of (£ -(S)-2-ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)- phenyl]-but-2-enyloxy}-phenyl)-propionic acid.
1H NMR (300 MHz, CDCI3) δ: 1.15 (3H, t), 2.1 (3H, s), 2.9-3.1 (2H, m), 3.36-3.43 (1 H, m), 3.55-3.64 (1H, m), 3.78 (3H, s), 4.00 (1H, dd), 4.70 (2H, dd), 6.0 (1 H, dt), 6.8-6.9 (8H, m), 7.19 (2H, d), 7.35 (2H, d). MS 462 (M+)(100%), 436, 359, 252.
EXAMPLE 9
Figure imgf000061_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester
The title compound was prepared from 2-acetylfluorene (12.0 g, 0.058 mmol) by a sequence analogous to that described in example 3 yielding 0.200 g (41 %) of (£)-(S)-2-ethoxy-3-{4-[3-
(9H-fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester.
1H NMR (300 MHz, CDCI3) δ: 1.16-1.22 (6H, m), 2.2 (3H, s), 2.96 (2H, d), 3.30-3.40 (1H, m),
3.51-3.65 (1H, m), 3.9 (2H, s), 3.98 (1 H, t), 4.15 (2H, q), 4.75 (2H, d), 6.04-6.13 (1H, m), 6.88
(2H, d), 7.17 (2H, d), 7.3-7.8 (7H, m). MS 456 (M+), 410, 325 (100%), 238.
Microanalysis Calculated % C: 78.92, H: 7.06. Found C: 78.72, H: 7.30. EXAMPLE 10
Figure imgf000062_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid
The title compound was prepared from (£ -(S)-2-ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2- enyloxy]-phenyl}-propionic acid ethyl ester (example 9) (0.230 g, 0.504 mol) and sodium hydroxide (1 M, 1.008 ml, 1.008 mmol) by a procedure analogous to that described in example 2 yielding 0.140 g (84%) of (£)-(S)-2-ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2-enyloxy]-phenyl}- propionic acid.
1H NMR (300 MHz, CDCI3) δ: 1.20 (3H, t), 2.18 (3H, s), 2.9-3.15 (2H, m), 3.4-3.6 (2H, m), 3.87 (2H, s), 4.05 (1H, dd), 4.75 (2H, d), 6.11 (1H, dt), 6.88 (2H, d), 7.17 (2H, d), 7.3-7.8 (7H, m).
EXAMPLE 11
Figure imgf000062_0002
(£)-(S)-3-{4-[3-(3,4-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 3,4-dimethoxyacetophenone (10.00 g, 0.055 mol) by a sequence analogous to that described in example 3 yielding 0.160 g (31%) of (£)-(S)-3-{4- [3-(3,4-dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester. 1H NMR (300 MHz, CDCI3) δ: 1.1-1.19 (6H, m), 2.17 (3H, s), 2.98 (2H, d), 3.37-3.45 (1H, m), 3.58-3.65 (1H, m), 3.9 (6H, ds), 4.02 (1H, t), 4.15 (2H, q), 4.7 (2H, d), 6.0 (1H, dt), 6.81-6.86 (3H, m), 7.0 (2H, d), 7.15 (2H, d). MS 428 (M+), 382, 355,297 (100%), 207.
EXAMPLE 12
Figure imgf000063_0001
(£)-(S)-3-{4-[3-(3,4-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-{4-[3-(3,4-dimethoxy-phenyl)-but-2-enyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester (example 11) (0.150 g, 0.350 mmol) and sodium hydroxide (1M, 1.05 ml, 1.05 mmol) by a procedure analogous to that described in example 2 yielding 0.120 g (86%) of (£)-(S)-3-{4-[3-(3,4-dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2- ethoxy-propionic acid. 1H NMR (300 MHz, CDCI3) δ: 1.15 (3H, t), 2.15 (3H, s), 2.9-3.15 (2H, m), 3.40-3.48 (1H, m), 3.56-3.63 (1H, m), 3.9 (6H, ds), 4.08 (1H, dd), 4.75 (2H, d), 6.01 (1 H, dt), 6.80-6.91 (3H, m), 7.0 (2H, d), 7.15 (2H, d). EXAMPLE 13
Figure imgf000064_0001
(£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 3,5-bis(trifluoromethyl)acetophenone (5.12 g, 0.02 mol) by a sequence analogous to that described in example 3 yielding 0.370 g (73%) of (£)- (S)-3-{4-[3-(3,5-bis-trifluoromethyl-phenyI)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester. 1H NMR (300 MHz, CDCI3) δ: 1.1-1.25 (6H, m), 2.20 (3H, s), 2.97 (2H, d), 3.3-3.4 (1H, m), 3.62-3.7 (1 H, m), 4.0 (1 H, t), 4.15 (2H, q), 4.75 (2H, d), 6.2 (1 H, dt), 6.85 (2H, d), 7.2 (2H, d), 7.78 (1H, br s), 7.87 ( 2H, br s). MS 504 (M+), 458, 431(100%), 373 , 267, 192
EXAMPLE 14
Figure imgf000064_0002
(£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-but-2-enyloxy]-phenyI}-2-ethoxy-propionic acid The title compound was prepared from (£)-(S)-3-{4-[3-(3,5-bis-trifluoromethyl-phenyl)-but-2- enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 13) (0.200 g, 0.396 mmol) and sodium hydroxide (1M, 0.792 ml, 0.792 mmol) by a procedure analogous to that described in example 2 yielding 0.150 g (79%) of (£)-(S)-3-{4-[3-(3,5-bis-trifluoromethyl-phenyl)-but-2- enyloxy]-phenyl}-2-ethoxy-propionic acid.
1H NMR (300 MHz, CDCI3) δ: 1.12 (3H, t), 2.18 (3H, s), 2.9 (1H, dd), 3.1 (1H, dd), 3.34-3.42 (1H, m), 3.5-3.65 (1H, m), 4.0 (1H, dd), 4.7 (2H, d), 6.11 (1H, dt), 6.83 (2H, d), 7.19 (2H, d) 7.72 (1H, br s), 7.83 (2H, br s).
EXAMPLE 15
Figure imgf000065_0001
(£J-(S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 3-biphenyl-4-yl-acrylic acid ethyl ester (2.5 g, 0.01 mol) by a sequence analogous to that described in example 3b-c yielding 0.370 g (73%) of
(£)-(S)-3-[4-(3-biphenyl-4-yl-aIlyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester.
1H NMR (200 MHz, CDCI3) δ: 1.1-1.25 (6H, m), 2.97 (2H, d), 3.3-3.4 (1H, m), 3.52-3.7 (1H, m), 4.0 (1H, t), 4.15 (2H, q), 4.75 (2H, dd), 6.35-6.5 (1H, dt), 6.75 (1H, d), 6.87 (2H, d), 7.15
(2H, d), 7.4-7.65 (9H, m). EXAMPLE 16
Figure imgf000066_0001
(£)-(S)-3-[4-(3-Biphenyl-4-yl-alIyloxy)-phenyl]-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-[4-(3-biphenyl-4-yl-allyloxy)-phenyl]-2- ethoxy-propionic acid ethyl ester (example 15) (0.200 g, 0.464 mmol) and sodium hydroxide (1 M, 0.928 ml, 0.928 mmol) by a procedure analogous to that described in example 2 yield- ing 0.043 g (23%) of (£)-(S)-3-[4-(3-biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid. 1H NMR (300 MHz, CDCI3) δ: 1.15 (3H, t), 2.9 (1H, dd), 3.12 (1 H, dd) 3.45-3.55 (2H, m), 3.84-3.96 (2H, m), 4.1 (1H, dd), 4.7 (2H, d), 6.35-6.5 (1H, dt), 6.78 (1H, d), 6.88 (2H, d), 7.15 (2H, d) 7.4-7.6 (9H, m).
EXAMPLE 17
Figure imgf000066_0002
(£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester
The title compound was prepared from 2-acetonaphthone (10.0 g, 0.06 mol) by a sequence analogous to that described in example 3 yielding 0.190 g (38%) of (£)-(S)-2~ethoxy-3-[4-(3- naphthalen-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester. 1H NMR (200 MHz, CDCI3) δ: 1.1-1.2 (6H, m), 2.20 (3H, s), 2.95 (2H, d), 3.3-3.4 (1H, m), 3.52-3.65 (1H, m), 3.95 (1H, t), 4.15 (2H, q), 4.76 (2H, d), 6.2 (1H, t), 6.85 (2H, d), 7.15 (2H, d), 7.35-7.42 (2H, m), 7.6 (1 H, dd), 7.75-7.85 (4H, m).
EXAMPLE 18
Figure imgf000067_0001
(£)-(S)-2-Ethoxy-3-[4-(3-naphthaIen-2-yl-but-2-enyloxy)-phenyl]-propionic acid
The title compound was prepared from (£)-(S)-2-ethoxy-3-[4-(3-naphthalen-2-yl-but-2- enyloxy)-phenyl]-propionic acid ethyl ester (example 17) (0.165 g, 0.394 mmol) and sodium hydroxide (1 M, 0.789 ml, 0.789 mmol) by a procedure analogous to that described in exam- pie 2 yielding 0.030 g (19%) of (£)-(S)-2-ethoxy-3-[4-(3-naphthalen-2-yl-but-2-enyloxy)- phenylj-propionic acid.
1H NMR (400 MHz, CDCI3) δ: 1.13 (3H, t), 2.18 (3H, s), 2.95 (1 H, dd), 3.05 (1H, dd), 3.3-3.45 (1 H, m), 3.65-3.63 (1H, m), 3.95 (1 H, dd), 4.72 (2H, d), 6.15 (1 H, t), 6.84 (2H, d), 7.14 (2H, d), 7.35-7.45 (2H, m), 7.6 (1H, d), 7.7-7.8 (4H, m).
EXAMPLE 19
Figure imgf000067_0002
(£)-(S)-2-Ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester The title compound was prepared from 2-acetylpyridine (9.6 g, 0.08 mol) by a sequence analogous to that described in example 3 yielding 0.230 g (23%) of (£)-(S)-2-ethoxy-3-[4-(3- pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester.
1H NMR (400 MHz, CDCI3) δ: 1.1-2.5 (6H, m), 2.21 (3H, s), 2.97 (2H, d), 3.3-3.4 (1H, m), 3.58-3.64 (1 H, m), 3.97 (1H, t), 4.15 (2H, q), 4.78 (2H, d), 6.65 (1H, t), 6.85 (2H, d), 7.05- 7.15 (3H, m), 7.42 (2H, d), 7.6 (1 H, dd), 8,52 (1 H, d).
EXAMPLE 20
Figure imgf000068_0001
(£)-(S)-2-Ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid
The title compound was prepared from (£)-(S)-2-ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)- phenylj-propionic acid ethyl ester (example 19) (0.220 g, 0.595 mmol) and sodium hydroxide (1 M, 1.19 ml, 1.19 mmol) by a procedure analogous to that described in example 2 yielding 0.200 g (98%) of (£)-(S)-2-ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid. 1H NMR (300 MHz, CDCI3) δ: 1.2 (3H, t), 2.1 (3H, s), 2.7-2.85 (1 H, m), 3.0-3.25 (2H, m), 3.5- 3.6 (1 H, m), 3.8-3.92 (1H, m), 4.6 (2H, d), 6.5 (1H, t), 6.75 (2H, d), 7.1-7.2 (3H, m), 7.35 (1 H, d), 7.6 (1 H, t), 8,5 (1 H, d).
EXAMPLE 21
Figure imgf000069_0001
(£ -(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 3,5-dibenzyloxyacetophenone (6.64 g, 0.02 mol) by a sequence analogous to that described in example.3 yielding 0.460 g (53%) of (£)-(S)-3-{4-[3- (3,5-bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester.
1H NMR (300 MHz, CDCI3) δ: 1.1-1.21 (6H, m), 2.14 (3H, s), 2.95 (2H, d) 3.28-3.41 (1H, m), 3.51-3.65 (1H, m), 3.94 (1H, t), 4.12 (2H, q), 4.7 (2H, d), 5.05 (4H, s), 6.05 (1H, t), 6.53-6.57 (1H, m), 6.67 (2H, d), 6.85 (2H, d), 7.12 (2H, d), 7.3-7.45 (10H, m).
EXAMPLE 22
Figure imgf000069_0002
(£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-{4-[3-(3,5-bis-benzyloxy-phenyl)-but-2- enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 21) (0.430 g, 0.741 mmol) and sodium hydroxide (1 M, 1.5 ml, 1.5 mmol) by a procedure analogous to that described in example 2 yielding 0.300 g (73%) of (£)-(S)-3-{4-[3-(3,5-bis-benzyloxy-phenyl)-but-2-enyloxy]- phenyl}-2-ethoxy-propionic acid.
1H NMR (300 MHz, CDCI3) δ: 1.15 (3H, t), 2.1 (3H, s), 2.95 (1H, dd), 3.05 (1H, dd), 3.36-3.44 (1H, m), 3.57-3.65 (1H, m), 4.05 (1H, dd), 4.68 (2H, d), 5.05 (4H, s), 6.05 (1H, t), 6.52 (1H, m), 6.65 (2H, d), 6.85 (2H, d), 7.15 (2H, d), 7.3-7.45 (10H, m).
EXAMPLE 23
Figure imgf000070_0001
(£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-allyloxy)-phenyl]-propionic acid ethyl ester
a)
Triethyl phosphonoacetate (8.9 g, 40.0 mmol) was added at 0°C over a period of 10 min. to a stirred suspension of sodium hydride (60% in oil, 1.44 g, 36.0 mmol) in dry THF (145 mL). After stirring at 0°C for 15 min. a solution of 2-naphthaldehyde (3.12 g, 20.0 mmol) in dry THF (15 mL) was added, the mixture slowly warmed to room temperature, and stirring con- tinued for 16h. The reaction mixture was quenched with water (100 mL) and acidified to pH 6 with 1N hydrochloric acid. Additional water (200 mL) was added, the organic phase separated, and the aqueous phase further extracted with ethyl acetate (300 mL). The combined organic phases were washed with water (200 mL x 3), dried (MgSO4), filtered and concentrated in vacuo to give 6.5 g of crude (£)-3-naphthalen-2-yl-acrylic acid ethyl ester. b)
Crude (£)-3-naphthalen-2-yl-acrylic acid ethyl ester (4.5 g, 20.0 mmol) was reduced by a procedure analogous to that described in example 1b. The product was purified by flash col- umn chromatography to give 3.1 g (86%) of (£)-3-naphthalen-2-yl-prop-2-en-1-ol.
c)
Under an atmosphere of nitrogen, (£)-3-naphthalen-2-yl-prop-2-en-1-ol (190 mg, 0.8 mmol), tributylphosphine (323 mg, 1.6 mmol) and (S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (184 mg, 1.0 mmol) were successively dissolved in dry benzene (20 mL). Solid 1 ,1'-(azodicarbonyl) dipiperidine (403 mg, 1.6 mmol) was added at 0°C with stirring. After 10 min. the reaction was warmed to room temperature and the stirring continued for 1 h. The reaction mixture was concentrated in vacuo and the product purified by flash column chromatography, eluting with heptane/ethyl acetate (3:2), to give 180 mg (55%) of the title com- pound.
1H NMR (CDCI3, 300 MHz) δ: 1.15 (t, 3H), 1 ,22 (t, 3H), 2.95 (d, 2H), 3.28-3.40 (m, 1 H), 3.55- 3.65 (m, 1 H), 3.96 (t, 1H), 4.15 (q, 2H), 4.72 (dd, 2H), 6.53 (dt, 1 H), 6.83-6.93 (m, 3H), 7.18 (d, 2H), 7.40-7.50 (m, 2H), 7.13 (dd, 1 H), 7.72-7.85 (m, 4H).
EXAMPLE 24
Figure imgf000071_0001
(£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-alIyloxy)-phenyl]-propionic acid
(£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-allyloxy)-phenyl]-propionic acid ethyl ester (example 23) (170 mg, 0.42 mmol) was dissolved in ethanol (20 mL) at 35°C and sodium hydroxide (1 N, 2.1 mL, 2.1 mmol) added. The mixture was stirred at 35°C for 1 h, the ethanol evapo- rated in vacuo and the mixture acidified to pH 1 with 1N hydrochloric acid. The product was isolated by extraction with ethyl acetate (30 mL x 2). The combined organic phases were dried (MgSO ), filtered and evaporated to give 155 mg (98%) of the title compound as crystals.
1H NMR (CDCI3, 300 MHz) δ: 1.18 (t, 3H), 2.90-3.12 (m, 2H), 3.35-3.48 (m, 1H), 3.55-3.68 (m, 1H), 4.03 (q, 1H), 4.70 (dd, 2H), 6.52 (dt, 1H), 6.80-6.95 (m, 3H), 7.18 (d, 2H), 7.40-7.48 (m, 2H), 7.60 (dd, 1 H), 7.70-7.80 (m, 4H).
EXAMPLE 25
Figure imgf000072_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(3-phenoxy-phenyl)-allyloxy]-phenyl}-propionic acid ethyl ester
The title compound was prepared from 3-phenoxybenzaldehyde (4.0 g, 20.0 mmol) by a sequence analogous to that described in example 23.
1H NMR (CDCI3, 300 MHz) δ: 1.15 (t, 3H), 1 ,22 (t, 3H), 2.95 (d, 2H), 3.30-3.40 (m, 1 H), 3.55- 3.68 (m, 1 H), 3.98 (t, 1 H), 4.15 (q, 2H), 4.72 (dd, 2H), 6.38 (dt, 1 H), 6.67 (d, 1H), 6.83-6.93 (m, 3H), 6.97-7.20 (m, 7H), 7.22-7.38 (m, 3H).
EXAMPLE 26
Figure imgf000073_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(3-phenoxy-phenyl)-allyloxy]-phenyl}-propionic acid
(£)-(S)-2-Ethoxy-3-{4-[3-(3-phenoxy-phenyl)-allyloxy]-phenyl}-propionic acid ethyl ester (example 25) (150 mg, 0.34 mmol) was dissolved in ethanol (7 mL) and sodium hydroxide (1N, 4.4 mL, 4.4 mmol) added. The mixture was heated slightly to obtain a clear solution and then stirred at room temperature for 1.5 h. The ethanol was evaporated in vacuo and the mixture acidified to pH 1 with 1 N hydrochloric acid. The product was isolated by extraction with ethyl acetate (40 mL x 2). The combined organic phases were dried (MgSO4), filtered and evaporated to give 130 mg (91%) of the title compound as an oil. 1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 2.95 (dd, 1H), 3.08 (dd, 1 H), 3.38-3.50 (m, 1H), 3.55-3-65 (m, 1H), 4.05 (q, 1H), 4.65 (dd, 1H), 6.35 (dt, 1H), 6.66 (d, 1H), 6.85-6.92 (m, 3H), 6.98-7.20 (m, 7H), 7.25-7.40 (m, 3H).
EXAMPLE 27
Figure imgf000073_0002
(S)-3-[4-(2-Benzofuran-3-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester The title compound was prepared from benzo[b]furan-2-carboxaldehyde (9.8 g, 0.07 mol) by a sequence analogous to that described in example 23.
1H NMR (CDCIs, 300 MHz) δ: 1.15 (t, 3H), 1.22 (t, 3H), 2.95 (d, 2H), 3.30-3.42 (m, 1H), 3.55- 3.65 (m, 1 H), 3.98 (t, 1 H), 4.15 (q, 2H), 4.73 (d, 2H), 6.65-6.70 (m, 3H), 6.88 (d, 2H), 7.15 (d, 2H), 7.20-7-30 (m, 2H), 7.45 (d, 1H), 7.53 (d, 1 H).
EXAMPLE 28
Figure imgf000074_0001
(S)-3-[4-(2-Benzofuran-3-yI-allyloxy)-phenyl]-2-ethoxy-propionic acid
The title compound was prepared from (S)-3-[4-(2-benzofuran-3-yl-allyloxy)-phenyl]-2- ethoxy-propionic acid ethyl ester (example 27) (127 mg, 0.3 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCI3, 300 MHz) δ: 1.15 (t, 3H), 3.30 (dd, 1 H), 3.08 (dd, 1H), 2.38-3.50 (m, 1H), 3.55-3.65 (m, 1 H), 4.05 (q, 1 H), 4.72 (d, 2H), 6.55-6.68 (m, 3H), 6.90 (d, 1H), 7-13-7.30 (m, 5H), 7.42 (d, 1 H), 7.50 (d, 1 H).
EXAMPLE 29
Figure imgf000075_0001
(£)-(S)-3-{4-[3-(4-Benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester '
The title compound was prepared from 4-benzyloxybenzaldehyde (21.2 g, 0.1 mol) by a sequence analogous to that described in example 23. The title compound was purified on HPLC, using ethyl acetate/heptane (20:80) as eluent.
1H NMR (CDCIs, 300 MHz) δ: 1.15 (t, 3H), 1.22 (t, 3H), 2.95 (d, 2H), 3.35 (m, 1H), 3.6 (m, 1H), 3.98 (t, 1H), 4.15 (q, 2H), 4.65 (dd, 2H), 5.05 (s, 2H), 2.28 (dt, 1 H), 6.65 (d, 1H), 6.85 (d, 2H), 6.93 (d, 2H), 7.15 (d, 2H), 7.30-7.48 (m, 7H).
EXAMPLE 30
Figure imgf000075_0002
(£)-(S)-3-{4-[3-(4-Benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid The title compound was prepared from (£)-(S)-3-{4-[3-(4-Benzyloxy-phenyl)-allyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester (example 29) (80 mg, 0.17 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCIs, 300 MHz): 1.18 (t, 3H), 2.95 (dd, 1 H), 3.12 (dd, 1H), 3.45-3.60 (m, 2H), 4.15 (dd, 1 H), 4.65 (dd, 2H), 5.06 (s, 2H), 6.25 (dt, 1H), 6.65 (d, 1 H), 6.90 (d, 2H), 6.93 (d, 2H), 7.15 (d, 2H), 7.30-7.45 (m, 7H).
EXAMPLE 31
Figure imgf000076_0001
(£)-(S)-3-[4-(3-Benzo[1 ,3]dioxol-5-yl-allyIoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from piperonal (3.0 g, 20 mmol) by a sequence analogous to that described in example 23. The title compound was purified on HPLC, using ethyl acetate/heptane (10:90) as eluent.
1H NMR (CDCIs, 300 MHz) δ: 1.15 (t, 3H), 1.22 (t, 3H), 2.96 (d, 2H), 3.30-3.42 (m, 1H), 3.55- 3.65 (m, 1 H), 3.97 (t, 1 H), 4.15 (q, 2H), 4.63 (dd, 2H), 5.96 (s, 2H), 6.25 (dt, 1H), 6.63 (d, 1 H), 6,75 (d, 1 H), 6.80-6.90 (m, 3H), 6.95 (d, 1 H), 7.15 (d, 2H). EXAMPLE 32
Figure imgf000077_0001
(£)-(S)-3-[4-(3-Benzo[1 ,3]dioxol-5-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-[4-(3-benzo[1 ,3]dioxol-5-yI-allyloxy)-phenyl]- 2-ethoxy-propionic acid ethyl ester (example 31) (100 mg, 0.25 mmol) by a procedure analogous to that described in example 26. 1H NMR (CDCI3, 300 MHz): 1.18 (t, 3H), 2.95 (dd, 1H), 3.08 (dd, 1H), 3.38-3.50 (m, 1 H),
3.55- 3.68 (m, 1H), 4.05 (dd, 1H), 4.65 (dd, 2H), 5.95 (s, 2H), 6.25 (dt, 1H), 6.63 (d, 1H), 6.75 (d, 1H), 6.83 (dd, 1 H), 6.88 (d, 2H), 6.95 (d, 1 H), 7.17 (d, 2H).
EXAMPLE 33
Figure imgf000077_0002
(£)-(S)-3-{4-[3-(4-Allyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester The title compound was prepared from 4-allyloxybenzaldehyde (3.24 g, 20 mmol) by a sequence analogous to that described in example 23. The title compound was purified on HPLC, using ethyl acetate/heptane (10:90) as eluent.
1H NMR (CDCI3, 300 MHz) δ: 1.18 (t, 3H), 1.22 (t, 3H), 2.95 (d, 2H), 3.30-3.42 (m, 1 H), 3.55- 3.68 (m, 1 H), 3.98 (t, 1 H), 4.17 (q, 2H), 4.53 (d, 2H), 4.65 (dd, 2H), 5.29 (dd, 1H), 5.40 (dd, 1H), 5.97-6.13 (m, 1H), 6.28 (dt, 1H), 6.65 (d, 1H), 6.88 (d, 4H), 7.15 (d, 2H), 7.35 (d, 2H).
EXAMPLE 34
Figure imgf000078_0001
(£)-(S)-3-{4-[3-(4-Allyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-{4-[3-(4-allyloxy-phenyl)-allyloxy]-phenyl}-2- ethoxy-propionic acid ethyl ester (example 33) (40 mg, 0.1 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCIs, 300 MHz): 1.18 (t, 3H), 2.95 (dd, 1H), 3.10 (dd, 1H), 3.39-3.50 (m, 1 H), 3.53-3.65 (m, 1 H), 4.05 (dd, 1H), 4.53 (d, 2H), 4.65 (d, 2H), 5.29 (dd, 1H), 5.40 (dd, 1H), 5.98-6.14 (m, 1 H), 6.28 (dt, 1H), 6.65 (d, 1 H), 6.85-6.95 (m, 4H), 7.15 (d, 2H), 7.35 (d, 2H). EXAMPLE 35
Figure imgf000079_0001
(£)-(S)-3-[4-(3-Benzofuran-7-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from benzofuran-7-carboxaldehyde (1.46 g, 10 mmol) by a sequence analogous to that described in example 23.
1H NMR (CDCI3, 300 MHz) δ: 1.15 (t, 3H), 1.22 (t, 3H), 2.95 (d, 2H), 3.30-3.42 (m, 1H), 3.55- 3.65 (m, 1H), 3.98 (t, 1 H), 4.15 (q, 2H), 4.75 (dd, 2H), 6,79 (d, 1 H), 6.87-7.00 (m, 4H), 7.13- 7.30 (m, 4H), 7.50 (dd, 1H), 7.65 (d, 1H).
EXAMPLE 36
Figure imgf000079_0002
(£)-(S)-3-[4-(3-Benzofuran-7-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-[4-(3-benzofuran-7-yl-aIlyloxy)-phenyl]-2- ethoxy-propionic acid ethyl ester (example 35) (100 mg, 0.25 mmol) by a procedure analogous to that described in example 26. 1H NMR (CDCI3, 300 MHz) δ: 1.15 (t, 3H), 2.95 (dd, 1H), 3.08 (dd, 1 H), 3.35-3.48 (m, 1 H) 3.55-3.68 (m, 1 H), 4.03 (dd, 1 H), 4.75 (dd, 2H), 6.78 (d, 1H), 6.90-7.00 (m, 4H), 7.13-7.32 (m, 4H), 7.50 (dd, 1 H), 7.65 (d, 1H), 10.1 (bs, 1 H).
EXAMPLE 37
Figure imgf000080_0001
(S)-3-[4-(3-Benzo[1 ,3]dioxol-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 2,3-methylenedioxybenzaldehyde (1.5 g, 10 mmol) by a sequence analogous to that described in example 23.
1H NMR (CDCI3, 300 MHz) δ: 1.18 (t, 3H), 1.22 (t, 3H), 2.95 (d, 2H), 3.30-3.42 (m, 1H), 3.55- 3.65 (m, 1H), 3.97 (t, 1 H), 4.15 (q, 2H), 4.65 (d, 2H), 6.00 (s, 2H), 6.55-6.92 (m, 7H), 7.15 (d, 2H).
EXAMPLE 38
Figure imgf000080_0002
(S)-3-[4-(3-Benzo[1 ,3]dioxol-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid The title compound was prepared from (S)-3-[4-(3-benzo[1 ,3]dioxol-4-yl-allyloxy)-phenyl]-2- ethoxy-propionic acid ethyl ester (example 37) (100 mg, 0.24 mmol) by a procedure analogous to that described in example 26. 1H NMR (CDCIs, 300 MHz) δ: 1.17 (t, 3H), 2.95 (dd, 1 H), 3.05 (dd, 1 H), 3.35-3.48 (m, 1H), 3.55-3.68 (m, 1H), 4.03 (dd, 1H), 4.65 (d, 2H), 6.00 (s, 2H), 6.55-6.95 (m, 7H), 7.19 (d, 2H).
EXAMPLE 39
Figure imgf000081_0001
(£)-(S)-2-Ethoxy-3-(4-[3-(9H-fluoren-2-yl)-allyloxy]-phenyI)-propionic acid ethyl ester
The title compound was prepared from fluorene-2-carboxaldehyde (9.7 g, 50 mmol) by a sequence analogous to that described in example 23.
1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 1.22 (t, 3H), 2.97 (d, 2H), 3.32-3.42 (m, 1 H), 3.55- 3.67 (m, 1 H), 3.90 (s, 2H), 3.98 (t, 1 H), 4.16 (q, 2H), 4.70 (dd, 2H), 6.45 (dt, 1H), 6.80 (d, 1 H), 6.90 (d, 2H), 7.1 (d, 2H), 7.24-7.46 (m, 3H), 7.55 (d, 1H), 7.62 (s, 1 H), 7.72-7.80 (m, 2H).
EXAMPLE 40
Figure imgf000082_0001
(£)-(S)-2-Ethoxy-3-(4-[3-(9H-fluoren-2-yl)-allyloxy]-phenyl)-propionic acid
The title compound was prepared from (£)-(S)-2-ethoxy-3-(4-[3-(9H-fluoren-2-yl)-allyloxy]- phenyl)-propionic acid ethyl ester (example 39) (275 mg, 0.6 mmol) by a procedure analogous to that described in example 26. 1H NMR (CDCIs, 300 MHz) δ: 1.20 (t, 3H), 3.46 (dd, 1 H), 3.12 (dd, 1H), 3.43-3.65 (m, 2H), 3.90 (s, 2H), 4.05 (dd, 1H), 4.70 (dd, 2H), 6.46 (dt, 1H), 6.80 (d, 1H), 6.92 (d, 2H), 7.17 (d, 2H), 7.23-7.46 (m, 3H), 7.53 (d, 1H), 7.60 (s, 1 H), 7.70-7.80 (m, 2H).
EXAMPLE 41
Figure imgf000082_0002
(S)-2-Ethoxy-3-[4-(3-quinolin-2-yl-allyIoxy)-phenyl]-propionic acid ethyl ester
The title compound was prepared from 2-quinoline-carboxaldehyde (5.12 g, 32.5 mmol) by a sequence analogous to that described in example 23. 1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 1.22 (t, 3H), 2.98 (d, 2H), 3.32-3.42 (m, 1 H), 3.55- 3.66 (m, 1 H), 3.98 (t, 1 H), 4.17 (q, 2H), 4.80 (d, 2H), 6.92 (d, 2H), 7.02 (m, 2H), 7.18 (d, 2H), 7.47-7.60 (m, 2H), 7.70 (dt, 1 H), 7.78 (d, 1 H), 8.05 (d, 1H), 8.13 (d, 1H).
EXAMPLE 42
Figure imgf000083_0001
(S)-2-Ethoxy-3-[4-(3-quinolin-2-yl-allyIoxy)-phenyl]-propionic acid
(S)-2-Ethoxy-3-[4-(3-quinolin-2-yl-allyloxy)-phenyl]-propionic acid ethyl ester (example 41) (150 mg, 0.37 mmol) was dissolved in ethanol (2 mL) and sodium hydroxide (1 N, 2.0 mL, 2.0 mmol) added. The mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated in vacuo, added 2-propanol (2 mL) and diethyl ether (2 mL). The title compound was isolated by filtration.
1H NMR (CDCIs/MeOD, 300 MHz) δ: 1.12 (t, 3H), 2.83 (dd, 1H), 3.02 (dd, 1H), 3.32 (m, 1H), 3.56 (dd, 1H), 3.84 (dd, 1 H), 4.85 (d, 2H), 6.90-7.10 (m, 4H), 7.25 (m, 2H), 7.5-7.6 (m, 1 H), 7.68-7.75 (m, 2H), 7.85 (d, 1H), 8.03 (d, 1 H), 8.23 (d, 1H).
EXAMPLE 43
Figure imgf000084_0001
(£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 3,5-dibenzyloxybenzaldehyde (3.1 g, 9.7 mmol) by a sequence analogous to that described in example 23. 1H NMR (CDCIs, 300 MHz) δ: 1.16 (t, 3H), 1.22 (t, 3H), 2.96 (d, 2H), 3.30-3.42 (m, 1 H), 3.54- 3.65 (m, 1 H), 3.98 (t, 1 H), 4.17 (q, 2H), 4.65 (d, 2H), 5.02 (s, 4H), 6.38 (dt, 1H), 6.55 (s, 1 H), 6.58-6.70 (m, 3H), 6.88 (d, 2H), 7.15 (d, 2H), 7.30-7.45 (m, 10H).
EXAMPLE 44
Figure imgf000085_0001
(£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-{4-[3-(3,5-bis-benzyloxy-phenyl)-allyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester (example 43) (587 mg, 1.1 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCI3, 300 MHz) δ: 1.15 (t, 3H), 2.95 (dd, 1 H), 3.08 (dd, 1H), 3.38-3.48 (m, 1H), 3.54-3.65 (m 1H), 4.03 (dd, 1H), 4.65 (d, 2H), 5.03 (s, 4H), 6.35 (dt, 1H), 6.54 (t, 1H), 6.60- 6.70 (m, 3H), 6.88 (d, 2H), 7.16 (d, 2H), 7.30-7.45 (m, 10 H).
EXAMPLE 45
Figure imgf000085_0002
(£)-(S)-3-{4-[3-(3,5-Dimethoxy-phenyl)-alIyloxy]-phenyI}-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 3,5 dimethoxybenzaldehyde (5.5 g, 33.1 mmol) by a sequence analogous to that described in example 23. 1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 1.22 (t, 3H), 2.95 (d, 2H), 3.30-3.40 (m, 1 H), 3.53- 3.65 (m, 1H), 3.78 (s, 6H), 3.97 (t, 1H), 4.15 (q, 2H), 4.65 (dd, 1 H), 6.33-6.43 (m, 2H), 6.55 (d, 2H), 6.88 (d, 2H), 7.15 (d, 2H).
EXAMPLE 46
Figure imgf000086_0001
(£)-(S)-3-{4-[3-(3,5-Dimethoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-{4-[3-(3,5-dimethoxy-phenyl)-allyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester (example 45) (300 mg, 0.7 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCI3, 300 MHz) δ: 1.18 (t, 3H), 2.95 (dd, 1H), 3.07 (dd, 1H), 3.37-3.48 (m, 1H), 3.55-3.67 (m, 1 H), 3.80 (s, 6H), 4.05 (dd, 1 H), 4.67 (d, 2H), 6.33-6.45 (m, 1 H), 6.55 (d, 2H), 6.65 (d, 1 H), 6.88 (d, 2H), 7.18 (d, 2H). EXAMPLE 47
Figure imgf000087_0001
(£)-(S)-2-Ethoxy-3-[4-(3-phenanthren-9-yl-allyloxy)-phenyl]-propionic acid ethyl ester
The title compound was prepared from phenanthrene-9-carboxaldehyde (4.1 g, 20.0 mmol) by a sequence analogous to that described in example 23.
1H NMR (CDCIs, 300 MHz) δ: 1.16 (t, 3H), 1.22 (t, 3H), 2.95 (d, 2H), 3.30-3.42 (m, 1H), 3.53-
3.65 (m,1H), 3.98 (t, 1 H), 4.15 (q, 2H), 4.47 (d, 2H), 6.47 (dt, 1 H), 6.74 (d, 2H), 7.08 (d, 2H),
7.38 (d, 1 H), 7.53-7.70 (m, 4H), 7.82 (s, 1H),7.85 (d, 1 H), 8.15 (d, 1 H), 8.65 (d, 1H), 8.72 (d,
1 H).
EXAMPLE 48
Figure imgf000087_0002
(£)-(S)-2-Ethoxy-3-{4-[3-(2-methoxy-naphthalen-1 -yl)-allyloxy]-phenyl}-propionic acid ethyl ester The title compound was prepared from 2-methoxy-1-naphthaldehyde (4.1 g, 22.1 mmol) by a sequence analogous to that described in example 23.
1H NMR (CDCIs, 300 MHz) δ: 1.16 (t, 3H), 1.22 (t, 3H), 2.97 (d, 2H), 3.30-3.42 (m, 1H), 3.55- 3.65 (m, 1 H), 3.93 (s, 3H), 3.97 (t, 1H), 4.15 (q, 2H), 4.85 (d, 2H), 6.48 (dt, 1H), 6.95 (d, 2H), 7.10-7.35 (m, 5H), 7.45 (dt, 1 H), 7.75-7.78 (m, 2H), 8.12 (d, 1H).
EXAMPLE 49
Figure imgf000088_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(2-methoxy-naphthalen-1-yl)-alIyloxy]-phenyl}-propionic acid
The title compound was prepared from (£)-(S)-2-ethoxy-3-{4-[3-(2-methoxy-naphthalen-1-yl)- allyloxy]-phenyl}-propionic acid ethyl ester (example 48) (327 mg, 0.75 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCI3, 300 MHz) δ: 1.16 (t, 3H), 2.95 (dd, 1 H), 3.08 (dd, 1 H), 3.35-3.48 (m, 1H), 3.53-3.65 (m, 1H), 3.93 (s, 3H), 4.05 (dd, 1 H), 4.82 (dd, 2H), 6.49 (dt, 1 H), 6.95 (d, 2H), 7.13 (d, 1H), 7.20 (d, 2H), 7.23-7.35 (m, 2H), 7.44 (dt, 1H), 7.74 (d, 2H), 8.12 (d, 1H).
EXAMPLE 50
Figure imgf000088_0002
(£)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a) Sodium (5.52 g, 0.24 mol) was added to ethanol (250 ml) at 20°C and the mixture stirred until the metal had fully reacted. Triethyl phosphonoacetate (62.72 g, 0.28 mol) was added, the mixture stirred for 20 min, then a solution of 4-bromoacetophenone (39.81 g, 0.20 mol) in ethanol (250 ml) was added and the reaction mixture heated to 80°C under reflux for 17h. The solution was cooled, the ethanol evaporated and the resulting orange residue partitioned between 1 N HCl (200 ml) and ethyl acetate (200 ml). The aqueous layer was collected and further extracted with ethyl acetate (2 x 200 ml). The organic layers were combined, washed with brine, dried (MgSO4) and evaporated to an orange gum. This was purified by column chromatography on silica gel (3% diethyl ether in n-heptane eluent) to give the product, (£)- ethyl 3-(4-bromophenyl)-but-2-enoate, as a colourless oil; 44.08 g (82%) 1H NMR (300 MHz, CDCI3) δ: 1.31 (3H, t), 2.54 (3H, s), 4.21 (2H, q), 6.11 (1H, s), 7.34 (2H, dm), 7.48 (2H, dm). MS: 268/270 (M+), 240/242, 239/241, 196/198, 116, 115 (100%). Microanalysis Calculated % C: 53.55, H: 4.87. Found % C: 53.86, H: 4.90.
b) A 1 M solution of DIBAL-H in toluene (42 ml, 42 mmol) was added dropwise, at -70°C over , 30 min, to a stirred solution of (£)-ethyl 3-(4-bromophenyl)-but-2-enoate (4.55 g, 16.92 mmol) in dry THF (100 ml), and the mixture stirred for 1 h. Methanol (5 ml) was carefully added, followed by 1 N HCl (300 ml) and the resulting mixture extracted with ethyl acetate (3 x 200 ml). The combined organic extracts were washed with brine, dried (Na2SO ), and evaporated to give the crude product as an off-white solid, which was purified by recrystallisation from hot 1:4 ether/n-heptane (250 ml) to give the product (£)-3-(4-bromophenyl)-but-2-en-1-ol as colourless needles: 3.10 g (81%)
Mpt. 58-59.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.41 (1H, br s), 2.05 (3H, d), 4.36 (2H, d), 5.96 (1H, tq), 7.27 (2H, dm), 7.44 (2H, dm). MS: 226/228 (M+), 211/213, 193/195, 183/185, 147 (100%), 132, 129, 115. Microanalysis Calculated % C: 52.89, H: 4.88, Br: 35.18. Found C: 53.24, H: 4.86, Br: 35.08. C)
Azodicarboxylic dipiperidide (0.756 g, 3.0 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (0.74 ml, 0.61 g, 3.0 mmol), (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (0.500 g, 2.10 mmol) and (£)-3-(4-bromophenyl)-but-2-en-1-ol (0.454 g, 2.0 mmol) in dry benzene (20 ml), the mixture warmed to room temperature, and stirred for 2.5 days. The resulting mixture was diluted with water and ethyl acetate (50 ml each), the aqueous layer collected and further extracted with ethyl acetate (50 ml). The organic layers were combined, washed with brine, dried (MgSO4) and evaporated. The crude product was then purified by column chromatography on silica gel (20% ethyl acetate in n-heptane eluent) to give (£)-(S)-ethyl 3-{4-[3-(4-bromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate as an oil; 0.780 g (87%).
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 2.10 (3H, s), 2.96 (2H, d), 3.30-3.45 (1 H, m), 3.55-3.70 (1 H, m), 3.98 (1H, t), 4.17 (2H, q), 4.70 (2H, d), 6.04 (1 H, t), 6.86 (2H, m), 7.16 (2H, m), 7.29 (2H, m), 7.44 (2H, m).
EXAMPLE 51
Figure imgf000090_0001
(£)-(S)-3-{4-[3-(4-Bromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
Sodium hydroxide (1M, 1.10 ml, 1.10 mmol) was added to a solution of (£)-(S)-ethyl 3-{4-[3- (4-bromophenyl)-but-2-enyloxyJ-phenyl}-2-ethoxy-propionate (example 50) (0.245 g, 0.548 mmol) in ethanol (10 ml) and the mixture stirred at room temperature for 18 h. The resulting mixture was partitioned between water (50 ml) and ethyl acetate (50 ml) and the aqueous layer acidified to pH1 by addition of 1N HCl. The aqueous layer was separated and further extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with brine, dried (MgSO4), evaporated and vacuum dried at 40°C for 18 h, to give (£)-(S)-3-{4-[3- (4-bromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid as a colourless gum which contained 0.1 molar equivalents of ethyl acetate; 0.22 g (96%).
1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 1.26 (ethyl acetate impurity, 0.3H, t), 2.04 (ethyl acetate impurity, 0.2H, s), 2.11 (3H, s), 2.96 (1 H, dd), 3.08 (1H, dd), 3.40-3.55 (1H, m), 3.55- 3-68 (1H, m), 4.06 (1H, dd), 4.15 (ethyl acetate impurity, 0.2H, q), 4.70 (2H, d), 6.04 (1H, t), 6.88 (2H, m), 7.17 (2H, m), 7.29 (2H, m), 7.44 (2H, m), carboxylic acid proton not observed. LCMS: 441/443 (M+Na), 209/211 (100%).
EXAMPLE 52
Figure imgf000091_0001
(£)-(S)-Ethyl 3-{4-[3-(4'-Chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a)
Tetrakis(triphenylphoshine)palladium(0) (0.26 g, 0.22 mmol, 4 mol%) was added, under nitrogen, to a stirred solution of (£)-ethyl 3-(4-bromophenyl)-but-2-enoate (1.5 g, 5.57 mmol) {prepared as detailed in example 50 a} in DME (70 ml), and the resulting orange coloured solution stirred at room temperature for 10 min. Aqueous 2M sodium carbonate (16.7 ml, 33.4 mmol) was then added, the mixture stirred for 10 min, then 4-chlorophenyl boronic acid (1.3 g, 8.36 mmol) was added, and the reaction mixture heated to 80°C for 18 h, under reflux. The reaction mixture was diluted with 1 N HCl (100 ml) and the products extracted into ethyl acetate (2 x 100 ml). The combined organic extracts were washed with brine, dried (MgSO4), and evaporated to give the crude product, which was purified by column chromatography on silica gel (20% ethyl acetate in n-heptane eluent) to give the product, (£)-ethyl-3- (4'-chloro-biphenyl-4-yl)-but-2-enoate as a colourless solid; 1.17 g (70%). 1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 2.60 (3H, s), 4.23 (2H, q), 6.20 (1H, s), 7.41 (2H, m), 7.52 (2H, m). MS: 300/302 (100%, M+), 271/273, 255/257, 228/230, 165. b)
A 1M solution of DIBAL-H in toluene (10 ml, 10 mmol) was added dropwise, at -70°C over 10 min, to a stirred solution of (£)-ethyl-3-(4'-chloro-biphenyl-4-yl)-but-2-enoate (1.0 g, 3.32 mmol) in dry THF (25 ml), and the mixture warmed to room temperature over 4 h. Methanol (1 ml) was carefully added, followed by 1N HCl (50 ml) and the resulting mixture extracted with ethyl acetate (2 x 50 ml). The combined organic extracts were washed with brine, dried (MgSO4), and evaporated to give the product, (£)-3-(4'-chloro-biphenyl-4-yl)-but-2-en-1-ol as a colourless solid: 0.86 g (100%). Mpt. 137-142°C. 1H NMR (300 MHz, CDCI3) δ: 1.79 (1 H, br s), 2.11 (3H, d), 4.40 (2H, d), 6.05 (1H, tq), 7.41 (2H, dm), 7.45-7.60 (6H, m).
c)
Azodicarboxylic dipiperidide (0.731 g, 2.9 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (0.71 ml, 0.58 g, 2.9 mmol), (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (0.483 g, 2.03 mmol) and (£)-3-(4'-chloro-biphenyl-4-yl)-but-2-en-1-ol (0.500 g, 1.93 mmol) in dry benzene (15 ml), the mixture warmed to room temperature, and stirred for 3 h. The resulting mixture was diluted with water and ethyl acetate (30 ml each), the aqueous layer collected and further extracted with ethyl acetate (30 ml). The organic layers were com- bined, washed with brine, dried (MgSO4) and evaporated. The crude product was then purified by column chromatography on silica (20% ethyl acetate in n-heptane eluent) to give (£)- (S)-ethyl 3-{4-[3-(4'-chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate as a gum; 0.69 g (75%). 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.16 (3H, s), 2.96 (2H, d), 3.30-3.45 (1 H, m), 3.55-3.68 (1H, m), 3.98 (1 H, t), 4.17 (2H, q), 4.74 (2H, d), 6.12 (1 H, t), 6.88 (2H, m), 7.18 (2H, m), 7.40 (2H, m), 7.45-7.60 (6H, m).
EXAMPLE 53
Figure imgf000092_0001
(£)-(S)-3-{4-[3-(4'-Chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
Sodium hydroxide (1M, 2.3 ml, 2.3 mmol) was added to a solution of (£)-(S)-ethyl 3-{4-[3-(4'- chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate (example 52) (0.600 g, 1.25 mmol) in ethanol (10 ml) and the mixture stirred at room temperature for 18h, then heated to 80°C for 2 h. The resulting mixture was partitioned between water (50 ml) and ethyl acetate (50 ml) and the aqueous layer acidified to pH1 by addition of 1 N HCl. The aqueous layer was separated and further extracted with ethyl acetate (2 x 50 ml). The combined organic layers were washed with brine, dried (MgSO ), evaporated, and the product and vacuum dried at 40°C for 72 h, to give (£)-(S)-3-{4-[3-(4'-chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2- ethoxy-propionic acid as a colourless solid; 0.53 g (94%).
1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 2.16 (3H, s), 2.97 (1H, dd), 3.08 (1H, dd), 3.40- 3.53 (1H, m), 3.55-3-68 (1H, m), 4.07 (1H, dd), 4.74 (2H, d), 6.11 (1H, t), 6.90 ,(2H, m), 7.17 (2H, m), 7.39 (2H, m), 7.45-7.60 (6H, m), carboxylic acid proton not observed.
EXAMPLE 54
Figure imgf000093_0001
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}- propionate
a)
Tetrakis(triphenylphoshine)palladium(0) (0.20 g, 0.18 mmol, 4 mol%) was added, under nitrogen, to a stirred solution of (£)-3-(4-bromophenyl)-but-2-en-1-ol (1.0 g, 4.40 mmol) {prepared as detailed in example 50 b} in DME (55 ml), and the resulting orange coloured solution stirred at room temperature for 10 min. Aqueous 2M sodium carbonate (13.2 ml, 26.4 mmol) was then added, the mixture stirred for 10 min, then 5-isopropyl-2- methoxyphenylboronic acid (1.28 g, 6.60 mmol) was added, and the reaction mixture heated to 80°C for 18 h, under reflux. The reaction mixture was diluted with 1 N HCl (100 ml) and the products extracted into ethyl acetate (2 x 100 ml). The combined organic extracts were washed with brine, dried (MgSO4), and evaporated to give the crude product, which was purified by column chromatography on silica gel (1% methanol in dichloromethane eluent) to give the product, 3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2-en-1-ol as a colourless oil; 1.15 g (88%).
1H NMR (300 MHz, CDCI3) δ: 1.26 (6H, d), 1.33 (1 H, br t), 2.12 (3H, s), 2.91 (1H, septet), 3.80 (3H, s), 4.39 (2H, br t), 6.04 (1H, 7), 6.92 (1H, d), 7.15-7.20 (2H, m), 7.42-7.55 (4H, m). MS: 296 (100%., M+), 281 , 263, 253.
b)
Azodicarboxylic dipiperidide (0.756 g, 3.0 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (0.74 ml, 0.61 g, 3.0 mmol), (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (0.50 g, 2.10 mmol) and 3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2-en-1-oI (0.593 g, 2.0 mmol) in dry benzene (15 ml), the mixture warmed to room temperature, and stirred for 4 h. The resulting mixture was diluted with water (100 ml) and ethyl acetate (50 ml), the aqueous layer collected and further extracted with ethyl acetate (50 ml). The organic layers were combined, washed with brine, dried (MgSO4) and evaporated. The crude product was then purified by column chromatography on silica (10% ethyl acetate in n-heptane eluent) to give (£)-(S)-ethyl 2-ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2- enyloxy]-phenyl}-propionate as a colourless oil; 0.67 g (65%). 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 1.26 (6H, d), 2.16 (3H, s), 2.91 (1H, septet), 2.96 (2H, d), 3.30-3.45 (1 H, m), 3.54-3.66 (1 H, m), 3.79 (3H, s), 3.98 (1 H, t), 4.17 (2H, q), 4.74 (2H, d), 6.10 (1 H, t), 6.84-6.95 (3H, m), 7.12-7.20 (4H, m), 7.42-7.57 (4H, m).
EXAMPLE 55
Figure imgf000095_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}- propionic acid
The title compound was prepared from (£)-(S)-ethyI 2-ethoxy-3-{4-[3-(5'-isopropyl-2'- methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate (example 54) (0.50 g, 0.968 mmol) and sodium hydroxide (1 M, 1.93 ml, 1.93 mmol) by a procedure analogous to that described in example 51, yielding (£)-(S)-2-ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2- enyloxy]-phenyl}-propionic acid as a colourless gum, which contained 0.44 mol equivalents of ethyl acetate; 0.48 g (94%). 1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 1.26 (6H, d), 1.26 (ethyl acetate impurity, 1.32H, t), 2.04 (ethyl acetate impurity, 0.88H, s), 2.16 (3H, s), 2.82-3.02 (2H, m), 3.08 (1H, dd), 3.40- 3.52 (1H, m), 3.52-3.68 (1H, m), 3.79 (3H, s), 4.06 (1 H, dd), 4.15 (ethyl acetate impurity, 0.88H, q), 4.75 (2H, d), 6.09 (1H, t), 6.88-6.95 (3H, m), 7.12-7.20 (4H, m), 7.42-7.57 (4H, m), carboxylic acid proton not observed.
EXAMPLE 56
Figure imgf000095_0002
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(5'-chloro-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}- propionate
a) (£)-Ethyl 3-(5'-chloro-2'-methoxy-biphenyl-4-yl)-but-2-enoate (1.07 g, 91 % yield) was prepared from 5-chloro-2-methoxyphenylboronic acid (1.0 g, 5.36 mmol) and (£)-ethyl 3-(4- bromophenyl)-but-2-enoate (0.96 g, 3.57 mmol) by a procedure analogous to that described in example 52 a.
1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 2.60 (3H, s), 3.81 (3H, s), 4.23 (2H, q), 6.20 (1 H, s), 6.91 (1 H, d), 7.25-7.33 (2H, m), 7.47-7.57 (4H, m). MS: 330/332 (100%, M+).
b)
(£)-Ethyl 3-(5'-chloro-2'-methoxy-biphenyl-4-yl)-but-2-enoate (0.90 g, 2.72 mmol) was reduced with DIBAL-H by a procedure analogous to that described in example 52 b to give (£)- 3-(5'-chloro-2'-methoxy-biphenyl-4-yl)-but-2-en-1-ol as a colourless oil; 0.785 g (100%). 1H NMR (300 MHz, CDCI3) δ: 1.49 (1H, br s), 2.11 (3H, s), 3.80 (3H, s), 4.39 (2H, d), 6.04 (1 H, t), 6.90 (1 H, d), 7.22-7.32 (2H, m), 7.47-7.57 (4H, m). MS: 288/290 (100%, M+), 270/272, 255/257, 245/247.
c)
The title compound (0.54 g, 61% yield) was prepared from (£)-3-(5'-chloro-2'-methoxy- biphenyl-4-yl)-but-2-en-1-ol (0.50 g, 1.73 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (0.433 g, 1.82 mmol) by a procedure analogous to that described in example 52 c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.16 (3H, s), 2.96 (2H, d), 3.30-3.43 (1H, m), 3.55-3.65 (1H, m), 3.79 (3H, s), 3.98 (1H, t), 4.17 (2H, q), 4.74 (2H, d), 6.10 (1H, t), 6.84-6.92 (3H, m), 7.12-7.20 (2H, m), 7.22-7.32 (2H, m), 7.45-7.50 (4H, m). LCMS: 331/333 (M+Na). EXAMPLE 57
Figure imgf000097_0001
(£)-(S)-3-{4-[3-(5'-Chloro-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid
The title compound was prepared from (£)-(S)-ethyl 2-ethoxy-3-{4-[3-(5'-chloro-2'-methoxy- biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate (example 56) (0.47 g, 0.92 mmol) and sodium hydroxide (1 M, 1.8 ml, 1.8 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-3-{4-[3-(5'-chIoro-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2- ethoxy-propionic acid as a colourless gum, which contained 0.2 mol equivalents of ethyl acetate; 0.43 g (98%).
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 1.26 (ethyl acetate impurity, 0.6H, t), 2.04 (ethyl acetate impurity, 0.4H, s), 2,16 (3H, s), 2.96 (1 H, dd), 3.10 (1 H, dd), 3.42-3.52 (1H, m), 3.53- 3.68 (1H, m), 3.80 (3H, s), 4.07 (1H, dd), 4.12 (ethyl acetate impurity, 0.4H), 4.74 (2H, d), 6.10 (1 H, t), 6.85-6.95 (3H, m), 7.12-7.20 (2H, m), 7.21-7.32 (2H, m), 7.45-7.50 (4H, m), carboxylic acid proton not observed. LCMS: 503/505 (M+Na).
EXAMPLE 58
Figure imgf000097_0002
(£)-(S)-Ethyl 3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate a)
(£)-Ethyl 3-(2',3'-Dichloro-biphenyl-4-yl)-but-2-enoate (1.07 g, 73%> yield) was prepared from 2,3-dichlorophenylboronic acid (1.26 g, 6.60 mmol) and (£)-ethyl 3-(4-bromophenyl)-but-2- enoate (1.0 g, 4.40 mmol) by a procedure analogous to that described in example 52 a. Mpt. 64-66°C. 1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 2.62 (3H, d), 4.23 (2H, q), 6.21 (1 H, m), 7.20-7.30 (2H, m), 7.40-7.50 (3H, m), 7.50-7.60 (2H, m). MS: 334/336/338 (100%,, M+), 305/307/309, 289/291/293, 262/264/266, 189/191.
b) (£)-Ethyl 3-(2',3'-dichloro-biphenyl-4-yl)-but-2-enoate (1.07 g, 3.19 mmol) was reduced with
DIBAL-H by a procedure analogous to that described in example 52 b to give (£)-3-(2',3'- dichloro-biphenyl-4-yl)-but-2-en-1-ol as a colourless solid; 0.74 g (79%).
Mpt. 95-100°C. 1H NMR (300 MHz, CDCI3) δ: 1.45 (1 H, br s), 2.13 (3H, s), 4.40 (2H, d), 6.07
(1H, t), 7.20-7.28 (2H, m), 7.35-7.42 (2H, m), 7.42-7.53 (3H, m).
C)
The title compound (0.41 g, 80% yield) was prepared from (£)-3-(2',3'-dichloro-biphenyl-4- yl)-but-2-en-1-ol (0.293 g, 1.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.25 g, 1.05 mmol) by a procedure analogous to that described in example 52 c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.18 (3H, s), 2.96 (2H, d), 3.30-3.43 (1 H, m), 3.55-3.65 (1 H, m), 3.98 (1 H, t), 4.17 (2H, q), 4.75 (2H, d), 6.13 (1 H, t), 6.84-6.92 (2H, m), 7.12-7.20 (2H, m), 7.21-7.32 (2H, m), 7.35-7.42 (2H, m), 7.43-7.53 (3H, m).
EXAMPLE 59
Figure imgf000098_0001
(£)-(S)-3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(2',3'-dichloro-biphenyl-4-yl)-but- 2-enyloxy]-phenyl}-2-ethoxy-propionate (example 58) (0.325 g, 0.63 mmol) and sodium hydroxide (1 M, 1.27 ml, 1.27 mmol) by a procedure analogous to that described in example 51 , giving (£)-(S)-3-{4-[3-(2',3'-dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid as a gum, which contained 0.28 mol equivalents of ethyl acetate; 0.24 g (80%).
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 1.26 (ethyl acetate impurity, 0.84H, t), 2.05 (ethyl acetate impurity, 0.56H, s), 2.18 (3H, m), 2.98 (1H, dd), 3.08 (1H, dd), 3.42-3.52 (1H, m), 3.53-3.68 (1 H, m), 3.80 (3H, s), 4.07 (1 H, dd), 4.12 (ethyl acetate impurity, 0.56H), 4.75 (2H, d), 6.13 (1 H, tm), 6.85-6.95 (2H, m), 7.14-7.20 (2H, m), 7.21-7.30 (2H, m), 7.35-7.42 (2H, m), 7.42-7.53 (3H, m), carboxylic acid proton not observed.
EXAMPLE 60
Figure imgf000099_0001
(£)-(S)-Ethyl 3-{4-[3-(2',6'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate
a)
(£)-Ethyl 3-(2',6'-dimethoxy-biphenyl-4-yl)-but-2-enoate (1.02 g, 73% yield) was prepared from 2,6-dimethoxyphenylboronic acid (1.20 g, 6.60 mmol) and (£)-ethyl 3-(4-bromophenyl)- but-2-enoate (1.0 g, 4.40 mmol) by a procedure analogous to that described in example 52 a. Mpt. 120-123.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.32 (3H, t), 2.62 (3H, d), 3.75 (6H, s), 4.23 (2H, q), 6.22 (1 H, m), 6.67 (2H, d), 7.29 (1 H, t), 7.38 (2H, dm), 7.53 (2H, dm). MS: 326 (100%, M+), 297, 281.
b) (£)-Ethyl 3-(2',6'-dimethoxy-biphenyl-4-yl)-but-2-enoate (0.90 g, 2.76 mmol) was reduced with DIBAL-H by a procedure analogous to that described in example 52 b to give (£)-3- (2',6'-dimethoxy-biphenyl-4-yl)-but-2-en-1-ol as a colourless solid; 0.82 g (100%). Mpt. 70-75°C. 1H NMR (300 MHz, CDCI3) δ: 1.44 (1H, br s), 2.12 (3H, d), 3.74 (6H, s), 4.38 (2H, d), 6.06 (1 H, tm), 6.66 (2H, d), 7.13-7.37 (3H, m), 7.42-7.50 (2H, m). MS: 284 (100%, M+), 266, 251 , 241.
c)
The title compound (0.41 g, 80% yield) was prepared from (£)-3-(2',6'-dimethoxy-biphenyl-4- yl)-but-2-en-1-ol (0.50 g, 1.76 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.44 g, 1.85 mmol) by a procedure analogous to that described in example 52 c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 2.16 (3H, m), 2.96 (2H, d), 3.30-3.43 (1 H, m), 3.53-3.65 (1 H, m), 3.73 (6H, s), 3.97 (1H, t), 4.17 (2H, q), 4.75 (2H, d), 6.10 (1 H, tm), 6.66 (2H, d), 6.84-6.90 (2H, m), 7.13-7.20 (2H, m), 7.27 (1 H, t), 7.30-7.38 (2H, m), 7.45- 7.52 (2H, m). LCMS: 527 (M+Na), 267 (100%).
EXAMPLE 61
Figure imgf000100_0001
(£)-(S)-3-{4-[3-(2',6'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(2',6'-dimethoxy-biphenyl-4-yl)- but-2-enyloxy]-phenyl}-2-ethoxy-propionate (example 60) (0.565 g, 1.12 mmol) and sodium hydroxide (1 M, 2.20 ml, 2.20 mmol) by a procedure analogous to that described in example
51 ; giving (£)-(S)-3-{4-[3-(2',6'-dimethoxy-biphenyl-4-yl)-but-2-enyIoxy]-phenyI}-2-ethoxy- propionic acid as a gum; 0.49 g (92%).
1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 2.16 (3H, m), 2.98 (1H, dd), 3.08 (1H, dd), 3.42- 3.52 (1H, m), 3.53-3.68 (1 H, m), 3.73 (6H, s), 4.07 (1 H, dd), 4.75 (2H, d), 6.10 (1 H, tm), 6.66 (2H, d), 6.86-6.92 (2H, m), 7.13-7.20 (2H, m), 7.27 (1H, t), 7.28-7.35 (2H, m), 7.45-7.50 (2H, m), carboxylic acid proton not observed. LCMS: 499 (M+), 267 (100%).
EXAMPLE 62
Figure imgf000101_0001
(£)-(S)-EthyI 3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a)
Sodium (1.37 g, 59.6 mmol) was added to ethanol (50 ml) at 20°C and the mixture stirred until the metal had fully reacted. Triethyl phosphonoacetate (17.78 g, 74.62 mmol) was added, the mixture stirred for 20 min, then a solution of 4-bromoacetophenone (9.90 g, 49.74 mmol) in ethanol (50 ml) was added and the reaction mixture heated to 80°C under reflux for 17h. The solution was cooled, the ethanol evaporated and the residue partitioned between 1N HCl (100 ml) and ethyl acetate (100 ml). The aqueous layer was collected and further extracted with ethyl acetate (2 x 200 ml). The organic layers were combined, washed with brine, dried (MgSO4) and evaporated to an orange gum. This was purified by column chro- matography on silica gel (2% diethyl ether in n-heptane eluent) to give the two double-bond isomer products as colourless oils.
(£)-Ethyi 3-(4-bromophenyl)-2-methyl-but-2-enoate; 5.38 g (38%).
1H NMR (300 MHz, CDCI3) δ: 1.34 (3H, t), 1.75 (3H, m), 2.22 (3H, m), 4.26 (2H, q), 7.04 (2H, dm), 7.49 (2H, dm). MS: 282/284 (M+), 253/255, 237/239, 208/210, 175, 157, 130, 129 (100%), 115. And
(Z)-Ethyl 3-(4-bromophenyl)-2-methyl-but-2-enoate; 3.15 g (22%).
1H NMR (300 MHz, CDCI3) δ: 0.90 (3H, t), 2.01 (3H, s), 2.06 (3H, s), 3.88 (2H, q), 7.00 (2H, dm), 7.41 (2H, dm). MS: 282/284 (M+), 253/255, 237/239, 208/210, 157, 130, 129 (100%), 115. b)
(£)-Ethyl 3-(4-bromophenyl)-2-methyl-but-2-enoate (2.83 g, 9.99 mmol) was reduced with DIBAL-H by a procedure analogous to that described in example 52b to give (£)-3-(4- bromophenyl)-2-methyl-but-2-en-1-ol as a colourless oil; 1.82 g (75%).
1H NMR (300 MHz, CDCI3) δ: 1.60 (1 H, br s), 1.66 (3H, m), 2.00 (3H, m), 4.29 (2H, s), 7.01 (2H, dm), 7.44 (2H, dm). MS: 240/242 (M+), 225/227, 183/185 (100%), 161 , 146, 143, 128, 115.
c)
The title compound (0.83 g, 87% yield) was prepared from (£)-3-(4-bromophenyl)-2-methyl- but-2-en-1-ol (0.50 g, 2.07 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.519 g, 2.18 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 1.23 (3H, t), 1.68 (3H, m), 2.04 (3H, m), 2.97 (2H, d), 3.30-3.43 (1 H, m), 3.53-3.68 (1H, m), 3.98 (1 H, t), 4.18 (2H, q), 4.61 (2H, s), 6.88 (2H, dm), 7.04 (2H, dm), 7.17 (2H, dm), 7.45 (2H, dm).
EXAMPLE 63
Figure imgf000102_0001
(£)-(S)-3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(4-bromophenyl)-2-methyl-but-2- enyloxy]-phenyl}-2-ethoxy-propionate (example 62) (0.710 g, 1.54 mmol) and sodium hydroxide (1 M, 3.10 ml, 3.10 mmol) by a procedure analogous to that described in example 51; giving (£)-(S)-3-{4-[3-(4-bromophenyl)-2-methyl-but-2-enyloxy]-phenyI}-2-ethoxy-propionic acid as a colourless solid, which contained approximately 13 mol% of ethyl acetate impurity; 0.67 g (98%). 1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 1.68 (3H, m), 2.04 (3H, m), 2.98 (1H, dd), 3.08 (1H, dd), 3.42-3.54 (1 H, m), 3.54-3.68 (1H, m), 4.07 (1 H, dd), 4.61 (2H, s), 6.90 (2H, dm), 7.04 (2H, dm), 7.17 (2H, dm), 7.45 (2H, dm), carboxylic acid proton not observed.
EXAMPLE 64
Figure imgf000103_0001
(Z)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a)
(Z)-Ethyl 3-(4-bromophenyl)-2-methyl-but-2-enoate (1.42 g, 5.01 mmol), which was prepared as described in example 62 a, was reduced with DIBAL-H by a procedure analogous to that described in example 52 b to give (Z)-3-(4-bromophenyl)-2-methyl-but-2-en-1-ol as a colourless oil; 1.19 g (98%).
1H NMR (300 MHz, CDCI3) δ: 1.38 (1 H, br s), 1.89 (3H, s), 1.97 (3H, s), 3.92 (2H, s), 7.01 (2H, dm), 7.42 (2H, dm). MS: 240/242 (M+), 225/227, 183/185 (100%), 161 , 146, 143, 128, 115.
c)
The title compound (0.91 g, 95% yield) was prepared from (Z)-3-(4-bromophenyl)-2-methyI- but-2-en-1-ol (0.50 g, 2.07 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.519 g, 2.18 mmol) by a procedure analogous to that described in example 52 c. 1H NMR (300 MHz, CDCI3) δ: 1.16 (3H, t), 1.21 (3H, t), 1.93 (3H, s), 2.02 (3H, s), 2.93 (2H, d), 3.28-3.42 (1H, m), 3.53-3.68 (1H, m), 3.95 (1H, t), 4.16 (2H, q), 4.25 (2H, s), 6.69 (2H, dm), 7.04 (2H, dm), 7.09 (2H, dm), 7.41 (2H, dm). EXAMPLE 65
Figure imgf000104_0001
(Z)-(S)-3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (Z)-(S)-ethyl 3-{4-[3-(4-bromophenyl)-2-methyl-but-2- enyloxy]-phenyl}-2-ethoxy-propionate (example 64) (0.82 g, 1.78 mmol) and sodium hydroxide (1 M, 3.60 ml, 3.60 mmol) by a procedure analogous to that described in example 51 ; giv- ing (Z)-(S)-3-{4-[3-(4-bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid as a colourless solid, which contained approximately 15 mol% of ethyl acetate impurity; 0.766 g (100%).
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.93 (3H, s), 2.02 (3H, s), 2.93 (1H, dd), 3.04 (1H, dd), 3.40-3.52 (1 H, m), 3.52-3.65 (1 H, m), 4.03 (1 H, dd), 4.26 (2H, s), 6.71 (2H, dm), 7.04 (2H, dm), 7.09 (2H, dm), 7.41 (2H, dm), carboxylic acid proton not observed.
EXAMPLE 66
Figure imgf000104_0002
(£)-(S)-Ethyl 2-Ethoxy-3-[4-(3-[1 ,1 ';3',1 "]terphenyl-4"-yl-but-2-enyloxy)-phenyl]-propionate
a) (£)-Ethyl 3-[1,1';3',1"]terphenyl-4"-yl-but-2-enoate (1.02 g, 68% yield) was prepared from 3- biphenylboronic acid (1.31 g, 6.60 mmol) and (£)-ethyl 3-(4-bromophenyl)-but-2-enoate (1.0 g, 4.40 mmol) by a procedure analogous to that described in example 52 a. 1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 2.62 (3H, d), 4.23 (2H, q), 6.21 (1H, s), 7.30-7.70 (12H, m), 7.82 (1 H, m). LCMS: 343 (100%, M+), 297.
b)
(£)-Ethyl 3-[1 ,1';3',1"]terphenyl-4"-yl-but-2-enoate (0.95 g, 2.77 mmol) was reduced with DIBAL-H by a procedure analogous to that described in example 52 b to give (£)-3- [1 ,1';3',1 "]terphenyl-4"-yl-but-2-en-1-ol as a colourless solid; 0.81 g (97%).
1H NMR (300 MHz, CDCI3) δ: 1.37 (1H, br s), 2.13 (3H, s), 4.40 (2H, d), 6.06 (1H, tm), 7.30- 7.70 (12H, m), 7.81 (1 H, m). LCMS: 283 (100%, M+H-H2O). Microanalysis Calculated % C: 87.96, H: 6.71. Found % C: 87.85, H: 6.74.
c)
The title compound (0.41 g, 80% yield) was prepared from (£)-3-[1 ,1';3',1"]terphenyl-4"-yl- but-2-en-1-ol (0.30 g, 1.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.25 g, 1.05 mmol) by a procedure analogous to that described in example 52 c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 2.18 (3H, s), 2.96 (2H, d), 3.30-3.43 (1H, m), 3.55-3.68 (1H, m), 3.98 (1H, t), 4.17 (2H, q), 4.75 (2H, d), 6.13 (1 H, t), 6.89 (2H, dm), 7.17 (2H, dm), 7.30-7.70 (12H, m), 7.81 (1H, m). Microanalysis Calculated % C: 80.74, H: 6.97. Found % C: 80.84, H: 7.28.
EXAMPLE 67
Figure imgf000105_0001
(£)-(S)-2-Ethoxy-3-[4-(3-[1 ,1 ';3',1 "]terphenyl-4"-yl-but-2-enyloxy)-phenyl]-propionic acid The title compound was prepared from (£)-(S)-ethyl 2-ethoxy-3-[4-(3-[1 ,1';3',1"]terphenyl-4"- yl-but-2-enyloxy)-phenyl]-propionate (example 66) (0.185 g, 0.36 mmol) and sodium hydroxide (1M, 0.71 ml, 0.71 mmol) by a procedure analogous to that described in example 51 ; giving (£)-(S)-2-ethoxy-3-[4-(3-[1 ,1 ';3',1 "]terphenyl-4"-yl-but-2-enyloxy)-phenyl]-propionic acid as a gum; 0.145 g (83%).
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 2.18 (3H, m), 2.99 (1H, dd), 3.09 (1H, dd), 3.40- 3.53 (1H, m), 3.53-3.68 (1 H, m), 4.07 (1 H, dd), 4.75 (2H, d), 6.13 (1 H, tm), 6.90 (2H, dm), 7.17 (2H, dm), 7.30-7.70 (12H, m), 7.81 (1 H, m), carboxylic acid proton not observed.
EXAMPLE 68
Figure imgf000106_0001
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(3'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate
a)
(£)-3-(3'-Methyl-biphenyl-4-yl)-but-2-enoate (0.795 g, 65% yield) was prepared from 3- tolylboronic acid (0.90 g, 6.60 mmol) and (£)-ethyl 3-(4-bromophenyl)-but-2-enoate (1.0 g, 4.40 mmol) by a procedure analogous to that described in example 52 a.
1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 2.43 (3H, s), 2.61 (3H, s), 4.23 (2H, q), 6.20 (1H, s), 7.18 (1H, dm), 7.34 (1 H, tm), 7.41 (2H, dm), 7.52-7.63 (4H, m). LCMS: 281 (M+H), 235 (100%).
b)
(£)-3-(3'-Methyl-biphenyl-4-yl)-but-2-enoate (0.74 g, 2.64 mmol) was reduced with DIBAL-H by a procedure analogous to that described in example 52 b to give (£)-3-(3'-methyl- biphenyl-4-yl)-but-2-en-1-ol as a colourless solid; 0.63 g (85%). 1H NMR (300 MHz, CDCI3) δ: 1.36 (1 H, br s), 2.12 (3H, s), 2.42 (3H, s), 4.39 (2H, d), 6.05 (1 H, tm), 7.16 (1 H, dm), 7.33 (1 H, tm), 7.40 (2H, dm), 7.48 (2H, dm), 7.56 (2H, dm). LCMS: 221 (100%, M+H-H2O).
c)
The title compound (0.365 g, 78%) yield) was prepared from (£)-3-(3'-methyl-biphenyl-4-yl)- but-2-en-1-ol (0.238 g, 1.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (0.25 g, 1.05 mmol) by a procedure analogous to that described in example 52 c. 1H NMR (300 MHz, CDCl3) δ: 1.17 (3H, t), 1.22 (3H, t), 2.17 (3H, s), 2.42 (3H, s), 2.96 (2H, d), 3.30-3.43 (1 H, m), 3.55-3.68 (1H, m), 3.98 (1H, t), 4.17 (2H, q), 4.74 (2H, d), 6.11 (1 H, t), 6.90 (2H, dm), 7.13-7.23 (3H, m), 7.33 (1H, t), 7.36-7.44 (2H, m), 7.45-7.60 (4H, m). Microanalysis Calculated % C: 78.57, H: 7.47. Found % C: 78.90, H: 7.70.
EXAMPLE 69
Figure imgf000107_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(3'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid
The title compound was prepared from (£)-(S)-2-ethoxy-3-{4-[3-(3'-methyl-biphenyl-4-yl)-but- 2-enyloxy]-phenyl}-propionate (example 68) (0.225 g, 0.49 mmol) and sodium hydroxide (1 M, 0.98 ml, 0.98 mmol) by a procedure analogous to that described in example 51 ; giving (£)- (S)-2-ethoxy-3-{4-[3-(3'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid as a gum; 0.20 g (95%). H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 2.17 (3H, m), 2.42 (3H, s), 2.97 (1H, dd), 3.09 (1 H, dd), 3.42-3.54 (1 H, m), 3.55-3.68 (1H, m), 4.07 (1 H, dd), 4.75 (2H, d), 6.11 (1H, tm), 6.90 (2H, dm), 7.10-7.23 (3H, m), 7.35 (1H, t), 7.37-7.44 (2H, m), 7.45-7.60 (4H, m), carboxylic acid proton not observed. EXAMPLE 70
Figure imgf000108_0001
(£)-(S)-Ethyl 3-{4-[3-(3'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a) 3-Acetylphenylboronic acid (7.10 g, 43.3 mmol) was coupled with (£)-3-(4-bromophenyl)-but- 2-en-1-ol (5.76 g, 25.0 mmol) by a procedure analogous to that described in example 54 a to give (£)-3-(3'-acetyl-biphenyl-4-yl)-but-2-en-1-ol as an off-white solid; 5.33 g (79%). This solid was recrystallised from aqueous ethanol to give a first crop of very pure (£)-3-(3'-acetyl- biphenyl-4-yl)-but-2-en-1-ol as colourless platelets; 2.78 g (41%) and a second crop of (£)-3- (3'-acetyl-biphenyl-4-yl)-but-2-en-1-ol as an amorphous off-white solid; 2.53 g (37%).
Mpt. 85-86°C. 1H NMR (300 MHz, CDCI3) δ: 1.46 (1H, br t), 2.13 (3H, d), 2.66 (3H, s), 4.41 (2H, br t), 6.07 (1 H, tm), 7.50-7.62 (5H, m), 7.80 (1 H, dm), 7.92 (1 H, dm), 8.19 (1 H, m). MS: 266 (M+), 251 , (M-Me), 248 (M-H2O), 223 (100%). Microanalysis Calculated % C: 81.17, H: 6.81. Found % C: 81.22, H: 6.83.
b)
The title compound (0.16 g, 65% yield) was prepared from (£)-3-(3'-acetyl-biphenyl-4-yl)-but- 2-en-1-ol (0.133 g, 0.50 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-pr^pionate (0.125 g, 0.525 mmol) by a procedure analogous to that described in example 52 c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.18 (3H, s), 2.66 (3H, s), 2.92 (2H, d), 3.30-3.43 (1H, m), 3.55-3.68 (1H, m), 3.98 (1H, t), 4.17 (2H, q), 4.75 (2H, d), 6.13 (1H, t), 6.89 (2H, dm), 7.17 (2H, dm), 7.50-7.64 (5H, m), 7.80 (1H, dm), 7.92 (1H, dm), 8.19 (1 H, m). EXAMPLE 71
Figure imgf000109_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-allyloxy]-phenyl}-propionic acid ethyl ester
a)
(£)-3-(4-Bromo-phenyl)-acrylic acid ethyl ester was prepared from 4-bromobenzaldehyde (20.0 g, 0.11 mol) by a procedure analogous to that described in example 23 a.
b) (£)-3-(4-Bromo-phenyl)-acrylic acid ethyl ester (450 mg, 2.0 mmol) was reacted with 5- isopropyl-2-methoxy-benzene boronic acid (776 mg, 4.0 mmol) by a procedure described in example 52 a, to give (E)-3-(5'-lsopropyl-2'-methoxy-biphenyl-4-yl)-acrylic acid ethyl ester.
c) (£)-3-(5'-lsopropyl-2'-methoxy-biphenyl-4-yI)-acrylic acid ethyl ester was reduced by DIBAL- H by a procedure analogous to that described in example 52 b to give (£)-3-(5'-isopropyl-2'- methoxy-biphenyl-4-yl)-prop-2-en-1-ol. d)
The title compound was prepared from (£)-3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-prop-2- en-1-ol by a procedure analogous to that described in 52 c.
1H NMR (300 MHz, CDCI3) δ: 1.13-1.30 (m, 12H), 2.85-3.0 (m, 3H), 3.30-3.42 (m, 1 H), 3.53-
3.67 (m, 1 H), 2.78 (s, 3H), 3.98 (t, 1 H), 4.15 (q, 2H), 4.70 (dd, 2H), 6.43 (dt, 1H), 6.75 (d,
1H), 6.85-6.95 (m, 3H), 7.15 (d, 4H), 7.44 (d, 2H), 7.52 (d, 2H).
EXAMPLE 72
Figure imgf000110_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-allyloxy]-phenyl}-propionic acid
The title compound was prepared from (£)-(S)-2-ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy- biphenyl-4-y!)-allyloxy]-phenyl}-propionic acid ethyl ester (example 71) (370 mg, 0.78 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 1.26 (d, 6H), 2.85-3.03 (m, 2H), 3.08 (dd, 1 H), 3.35-3.48 (m, 1H), 3.55-3.68 (m, 1H), 3.75 (s, 3H), 4.03 (dd, 1H), 4.67 (d, 2H), 6.43 (dt, 1H), 6.75 (d. 1 H), 6.87-6.95 (m, 3H), 7.13-7.23 (m, 4H), 7.43 (d, 2H), 7.53 (d, 2H). EXAMPLE 73
Figure imgf000111_0001
(£)-(S)-3-{4-[3-(3,5-Distyryl-phenyl)-allyIoxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
a)
Bu4NBr (2.0 g, 6.3 mmol), K2CO3 (7.8 g, 56.7 mmol), Pd(Oac)2 (250 mg, 1.1 mmol) and styrene (20 mL, 175 mmol) were stirred for 5 min under nitrogen. To the mixture was added 3,5- dibromobenzaldehyde (5.0 g, 18.9 mmol) in dry DMF (5.0 mL), and the mixture was stirred at 65°C for 16h. The reaction mixture was diluted with ethyl acetate (20 mL) and the solution filtered. The filtrate was diluted with water and extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, dried over MgSO4, and concentrated under vacuum. To the residue was added a mixture of toluene/petroleum ether (1:1) (50 mL) and 3,5-distyryl- benzaldehyde (4.95 g, 85%) was isolated by filtration.
b)
The title compound was prepared from 3,5-distyryl-benzaldehyde ( 3.8 g, 10.0 mmol) by a sequence analogous to that described in example 23 b-c. 1H NMR (CDCI3, 300 MHz) δ: 1.15 (t, 3H), 1.22 (t, 3H), 2.98 (d, 2H), 3.32-3.42 (m, 1H), 3.55- 3.68 (m, 1H), 3.98 (t, 1H), 4.12 (t, 1H), 4.18 (q, 2H), 4.72 (dd, 2H), 6.50 (dt, 1H), 6.78 (d, 1H), 6.90 (d, 1H), 7.08-7.32 (m, 8H), 7.39 (t, 4H), 7.45 (s, 2H), 7.53 (d, 5H). EXAMPLE 74
Figure imgf000112_0001
(£)-(S)-3-{4-[3-(3,5-Distyryl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid
(£)-(S)-3-{4-[3-(3,5-Distyryl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 73) (335 mg, 0.6 mmol) was dissolved in warm ethanol (20 mL) and sodium hydroxide (1N, 0.9 mL, 0.9 mmol) added. The mixture was stirred at room temperature for 16h. The title compound as a sodium salt was isolated by filtration and washed with ethanol/water (10:1), yielding 190 mg (57%).
1H NMR (CDCI3, 300 MHz) δ: 0.98 (t, 3H), 2.63 (dd, 1H), 2.85 (dd, 1 H), 3.05-3.15 (m, 1H), 3.50-3.64 (m, 2H), 4.75 (d, 2H), 6.68 (dt, 1H), 6.80 (d, 1H), 6.90 (d, 2H), 7.15 (d, 2H), 7.25- 7.48 (m, 10H), 7.60-7.70 (m, 6H), 7.75 (s, 1H).
EXAMPLE 75
Figure imgf000112_0002
(E)-(S)-3-{4-[3-(3,5-Diisopropoxy-phenyl)-allyloxy]-phenyI}-2-ethoxy-propionic acid ethyl ester
a)
To a solution of 3,5-dihydroxybenzaldehyde (3.0 g, 22.0 mmol) in DMF (17 mL) was added potassium carbonate (12.1 g, 87.0 mmol) and 2-bromopropane (28.5 g, 232 mmol). The reaction mixture was heated at 100°C for 3 h. The mixture was filtered and washed with ethyl acetate. The filtrate was added water and the organic phase isolated. The aqueous phase was extracted once more with ethyl acetated. The combined organic phases were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash chromatogra- phy eluting with toluene to give 3.8 g (79%) of 3,5-diisopropoxy-benzaldehyde as a yellow oil. 1H NMR (CDCI3) 300 MHz) δ: 1.35 (d, 12H), 4.60 (heptet, 2H), 6.68 (t, 1 H), 6.97 (d, 2H).
b)
The title compound was prepared from 3,5-diisopropoxy-benzaldehyde by a sequence analogous to that described in example 23.
1H NMR (CDCIs, 300 MHz) δ: 1.15 (t, 3H), 1.22 (t, 3H), 1.32 (d, 12H), 2.96 (d, 2H), 3.32-3.42 (m, 1H), 3.55-3.65 (m,1H), 3.98 (t, 1 H), 4.16 (q, 2H), 4.53 (heptet, 2H), 4.65 (dd, 2H), 6.30- 6.40 (m, 2H), 6.52 (d, 2H), 6.62 (d, 1H), 6.88 (d, 2H), 7.15 (d, 2H).
EXAMPLE 76
Figure imgf000113_0001
(E)-(S)-3-{4-[3-(3,5-Diisopropoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (E)-(S)-3-{4-[3-(3,5-diisopropoxy-phenyl)-aIIyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester (example 75) (800 mg, 1.7 mmol) by a procedure analogous to that described in example 26. H NMR (CDCI3, 300 MHz) δ: 1.18 (t, 3H), 1.32 (d, 12H), 2.95 (dd, 1 H), 3.10 (dd, 1H), 3.40- 3.52 (m, 1 H), 3.55-3.65 (m, 1H), 4.05 (dd, 1H), 4.53 (heptet, 2H), 6.30-6.40 (m, 2H), 6.52 (d, 2H), 6.62 (d, 1 H), 6.88 (d, 2H), 7.15 (d, 2H).
EXAMPLE 77
Figure imgf000114_0001
(S)-3-{4-[3-(3-Bromo-5-styryl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
a)
A mixture of styrene (2.0 g, 18.9 mmol), potassium carbonate (7.8 g, 56.7 mmol), tetra-N- butylammonium bromide (2.0 g, 6.3 mmol) and palladium(ll) acetate (250 mg, 1.11 mmol), under nitrogen, was stirred for 10 min. A solution of 3,5-dibromobenzaldehyde (5.0 g, 18.9 mmol) in dry DMF (10 mL) was added and the mixture heated at 65°C for 16 h; The reaction mixture was concentrated in vacuo, and the product purified by flash chromatography (heptane/ethyl acetate 1 :4) to give 1.7 g of 3-bromo-5-styryl-benzaldehyde.
b)
The title compound was prepared from 3-bromo-5-styryl-benzaldehyde by a sequence analogous to that described in example 23.
1H NMR (CDCI3, 300 MHz) δ: 1.18 (t, 3H), 1.23 (t, 3H), 2.96 (d, 2H), 3.30-3.42 (m, 1H), 3.55-
3.65 (m, 1 H), 3.98 (t, 1 H), 4.15 (q, 2H), 4.68 (d, 2H), 6.43 (dt, 1 H), 6.66 (d, 1H), 6.88 (d, 2H), 6.93-7.56 (m, 12H). EXAMPLE 78
Figure imgf000115_0001
(S)-3-{4-[3-(3-Bromo-5-styryl-phenyl)-aIlyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (S)-3-{4-[3-(3-bromo-5-styryl-phenyl)-allyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester (example 77) (800 mg, 1.7 mmol) by a procedure analogous to that described in example 26. 1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 2.98 (dd, 1 H), 3.10 (dd, 1H), 3.40-3.53 (m, 1H), 3.54-3.68 (m, 1 H), 4.05 (dd, 1 H), 4.68 (dd, 2H), 6.43 (dt, 1H), 6.68 (s, 1 H), 6.88 (d, 2H), 6.94- 7.56 (m, 12H).
EXAMPLE 79
Figure imgf000115_0002
(E)-(S)-2-Ethoxy-3-[4-(3-phenyl-allyloxy)-phenyl]-propionic acid ethyl ester
The title compound was prepared from 3-phenyl-prop-2-en-1-oI (270 mg, 2.0 mmol) by a sequence analogous to that described in example 23c.
1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 1.22 (t, 3H), 2.95 (d, 2H), 3.30-3.42 (m, 1H), 3.53- 3.65 (m, 1H), 3.98 (t, 1 H), 4.15 (q, 2H), 4.68 (dd, 2H), 6.41 (dt, 1 H), 6.73 (dt, 1H), 6.88 (d, 2H), 7.15 (d, 2H), 7.21-7.38 (m, 3H), 7.38-7.43 (m, 2H). EXAMPLE 80
Figure imgf000116_0001
(E)-(S)-2-Ethoxy-3-[4-(3-phenyl-allyloxy)-phenyI]-propionic acid
The title compound was prepared from (E)-(S)-2-ethoxy-3-[4-(3-phenyl-allyloxy)-phenyI]- propionic acid ethyl ester (example 79) (700 mg, 2.0 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 2.95 (dd,.1H), 3.10 (dd, 1 H), 4.42-3.53 (m, 1H),
3.53-3.64 (m, 1 H), 4.05 (dd, 1 H), 4.68 (dd, 2H), 6.42 (dt, 1H), 6.72 (d, 1H), 6.89 (d, 2H), 7.15
(d, 1H), 7.22-7.37 (m, 3H), 7.40 (d, 2H).
EXAMPLE 81
Figure imgf000116_0002
(E)-(S)-3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
a) (E)-3-(4-Bromo-phenyl)-acrylic acid ethyl ester was prepared from 3-bromobenzaldehyde (20.0 g, 0.11 mol) by a sequence analogous to that described in example 23a. b)
The title compound was prepared from (E)-3-(4-bromo-phenyl)-acrylic acid ethyl ester and
2,3-dichlorobenzene boronic acid by a sequence analogous to that described in example
52a-c.
1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 1.23 (t, 3H), 2.95 (d, 2H), 3.30-3.42 (m, 1H), 3.53-
3.65 (m, 1 H), 3.98 (t, 1 H), 4.15 (q, 2H), 4.70 (dd, 2H), 6.47 (dt, 1 H), 6.7 (d, 1 H), 6.88 (d, 2H),
7.15 (d, 2H), 7.20-7.28 (m, 2H), 7.35 (d, 2H), 7.43-7.52 (m, 3H).
EXAMPLE 82
Figure imgf000117_0001
(E)-(S)-3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (E)-(S)-3-{4-[3-(2',3'-dichloro-biphenyl-4-yl)-allyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester (example 81) by a procedure analogous to that described in example 26.
1H NMR (MeOD, 300 MHz) δ: 1.12 (t, 3H), 2.88 (dd, 1 H), 3.0 (dd, 1 H), 3.30-3.42 (m, 1H), 3.3-3.65 (m, 1H), 4.0 (dd, 1H), 4.70 (dd, 2H), 6.52 (dt, 1H), 6.80 (d, 1H), 6.90 (d, 2H), 7.18 (d, 2H), 7.25-7.40 (m, 4H), 7.48-7.55 (m, 3H).
EXAMPLE 83
Figure imgf000118_0001
(E)-(S)-3-{4-[3-(3,5-Bis-phenylethynyI-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
a)
A mixture of potassium carbonate (2.1 g, 15.2 mmol), tetra-N-butylammonium bromide (0.75 g, 2.4 mmol) and palladium(ll) acetate (75 mg, 0.33 mmol) in dry DMF (8 ML), under nitrogen, was stirred for 10 min. 3-(3,5-Dibromophenyl)-acrylic acid ethyl ester (1.2 g, 3.6 mmol) was added and the mixture cooled on ice. Phenylacetylene (4.0 mL, 36.0 mmol) was added and the mixture stirred at room temperature for 7 days. The reaction mixture was added water and the product extracted with ethyl acetate (x 3). The combined organic phases were dried and concentrated in vacuo to give crude 3-(3,5-bis-phenylethynyl-phenyl)-acrylic acid ethyl ester.
b)
The title compound was prepared from 3-(3,5-bis-phenylethynyl-phenyl)-acrylic acid ethyl ester by a sequence analogous to that described in example 23b-c.
1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 1.23 (t, 3H), 2.96 (d, 2H), 3.30-3.42 (m, 1H), 3.55- 3.67 (m, 1 H), 3.98 (t, 1H), 4.15 (q, 2H), 4.70 (d, 2H), 6.46 (dt, 1 H), 6.68 (d, 1H), 6.88 (d, 2H), 7.15 (d, 2H), 7.30-7.38 (m, 6H), 7.48-7.58 (m, 6H), 7.60 (s, 1H). EXAMPLE 84
Figure imgf000119_0001
(E)-(S)-3-{4-[3-(3,5-Bis-phenylethynyl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (E)-(S)-3-{4-[3-(3,5-bis-phenylethynyl-phenyl)- allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 83) (130 mg, 0.24 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 2.96 (dd, 1H), 3.98 (dd, 1H), 3.37-3.48 (m, 1H), 3.53-3.67 (m, 1H), 4.03 (dd, 1 H), 4.68 (d, 2H), 6.47 (dt, 1H), 6.68 (d, 1 H), 6.88 (d, 2H), 7.18 (d, 2H), 7.30-7.42 (m, 6H), 7.48-7.58 (m, 6H), 7.60 (s, 1 H).
EXAMPLE 85
Figure imgf000119_0002
(E)-(S)-3-{4-[3-(3,5-Diphenethyl-phenyl)-allyloxy]-phenyI}-2-ethoxy-propionic acid ethyl ester a)
A solution of 3,5-distyryl-benzaldehyde (2.0 g, 6.44 mmol) (prepared as described in example 79) in ethyl acetate (150 mL) was hydrogenated at 3 atm for 16 h using 5% Pd-C (2 g) as catalyst. The catalyst was removed by filtration and the solvent evaporated to give (3,5- diphenethyl-phenyl)-methanol (2.0 g) as an oil.
b)
To a solution of (3,5-diphenethyl-phenyl)-methanol (2.0 g, 6.4 mmol) in dry dichloromethane (30 mL) was added pyridinium chlorochromate (1.4 g, 6.4 mmol) and the mixture was stirred at room temperature for 16 h. The product was purified by flash chromatography using dichloromethane as solvent to give 1.3 g 3,5-diphenethyl-benzaldehyde.
c)
The title compound was prepared from 3,5-diphenethyl-benzaldehyde by a sequence analo- gous to that described in example 23.
EXAMPLE 86
Figure imgf000120_0001
(E)-(S)-3-{4-[3-(3,5-Diphenethyl-phenyl)-allyIoxy]-phenyI}-2-ethoxy-propionic acid
The title compound was prepared from (E)-(S)-3-{4-[3-(3,5-Diphenethyl-phenyl)-allyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester (example 85) (449 mg, 0.80 mmol) by a procedure analogous to that described in example 26. 1H NMR (CDCIs, 300 MHz) δ: 1.18 (t, 3H), 2.96 (dd, 1 H), 3.08 (dd, 1H), 3.35-3.48 (m, 1H), 3.55-3.67 (m, 1 H), 4.03 (dd, 1H), 4.65 (dd, 1 H), 6.35 (dt, 1H), 6.68 (d, 1 H), 6.82-6.92 (m, 3H), 7.04 (d, 2H), 7.12-7.32 (m, 12H).
EXAMPLE 87
Figure imgf000121_0001
3-{4-[3-(3,5-Bis-cyclopentyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from dihydroxybenzaldehyde (1.0 g, 7.2 mmol) and cyclopentylbromide (4.0 g, 29.0 mmol) by a sequence analogous to that described in example 75. 1H NMR (CDCl3, 300 MHz) δ: 1.18 (t, 3H), 1.21 (t, 3H), 1.50-1.68 (m, 4H), 1.68-1.97 (m,
12H), 2.95 (d, 2H), 3.28-3.42 (m, 1H), 3.54-3.65 (m, 1 H), 3.97 (t, 1 H), 4.15 (q, 2H), 4.67 (dd, 2H), 4.67-4.77 (m, 2H), 6.28-6.40 (m, 2H), 6.50 (d, 2H), 6.60 (d, 1H), 6.87 (d, 2H), 7.15 (d, 2H).
EXAMPLE 88
Figure imgf000122_0001
(E)-(S)-3-{4-[3-(3,5-Bis-cyclopentyloxy-phenyI)-allyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (E)-(S)-3-{4-[3-(3,5-bis-cyclopentyloxy-phenyl)- allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 87) (220 mg, 0.42 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCI3, 300 MHz) δ: 1.18 (t, 3H), 1.52-1.70 (m, 4H), 1.70-1.98 (m, 12H), 2.95 (dd, 1H), 3.07 (dd, 1H), 3.37-3.48 (m, 1H), 3.55-3.65 (m, 1H), 4.03 (dd, 1H), 4.65 (dd, 2H), 4.70- 4.78 (m, 2H), 6.29-6.40 (m, 2H), 6.50 (d, 2H), 6.60 (d, 1 H), 6.88 (d, 2H), 7.15 (d, 2H).
EXAMPLE 89
Figure imgf000122_0002
(E)-(S)-3-(4-{3-[3,5-Bis-(2,2,2-trifluoro-ethoxy)-phenyl]-allyloxy}-phenyl)-2-ethoxy-propionic acid ethyl ester a)
To a solution of 3,5-dihydroxybenzaldehyde (2.0 g, 14.5 mmol) in DMF (35 mL) was added potassium carbonate (11.0 g, 80.0 mmol) and 1 ,1 ,1-trifluoro-2-iodoethane (33.3 g, 160 mmol). The reaction mixture was heated I a sealed reactor at 50°C for 7 days. The mixture was filtered and washed with ethyl acetate. The filtrate was added water and the organic phase isolated. The aqueous phase was extracted once more with ethyl acetated. The combined organic phases were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash chromatography eluting with toluene to give 906 mg (18%) of 3,5-bis- (2,2,2-trifluoro-ethoxy)-benzaldehyde . 1H NMR (CDCI3, 300 MHz) δ: 4.43 (q, 4H), 6.85 (t, 1 H), 7.15 (d, 2H), 9.95 (s, 1H).
b)
The title compound was prepared from 3,5-bis-(2,2,2-trifluoro-ethoxy)-benzaldehyde by a sequence analogous to that described in example 23. 1H NMR (CDCIs, 300 MHz) δ: 1.15 (t, 3H), 1.22 (t, 3H), 2.95 (d, 2H), 3.30-3.40 (m,1H), 3.55- 3.67 (m, 1H), 3.97 (t, 1H), 4.15 (q, 2H), 4.33 (q, 4H), 4.65 (d, 2H), 6.32-6.48 (m, 2H), 6.55- 6.70 (m, 3H), 6.85 (d, 2H), 7.15 (d, 2H).
EXAMPLE 90
Figure imgf000123_0001
(E)-(S)-3-(4-{3-[3,5-Bis-(2,2,2-trifluoro-ethoxy)-phenyl]-allyIoxy}-phenyl)-2-ethoxy-propionic acid The title compound was prepared from (E)-(S)-3-(4-{3-[3,5-bis-(2,2,2-trifluoro-ethoxy)-phenyl]- allyloxy}-phenyl)-2-ethoxy-propionic acid ethyl ester (example 89) (200 mg, 0.36 mmol) by a procedure analogous to that described in example 26.
1H NMR (CDCIs, 300 MHz) δ: 1.20 (t, 3H), 2.97 (dd, 1 H), 3.10 (dd, 1H), 3.41-3.53 (m, 1H), 3.55-3.68 (m, 1 H), 4.05 (dd, 1H), 4.35 (q, 4H), 4.67 (d, 2H), 6.35-6.48 (m, 2H), 6.60-6.70 (m, 3H), 6.87 (d, 2H), 7.15 (d, 2H).
EXAMPLE 91
Figure imgf000124_0001
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-but-2-enyloxy]-phenyl}-propionate
a)
Sodium (5.52 g, 0.24 mol) was added to ethanol (250 ml) at 20°C and the mixture stirred until the metal had fully reacted. Triethyl phosphonoacetate (62.72 g, 0.28 mol) was added as an ethanol (50 ml) solution, the mixture stirred for 20 min, then a solution of 4- iodoacetophenone (49.21 g, 0.20 mol) in ethanol (300 ml) was added and the reaction mix- ture heated to 80°C under reflux for 17h. The solution was cooled, the ethanol evaporated and the resulting orange residue partitioned between 1 N HCl (200 ml) and ethyl acetate (200 ml). The aqueous layer was collected and further extracted with ethyl acetate (3 x 200 ml). The organic layers were combined, washed with brine, dried (MgSO4) and evaporated to an orange/yellow oil, which was purified by column chromatography on silica gel (2% diethyl ether in n-heptane eluent) to give the product, (£)-ethyl 3-(4-iodophenyl)-but-2-enoate, as a pale yellow oil; 54.83 g (87%)
1H NMR (300 MHz, CDCI3) δ: 1.31 (3H, t), 2.53 (3H, s), 4.21 (2H, q), 6.11 (1H, s), 7.20 (2H, dm), 7.69 (2H, dm). 13CNMR (75MHz, CDCI3) δ: 13.0 (q), 16.4 (q), 58.6 (t), 93.7 (s), 116.2 (d), 126.7 (d), 136.3 (d), 140.3 (s), 152.8 (s), 165.2 (s). MS: 316 (M+), 287, 271 , 244, 144, 115 (100%). Microanalysis Calculated % C: 45.59, H: 4.14. Found % C: 45.72, H: 4.20. b)
Tetrakis(triphenylphoshine)palIadium(0) (0.69 g, 0.60 mmol, 6 mol%) was added, under nitrogen, to a stirred solution of (£)-ethyl 3-(4-iodophenyI)-but-2-enoate (3.16 g, 10.0 mmol) in DME (100 ml), and the resulting orange coloured solution stirred at room temperature for 10 min. Aqueous 2M sodium carbonate (30.0 ml, 60.0 mmol) was then added, the mixture stirred for 10 min, then furan-2-boronic acid (2.25 g, 20.11 mmol) was added, and the reaction mixture heated to 80°C for 20 h, under reflux. The reaction mixture was cooled, diluted with water (100 ml) and the products extracted into ethyl acetate (3 x 100 ml). The combined organic extracts were washed with brine, dried (MgSO4), and evaporated to give the crude product, which was purified by column chromatography on silica gel (3% diethyl ether in n- heptane eluent) to give the product, (£)-ethyl 3-(4-furan-2-yl-phenyl)-but-2-enoate as an off- white solid; 2.46 g (96%).
Mpt. 85.5-56.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.32 (3H, t), 2.59 (3H, d), 4.22 (2H, q), 6.18 (1H, m), 6.49 (1H, dd), 6.70 (1H, d), 7.46-7.56 (3H, m), 7.66 (2H, dm). MS: 256 (100%, M+), 227, 211 , 184, 153, 115. Microanalysis Calculated % C: 74.98, H: 6.29. Found % C: 74.99, H: 6.39.
c)
(£)-Ethyl 3-(4-furan-2-yl-phenyI)-but-2-enoate was reduced with DIBAL-H by a procedure analogous to that described in example 50b, to give the colourless solid (£)-3-(4-furan-2-yl- phenyl)-but-2-en-1-ol.
d)
The title compound (678 mg, 77%) was prepared from (£)-3-(4-furan-2-yl-phenyl)-but-2-en-1- ol (430 mg, 2.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (526 mg, 2.21 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 2.14 (3H, d), 2.96 (2H, d), 3.31-3.41 (1H, m), 3.55-3.66 (1H, m), 3.98 (1H, t), 4.16 (2H, q), 4.73 (2H, d), 6.10 (1H, tm), 6.47 (1H, dd), 6.64 (1H, d), 6.88 (2H, dm), 7.17 (2H, dm), 7.43-7.48 (3H, m), 7.62 (2H, dm). LCMS: 457 (M+Na), 452 (M+NH4), 197 (100%). EXAMPLE 92
Figure imgf000126_0001
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(2'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate
a)
The colourless solid, (£)-ethyl 3-(2'-methyl-biphenyI-4-yl)-but-2-enoate was prepared from (£)-ethyl 3-(4-iodophenyl)-but-2-enoate (example 91a) and orffro-tolyl boronic acid by a pro- cedure analogous to that described in example 91b.
b)
The colourless oil (£)-3-(2'-methyl-biphenyl-4-yl)-but-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(2'-methyl-biphenyl-4-yl)-but-2-enoate by a procedure analogous to that described in example 50b.
c)
The title compound (1.80 g, 78%) was prepared as a colourless oil from (£)-3-(2'-methyl- biphenyl-4-yl)-but-2-en-1-ol (1.19 g, 4.99 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)- propionate (1.31 g, 6.48 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 2.17 (3H, d), 2.28 (3H, s), 2.96 (2H, d), 3.30-3.41 (1 H, m), 3.54-3.66 (1H, m), 3.98 (1 H, t), 4.16 (2H, q), 4.74 (2H, d), 6.11 (1 H, tm), 6.88 (2H, dm), 7.16 (2H, dm), 7.20-7.32 (6H, m), 7.47 (2H, dm). LCMS: 679 (M+221), 633 (679-EtOH), 481 (M+Na), 476 (M+NH4), 221 (100%). EXAMPLE 93
Figure imgf000127_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(2'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid
The title compound was prepared by hydrolysis of (£)-(S)-ethyl 2-ethoxy-3-{4-[3-(2'-methyl- biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate (example 92) (918 mg, 2.0 mmol) with sodium hydroxide by a procedure analogous to that described in example 51 , yielding (£)-(S)- 2-ethoxy-3-{4-[3-(2'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid as a colourless gum, which contained 0.25 mol equivalents of ethyl acetate; 586 mg (64%). 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.27 (0.75H, t, AcOEt), 2.04 (0.75H, s, AcOEt), 2.19 (3H, d), 2.29 (3H, s), 2.96 (1H, dd), 3.09 (1 H, dd), 3.41-3.53 (1 H, m), 3.53-3.65 (1H, m), 4.06 (1 H, dd), 4.12 (0.5H, q, AcOEt), 4.75 (2H, d), 6.12 (1 H, tm), 6.89 (2H, dm), 7.16 (2H, dm), 7.20-7.34 (6H, m), 7.48 (2H, dm), carboxylic acid proton not observed. LCMS: 651 (M+221), 453 (M+Na), 221 (100%).
EXAMPLE 94
Figure imgf000127_0002
(£)-(S)-Ethyl 3-{4-[3-(2',5'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate
a) The colourless oil, (£)-ethyl 3-(2',5'-dimethoxy-biphenyl-4-yl)-but-2-enoate was prepared from (£)-ethyl 3-(4-bromophenyl)-but-2-enoate (example 50a) and 2,5-dimethoxyphenyl boronic acid by a procedure analogous to that described in example 52a.
b)
The colourless gum (£)-3-(2',5'-dimethoxy-biphenyl-4-yl)-but-2-en-1-oI was prepared by DIBAL-H reduction of (£)-ethyl 3-(2',5'-dimethoxy-biphenyl-4-yl)-but-2-enoate by a procedure analogous to that described in example 52b.
c)
The title compound (0.765 g, 61%) was prepared as a colourless gum from (£)-3-(2',5'- dimethoxy-biphenyI-4-yl)-but-2-en-1-ol (0.711 g, 2.50 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (0.655 g, 2.75 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 2.16 (3H, d), 2.96 (2H, d), 3.31-3.41 (1 H, m), 3.55-3.65 (1H, m), 3.76 (3H, s), 3.81 (3H, s), 3.98 (1 H, t), 4.17 (2H, q), 4.74 (2H, d), 6.10 (1H, tm), 6.81-6.95 (5H, m), 7.16 (2H, dm), 7.45-7.53 (4H, m). LCMS: 771 (M+267), 527 (M+Na), 422 (M+NH4), 267 (100%).
EXAMPLE 95
Figure imgf000128_0001
(£)-(S)-3-{4-[3-(2',5'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(2',5'-dimethoxy-biphenyl-4-yl)- but-2-enyloxy]-phenyl}-2-ethoxy-propionate (Example 94) (0.62 g, 1.23 mmol) and sodium hydroxide (1 M, 2.0 ml, 2.0 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-ethyl 3-{4-[3-(2',5'-dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid as a colourless glass; 0.485 g (83%).
1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 2.16 (3H, d), 2.96 (1H, dd), 3.10 (1H, dd), 3.42- 3.51 (1 H, m), 3.51-3.65 (1 H, m), 3.75 (3H, s), 3.80 (3H, s), 4.05 (1H, dd), 4.74 (2H, d), 6.10 (1H, tm), 6.81-6.94 (5H, m), 7.17 (2H, dm), 7.43-7.53 (4H, m), carboxylic acid proton not observed. LCMS: 743 (M+267), 499 (M+Na), 494 (M+NH4), 267 (100%).
EXAMPLE 96
Figure imgf000129_0001
(£)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a)
A solution of triethyl 2-phosphonobutyrate (17.7 g, 70.0 mmol) in dry THF (30 ml) was added dropwise, at 0°C, to a stirred suspension of sodium hydride (50% dispersion in mineral oil, 2.90 g, 60.4 mmol) in dry THF (30 ml) and the mixture stirred for 30 min. A solution of 4- bromoacetophenone (7.96 g, 39.99 mmol) in THF (80 ml) was added over 20 min., the re- suiting mixture warmed to room temperature and stirring continued overnight. Second portions of triethyl 2-phosphonobutyrate (10.11 g, 40.1 mmol) and sodium hydride (2.90 g, 60.4 mmol) were then added at room temperature, and stirring continued for a further 24 h; TLC at this stage showed that a substantial amount of unreacted 4-bromo acetophenone starting material was still present. The reaction was worked up by adding 1 N HCl (200 ml) and ethyl acetate (100ml), the organic layer collected and the aqueous layer extracted with ethyl acetate (3 x 100ml). The combined organic layers were washed with brine, dried (MgSO4) and concentrated to give an orange gum, which was purified by column chromatography on silica gel (2% diethyl ether in n-heptane eluent) to give the orange oil, (£ Z)-ethyl 3-(4- bromophenyl)-2-ethyl-but-2-enoate (3.47 g, 29%) as a mixture of double-bond isomers.
b) A toluene solution of DIBAL-H (1M, 29.0 ml, 29.0 mmol) was added dropwise at -70°C to a stirred THF (100 ml) solution of (£XZ)-ethyl 3-(4-bromophenyl)-2-ethyl-but-2-enoate (3.45 g, 11.6 mmol), and the solution stirred for 40 min. Methanol (1 ml) was carefully added, followed by 1N HCl (300 ml) and ethyl acetate (200 ml). The aqueous layer was separated and further extracted with ethyl acetate (2 x 150 ml). The combined organic layers were washed with brine, dried (MgSO ), and concentrated to give an orange gum, which was separated into its two major constituents by column chromatography on silica gel (15% ethyl acetate in n-heptane eluent). The two products, in order of elution, were (Z)-3-(4-bromo-phenyl)-2-ethyl- but-2-en-1-ol (0.365 g, 12%) and (£)-3-(4-bromophenyl)-2-ethyl-but-2-en-1-ol (0.89 g, 30%).
c)
The title compound (843 mg, 89%) was prepared from (£)-3-(4-bromophenyl)-2-ethyl-but-2- en-1-ol (510 mg, 2.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (500 mg, 2.10 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 0.94 (3H, t), 1.20 (3H, t), 1.23 (3H, t), 2.01 (3H, s), 2.05 (2H, q), 2.97 (2H, d), 3.31-3.43 (1H, m), 3.54-3.68 (1H, m), 3.99 (1H, t), 4.17 (2H, q), 4.61 (2H, s), 6.89 (2H, dm), 7.04 (2H, dm), 7.18 (2H, dm), 7.45 (2H, dm).
EXAMPLE 97
Figure imgf000130_0001
(£)-(S)-3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(4-bromophenyl)-2-ethyI-but-2- enyloxy]-phenyl}-2-ethoxy-propionate (Example 96) (0.78 g, 1.64 mmol) and sodium hydroxide (1M, 3.3 ml, 3.3 mmol) by a procedure analogous to that described in example 51, yielding (£)-(S)-3-{4-[3-(4-bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid (0.703 g, 96%) as a pale yellow oil, which contained a small amount of dichloromethane; 0.703 g (96%).
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 1.26 (ethyl acetate impurity, 0.6H, t), 2.04 (ethyl acetate impurity, 0.4H, s), 2.16 (3H, s), 2.96 (1 H, dd), 3.10 (1 H, dd), 3.42-3.52 (1H, m), 3.53- 3.68 (1 H, m), 3.80 (3H, s), 4.07 (1H, dd), 4.12 (ethyl acetate impurity, 0.4H), 4.74 (2H, d), 5.30 (CH2CI2, trace), 6.10 (1H, t), 6.85-6.95 (3H, m), 7.12-7.20 (2H, m), 7.21-7.32 (2H, m), 7.45-7.50 (4H, m), carboxylic acid proton not observed.
EXAMPLE 98
Figure imgf000131_0001
(Z)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
The title compound (535 mg, 81%) was prepared from (Z)-3-(4-bromophenyl)-2-ethyl-but-2- en-1-ol (prepared as described in example 96b) (355 mg, 1.39 mmol) and (S)-ethyl 2-ethoxy- 3-(4-hydroxyphenyl)-propionate (348 mg, 1.46 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.11 (3H, t), 1.16 (3H, t), 1.21 (3H, t), 2.04 (3H, s), 2.37 (2H, q), 2.93 (2H, d), 3.29-3.40 (1 H, m), 3.53-3.65 (1H, m), 3.95 (1 H, t), 4.16 (2H, q), 4.25 (2H, s), 6.70 (2H, dm), 7.03-7.12 (4H, m), 7.40 (2H, dm). Microanalysis Calculated % C: 63.16, H: 6.57. Found % C: 63.34, H: 6.66.
EXAMPLE 99
Figure imgf000131_0002
(Z)-(S)-3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (Z)-(S)-ethyl 3-{4-[3-(4-bromophenyl)-2-ethyl-but-2- enyloxy]-phenyl}-2-ethoxy-propionate (Example 98) (475 mg, 1.0 mmol) and sodium hydrox- ide (1 M, 2.0 ml, 2.0 mmol) by a procedure analogous to that described in example 51 , yielding (Z)-(S)-3-{4-[3-(4-bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid (0.424 g, 95%) as a pale yellow oil.
1H NMR (300 MHz, CDCI3) δ: 1.11 (3H, t), 1.18 (3H, t), 2.04 (3H, s), 2.37 (2H, q), 2.94 (1H, dd), 3.04 (1H, dd), 3.40-3.53 (1H, m), 3.53-3.64 (1H, m), 4.03 (1H, dd), 4.25 (2H, s), 6.71 (2H, dm), 7.02-7.14 (4H, m), 7.40 (2H, dm), carboxylic acid proton not observed.
EXAMPLE 100
Figure imgf000132_0001
(£)-(S)-Ethyl 3-{4-[3-(4'-ferf-Butyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a) The colourless oil, (£)-ethyl 3-(4'-ferf-butyl-biphenyl-4-yl)-but-2-enoate was prepared from (£)-ethyl 3-(4-bromophenyl)-but-2-enoate (example 50a) and 4-ferf-butylphenylboronic acid by a procedure analogous to that described in example 52a
b) The colourless gum (£)-3-(4'-feτ-butyl-biphenyI-4-yl)-but-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(4'-ferf-butyl-biphenyl-4-yl)-but-2-enoate by a procedure analogous to that described in example 52b.
c) The title compound (0.375 g, 75%) was prepared as a colourless gum from (E)-3-(4'-tert- butyl-biphenyl-4-yl)-but-2-en-1-ol (0.280 g, 1.00 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (0.250 g, 1.05 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 1.37 (9H, s), 2.17 (3H, d), 2.97 (2H, d), 3.30-3.43 (1 H, m), 3.53-3.67 (1H, m), 3.98 (1 H, t), 4.17 (2H, q), 4.73 (2H, d), 6.11 (1H, tm), 6.88 (2H, dm), 7.17 (2H, dm), 7.43-7.60 (8H, m). LCMS: 763 (M+263), 523 (M+Na), 263 (100%).
EXAMPLE 101
Figure imgf000133_0001
(£)-(S)-Ethyl 3-{4-[3-(3',5'-Bis-trifluoromethyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate
a)
The colourless solid, (£)-ethyl 3-(3',5'-bis-trifluoromethyl-biphenyl-4-yl)-but-2-enoate was prepared from (£)-ethyl 3-(4-iodophenyl)-but-2-enoate (example 91a) and 3,5-bis-
(trifluoromethyl)phenyl boronic acid by a procedure analogous to that described in example 91b.
b) The colouriess solid (£)-3-(3',5'-bis-trifluoromethyl-biphenyl-4-yl)-but-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(3',5'-bis-trifluoromethyl-biphenyl-4-yl)-but-2-enoate by a procedure analogous to that described in example 50b.
c) The title compound (656 mg, 81%) was prepared as a colourless oil from (£)-3-(3',5'-bis- trifluoromethyl-biphenyl-4-yI)-but-2-en-1-ol (500 mg, 1.39 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (348 mg, 1.46 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.18 (3H, d), 2.97 (2H, d), 3.30-3.43 (1H, m), 3.56-3.69 (1 H, m), 3.98 (1H, t), 4.17 (2H, q), 4.75 (2H, d), 6.15 (1H, tm), 6.89 (2H, dm), 7.18 (2H, dm), 7.52-7.62 (4H, m), 7.85 (1 H, s), 8.01 (2H, s). LCMS: 603 (100%, M+Na), 598 (M+NH4), 343.
EXAMPLE 102
Figure imgf000134_0001
(£)-(S)-3-{4-[3-(3',5'-Bis-trifluoromethyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(3',5'-bis-trifluoromethyl-biphenyl- 4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate (Example 101) (625 mg, 1.08 mmol) and sodium hydroxide (1 M, 4.3 ml, 4.3 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-3-{4-[3-(3',5'-bis-trifluoromethyl-biphenyl-4-yl)-but-2-enyloxy]- phenyl}-2-ethoxy-propionic acid (535 mg, 90%) as a colourless gum. 1H NMR (300 MHz, CDCI3) δ: 1.20 (3H, t), 2.18 (3H, d), 2.98 (1 H, dd), 3.10 (1H, dd), 3.43- 3.53 (1 H, m), 3.53-3.66 (1 H, m), 4.07 (1H, dd), 4.76 (2H, d), 6.15 (1 H, tm), 6.90 (2H, dm), 7.19 (2H, dm), 7.50-7.62 (4H, m), 7.85 (1H, s), 8.01 (2H, s), carboxylic acid proton not observed. EXAMPLE 103
Figure imgf000135_0001
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4'-isopropyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate
a)
The colourless solid, (£)-ethyI 3-(4'-isopropyl-biphenyl-4-yl)-but-2-enoate was prepared from (£)-ethyl 3-(4-bromophenyl)-but-2-enoate (example 50a) and 4-isopropylphenyl boronic acid by a procedure analogous to that described in example 52a.
Mpt. 96.5-97.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.29 (6H, d), 1.32 (3H, t), 2.61 (3H, d), 2.97 (1 H, septet), 4.22 (2H, q), 6.20 (1H, m), 7.32 (2H, dm), 7.50-7.65 (6H, m). MS: 308 (100%, M+), 293, 178. Microanalysis Calculated % C: 81.78, H: 7.84. Found % C: 81.96, H: 8.22.
b)
The colourless solid (£)-3-(4'-isopropyl-biphenyl-4-yl)-but-2-en-1-ol was prepared by DIBAL-
H reduction of (£)-ethyl 3-(4'-isopropyl-biphenyl-4-yl)-but-2-enoate by a procedure analogous to that described in example 50b.
Mpt. 110.5-112.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.29 (6H, d), 2.10 (3H, s), 2.94 (1H, sep- tet), 4.37 (2H, d), 6.03 (1H, t), 7.29 (2H, dm), 7.40-7.60 (6H, m). MS: 266 (M+), 251 (M-Me),
223 (100%, M-/-Pr). Microanalysis Calculated % C: 85.67, H: 8.32. Found % C: 85.55, H:
8.55.
c) The title compound (410 mg, 84%) was prepared as a colourless solid from (£)-3-(4'- isopropyl-biphenyI-4-yl)-but-2-en-1-ol (266 mg, 1.00 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (250 mg, 1.05 mmol) by a procedure analogous to that described in example 52c.
Mpt. 70-73°C. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 1.29 (6H, d), 2.17 (3H, d), 2.89-3.01 (3H, m), 3.30-3.41 (1H, m), 3.55-3.66 (1H, m), 3.98 (1 H, t), 4.17 (2H, q), 4.74 (2H, d), 6.11 (1 H, tm), 6.88 (2H, dm), 7.17 (2H, dm), 7.30 (2H, dm), 7.46-7.57 (6H, m). LCMS: 735 (M+249), 509 (M+Na), 249 (100%).
EXAMPLE 104
Figure imgf000136_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(4'-isopropyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid
The title compound was prepared from (£)-(S)-ethyl 2-ethoxy-3-{4-[3-(4'-isopropyl-biphenyl- 4-yl)-but-2-enyloxy]-phenyl}-propionate (Example 103) (400 mg, 0.822 mmol) and sodium hydroxide (1M, 3.29 ml, 3.29 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-2-ethoxy-3-{4-[3-(4'-isopropyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}- propionic acid (380 mg, 100%) as a beige coloured solid.
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 1.29 (6H, d), 2.17 (3H, d), 2.89-3.01 (2H, m), 3.10 (1 H, dd), 3.42-3.64 (2H, m), 4.06 (1H, dd), 4.74 (2H, d), 6.11 (1 H, tm), 6.90 (2H, dm), 7.16 (2H, dm), 7.30 (2H, dm), 7.46-7.57 (6H, m), carboxylic acid proton not observed. LCMS: 707 (M+249), 481 (M+Na), 249 (100%).
^
EXAMPLE 105
Figure imgf000137_0001
(E)-(S)- 3-{4-[3-(3,5-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethόxy-propionic acid ethyl ester
The title compound was prepared from 3',5'-dimethoxyacetophenone (7.0 g, 0.0388 mol) by a sequence analogous to that described in example 3, yielding 0.165 g (35%) of (£)-(S)- 3- , {4-[3-(3,5-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester. 1H NMR (200 MHz, CDCI3) δ: 1.1-1.27 (6H, m), 2.97 (2H, d), 3.3-3.4 (1H, m), 3.52-3.7 (1 H, m), 4.0 (1 H, t), 4.15 (2H, q), 4.7 (2H, d), ), 6.39 (1H, dd), 6.57 (2H, dd), 6.88 (2H, d), 7.17 (2H, d).
EXAMPLE 106
Figure imgf000137_0002
(£)-(S)-3-{4-[3-(3'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(3'-acetyl-biphenyl-4-yI)-but-2- enyloxy]-phenyl}-2-ethoxy-propionate (Example 105) (140 mg, 0.288 mmol) and sodium hydroxide (1 M, 0.58 ml, 0.58 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-3-{4-[3-(3'-acetyl-biphenyI-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid (33 mg, 25%) as a yellow coloured solid.
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 2.18 (3H, d), 2.66 (3H, s), 2.97 (1H, dd), 3.10 (1 H, dd), 3.41-3.65 (2H, m), 4.07 (1 H, dd), 4.75 (2H, d), 6.13 (1H, tm), 6.90 (2H, dm), 7.17 (2H, dm), 7.49-7.63 (5H, m), 7.80 (1H, dm), 7.93 (1H, dm), 8.19 (1H, m), carboxylic acid proton not observed. LCMS: 707 (M+249), 481 (M+Na), 249 (100%).
EXAMPLE 107
Figure imgf000138_0001
(£)-(S)-Ethyl 3-{4-[3-(4'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a)
(£)-3-(4-lodophenyl)-but-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(4- iodophenyl)-but-2-enoate (example 91a) by a procedure analogous to that described in example 50b.
1H NMR (300 MHz, CDCI3) δ: 1.36 (1H, br s), 2.04 (3H, d), 2.66 (3H, s), 4.36 (2H, br d), 5.96 (1 H, tm), 7.15 (2H, dm), 7.65 (2H, dm).
b]
The pale yellow solid, (£)-1-[4'-(3-hydroxy-1-methyl-propenyl)-biphenyl-4-yl]-ethanone was prepared from 4-acetylphenyI boronic acid and (£)-3-(4-iodophenyl)-but-2-en-1-ol by a procedure analogous to that described in example 54a. 1H NMR (300 MHz, CDCI3) δ: 1.55 (1 H, br s), 2.12 (3H, d), 2.64 (3H, s), 4.41 (2H, d), 6.07 (1H, tm), 7.52 (2H, dm), 7.61 (2H, dm), 7.70 (2H, dm), 8.03 (2H, dm). C)
The title compound (275 mg, 75%) was prepared from (£)-1-[4'-(3-hydroxy-1-methyl- propenyl)-biphenyl-4-yl]-ethanone (200 mg, 0.75 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (188 mg, 0.79 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.18 (3H, d), 2.64 (3H, s), 2.97 (2H, d), 3.30-3.42 (1H, m), 3.55-3.67 (1H, m), 3.98 (1H, t), 4.17 (2H, q), 4.75 (2H, d), 6.14 (1H, tm), 6.89 (2H, dm), 7.17 (2H, dm), 7.54 (2H, dm), 7.61 (2H, dm), 7.70 (2H, dm), 8.03 (2H, dm).
EXAMPLE 108
Figure imgf000139_0001
(£)-(S)-3-{4-[3-(4'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(4'-acetyl-biphenyl-4-yl)-but-2- enyloxy]-phenyl}-2-ethoxy-propionate (Example 107) (200 mg, 0.411 mmol) and sodium hydroxide (1 M, 1.64 ml, 1.64 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-3-{4-[3-(4'-acetyl-biphenyl-4-yI)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid (70 mg, 37%) as a yellow coloured solid.
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 2.18 (3H, d), 2.64 (3H, s), 2.97 (1 H, dd), 3.11 (1H, dd), 3.45-3.65 (2H, m), 4.08 (1 H, dd), 4.75 (2H, d), 6.14 (1H, tm), 6.90 (2H, dm), 7.17 (2H, dm), 7.54 (2H, dm), 7.61 (2H, dm), 7.70 (2H, dm), 8.03 (2H, dm), carboxylic acid proton not observed. LCMS: 707 (M+249), 459 (M+H), 249 (100%). EXAMPLE 109
Figure imgf000140_0001
(£)-(S)-Ethyl 2-Ethoxy-3-[4-(3-[1 ,1';3',1"]terphenyl-5'-yl-allyloxy)-phenyl]-propionate
a)
Sodium (0.90 g, 39.1 mmol) was added to ethanol (50 ml) at 20°C and the mixture stirred until the metal had fully reacted. Triethyl phosphonoacetate (10.1 g, 45 mmol) was added, the mixture stirred for 10 min, then a solution of 3,5-dibromobenzaldehyde (7.92 g, 30 mmol) in ethanol (50 ml) was added and the reaction mixture heated to 80°C under reflux for 72h. The solution was cooled, the ethanol evaporated and the resulting yellow residue partitioned between 1 N HCl (100 ml) and ethyl acetate (100 ml). The aqueous layer was collected and further extracted with ethyl acetate (3 x 100 ml). The organic layers were combined, washed with brine, dried (MgSO4) and evaporated to a yellow solid, which was purified by column chromatography on silica gel (2% diethyl ether in n-heptane eluent) to give the product, (£)- ethyl 3-(3,5-dibromophenyl)-acrylate, as a colourless solid; 4.54 g (45%). Mpt. 80-82°C. 1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 4.27 (2H, q), 6.42 (1H, d), 7.51 (1 H, d), 7.58 (2H, d), 7.66 (1H, t). MS: 336/334/332 (M+), 308/306/304, 291/289/287 (100%, M- Oet), 180/182.
b)
The colourless solid, (£)-ethyl 3-[1 ,1';3',1"]terphenyl-5'-yl-acrylate was prepared from (£)- ethyl 3-(3,5-dibromophenyl)-acrylate and phenylboronic acid by a procedure analogous to that described in example 52a.
Mpt. 78.5-81.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.36 (3H, t), 4.29 (2H, q), 6.58 (1 H, d), 7.33- 7.54 (6H, m), 7.60-7.68 (4H, m), 7.72 (2H, d), 7.81 (1H, t), 7.82 (1H, d). MS: 328 (100%, M+), 283, 256, 252, 241 , 239. C)
The colourless solid (£)-3-[1 ,1';3',1"]terphenyl-5'-yl-prop-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-[1 ,1';3',1"]terphenyl-5'-yl-acrylate by a procedure analogous to that described for example 52b. Mpt. 140-141.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.54 (1 H, br s), 4.38 (2H, d), 6.50 (1 H, dt), 6.75 (1 H, d), 7.30-7.52 (6H, m), 7.53-7.73 (7H, m). MS: 286 (M+), 258 (100%), 243, 230, 165, 91 , 77.
d) The title compound (426 mg, 80%) was prepared from (£)-3-[1 ,1 ';3',1 "]terphenyl-5'-yl-prop-2- en-1-ol (300 mg, 1.05 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyI)-propionate (262 mg, 1.10 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.16 (3H, t), 1.22 (3H, t), 2.96 (2H, d), 3.29-3.41 (1 H, m), 3.54- 3.66 (1H, m), 3.98 (1H, t), 4.16 (2H, q), 4.73 (2H, d), 6.54 (1H, dt), 6.85 (1H, d), 6.90 (2H, dm), 7.17 (2H, dm), 7.30-7.50 (6H, m), 7.55-7.71 (7H, m). LCMS: 775 (M+269), 729 (100%, M+269-EtOH), 461 (M+H-EtOH), 269.
EXAMPLE 110
Figure imgf000141_0001
(£)-(S)-2-Ethoxy-3-[4-(3-[1 ,1 ';3',1 "]terphenyl-5'-yl-allyloxy)-phenyl]-propionic acid
The title compound was prepared from (£)-(S)-ethyl 2-ethoxy-3-[4-(3-[1 ,1';3',1"]terphenyl-5'- yl-a!lyloxy)-phenyl]-propionate (Example 109) (405 mg, 0.8 mmol) and sodium hydroxide (1 M, 1.6 ml, 1.6 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-2-ethoxy-3-[4-(3-[1 ,1';3',1"]terphenyl-5'-yl-allyIoxy)-phenyI]-propionic acid (352 mg, 92%) as a colourless glass. 1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 2.97 (1H, dd), 3.09 (1H, dd), 3.41-3.53 (1H, m), 3.53-3.65 (1H, m), 4.07 (1H, dd), 4.73 (2H, dd), 6.54 (1H, dt), 6.85 (1H, dm), 6.92 (2H, dm), 7.17 (2H, dm), 7.32-7.50 (6H, m), 7.55-7.71 (7H, m), carboxylic acid proton not observed. LCMS: 747 (M+269), 501 (M+Na), 496 (M+NH4), 269 (100%).
EXAMPLE 111
Figure imgf000142_0001
(£,£)-(S)-Ethyl 3-(4'-{3-[4-(2-Ethoxy-2-ethoxycarbonyl-ethyl)-phenoxy]-1-methyl-propenyl}- biphenyl-3-yl)-but-2-enoate
a) The yellow oil (£,£)-ethyl 3-[4'-(3-hydroxy-1 -methyl-propenyl)-biphenyl-3-yl]-but-2-enoate was prepared from (£)-1-[4'-(3-hydroxy-1-methyl-propenyl)-biphenyl-3-yl]-ethanone (example
105a) and triethyl phosphonoacetate by a reaction analogous to that described for example
50a.
1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 1.37 (1H, br t), 2.13 (3H, d), 2.62 (3H, d), 4.23 (2H, q), 4.41 (2H, br t), 6.06 (1H, tm), 6.19 (1H, m), 7.40-7.62 (7H, m), 7.68 (1H, m). MS: 336
(M+), 334, 308, 293, 43 (100%).
b)
The title compound (230 mg, 58%) was prepared from (E,£)-ethyl 3-[4'-(3-hydroxy-1-methyI- propenyI)-biphenyI-3-yl]-but-2-enoate (235 mg, 0.70 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (175 mg, 0.73 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 1.33 (3H, t), 2.17 (3H, d), 2.62 (3H, d), 2.96 (2H, d), 3.30-3.42 (1H, m), 3.55-3.67 (1H, m), 3.98 (1H, t), 4.17 (2H, q), 4.23 (2H, q), 4.75 (2H, d), 6.13 (1 H, tm), 6.20 (1H, m), 6.89 (2H, dm), 7.17 (2H, dm), 7.42-7.62 (7H, m), 7.67 (1H, m). MS: 556 (M+), 319 (100%).
EXAMPLE 112
Figure imgf000143_0001
(£,£)-(S)- 3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-1-methyl-propenyl}-biphenyl-3-yl)- but-2-enoic acid
The title compound was prepared from (£,£)-(S)-ethyl 3-(4'-{3-[4-(2-ethoxy-2- ethoxycarbonyl-ethyI)-phenoxy]-1-methyI-propenyl}-biphenyl-3-yl)-but-2-enoate (example 111) (190 mg, 0.34 mmol) and sodium hydroxide (1M, 1.4 ml, 1.4 mmol) by a procedure analogous to that described in example 51 , yielding (E,E)-(S)- 3-(4'-{3-[4-(2-carboxy-2- ethoxy-ethyl)-phenoxy]-1-methyl-propenyl}-biphenyl-3-yl)-but-2-enoic acid (135 mg, 79%) as a colourless solid.
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 2.18 (3H, m), 2.64 (3H, s), 3.01 (1H, dd), 3.08 (1 H, dd), 3.40-3.70 (2H, m), 4.07 (1 H, dd), 4.75 (2H, dd), 6.12 (1 H, br m), 6.23 (1H, s), 6.89 (2H, dm), 7.18 (2H, dm), 7.40-7.70 (8H, m), carboxylic acid protons not observed.
EXAMPLE 113
Figure imgf000143_0002
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(3'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate
a)
The colourless oil (£)-ethyl 3-(3'-methoxy-biphenyl-4-yl)-but-2-enoate was prepared from (£)- ethyl 3-(4-bromophenyl)-but-2-enoate (example 50a) and 3-methoxyphenyl boronic acid by a procedure analogous to that described in example 52a.
1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 2.61 (3H, d), 3.87 (3H, s), 4.23 (2H, q), 6.20 (1H, m), 6.91 (1 H, ddd), 7.13 (1 H, dd), 7.19 (1 H, ddd), 7.37 (1H, dd), 7.51-7.62 (4H, m). MS: 296 (100%, M+), 281 , 267, 251 , 224. Microanalysis Calculated % C: 77.00, H: 6.80. Found % C: 77.02, H: 6.93.
b)
The colourless solid (£)-3-(3'-methoxy-biphenyl-4-yl)-but-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(3'-methoxy-biphenyl-4-yl)-but-2-enoate as described for example 52b.
, Mpt. 62-68°C. 1H NMR (300 MHz, CDCI3) δ: 1.40 (1H, br s), 2.12 (3H, d), 3.87 (3H, s), 4.39 (2H, d), 6.05 (1H, tm), 6.89 (1 H, ddd), 7.13 (1H, dd), 7.19 (1H, ddd), 7.35 (1H, dd), 7.49 (2H, dm), 7.56 (2H, dm). MS: 254 (M+), 239, 211 (100%).
c)
The title compound (280 mg, 59%) was prepared as a colourless solid from (£)-3-(3'~ methoxy-biphenyl-4-yl)-but-2-en-1-ol (254 mg, 1.00 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (250 mg, 1.05 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 2.17 (3H, d), 2.96 (2H, d), 3.30-3.42 (1H, m), 3.55-3.67 (1H, m), 3.87 (3H, s), 3.98 (1H, t), 4.17 (2H, q), 4.74 (2H, d), 6.12 (1H, tm), 6.85-6.92 (3H, m), 7.11-7.22 (4H, m), 7.35 (1 H, dd), 7.47-7.59 (4H, m). MS: 474 (M+), 237 (100%). Microanalysis Calculated % C: 75.92, H: 7.22. Found % C: 76.04, H: 7.39. EXAMPLE 114
Figure imgf000145_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(3'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyI}-propionic acid
The title compound was prepared from (£)-(S)-ethyl 2-ethoxy-3-{4-[3-(3'-methoxy-biphenyl-4- yl)-but-2-enyloxy]-phenyl}-propionate (example 113) (230 mg, 0.49 mmol) and sodium hydroxide (1M, 0.97 ml, 0.97 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-2-ethoxy-3-{4-[3-(3'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid (183 mg, 85%) as a colourless solid.
1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 2.17 (3H, d), 2.97 (1H, dd), 3.10 (1H, dd), 3.41- 3.53 (1 H, m), 3.53-3.65 (1H, m), 3.87 (3H, s), 4.07 (1H, dd), 4.74 (2H, dd), 6.11 (1H, tm), 6.86-6.93 (3H, m), 7.11-7.22 (4H, m), 7.35 (1 H, dd), 7.47-7.59 (4H, m), carboxylic acid pro- ton not observed. LCMS: 683 (M+237), 469 (M+Na), 237 (100%).
EXAMPLE 115
Figure imgf000145_0002
(£)-(S,S/?)-Ethyl 2-Ethoxy-3-(4-{3-[3'-(1-hydroxy-ethyl)-biphenyl-4-yl]-but-2-enyloxy}-phenyl)- propionate a)
The colourless solid (£)-(S/f?)-3-[3'-(1-hydroxy-ethyl)-biphenyI-4-yl]-but-2-en-1-ol was prepared by DIBAL-H reduction of (£)-1-[4'-(3-hydroxy-1-methyl-propenyl)-biphenyl-3-yl]- ethanone (example 105a) by a procedure analogous to that described in example 52b. Mpt. 94-100°C. H NMR (300 MHz, DMSO-d6) δ: 1.37 (3H, d), 2.02 (3H, d), 4.18 (2H, br dd), 4.75 (1 H, br t, OH), 4.78 (1H, dq), 5.21 (1 H, d, OH), 5.98 (1H, tm), 7.33 (1 H, dm), 7.40 (1 H, dd), 7.48-7.54 (3H, m), 7.60-7.66 (3H, m). MS: 268 (100%, M+), 253, 235, 225. Microanalysis Calculated % C: 80.56, H: 7.51. Found % C: 80.21 , H: 7.78.
b)
The title compound (490 mg, 57%) was prepared as a colourless oil from (£)-(S )-3-[3'-(1- hydroxy-ethyl)-biphenyl-4-yI]-but-2-en-1-ol (500 mg, 1.86 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (422 mg, 1.77 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 1.56 (3H, d), 1.89 (1H, d, OH), 2.18 (3H, d), 2.97 (2H, d), 3.30-3.42 (1 H, m), 3.54-3.66 (1H, m), 3.98 (1 H, t), 4.17 (2H, q), 4.75 (2H, d), 4.99 (1 H, dq), 6.12 (1 H, tm), 6.85 (2H, dm), 7.18 (2H, dm), 7.32-7.48 (2H, m), 7.48- 7.67 (6H, m).
EXAMPLE 116
Figure imgf000146_0001
(£)-(S,S )-2-Ethoxy-3-(4-{3-[3'-(1-hydroxy-ethyl)-biphenyl-4-yl]-but-2-enyloxy}-phenyl)- propionic acid
The title compound was prepared from (£)-(S,S/ )~ethyl 2-ethoxy-3-(4-{3-[3'-(1-hydroxy- ethyl)-biphenyl-4-yl]-but-2-enyloxy}-phenyI)-propionate (example 115) (460 mg, 0.94 mmol) and sodium hydroxide (1 M, 1.9 ml, 1.9 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S,S )-ethyl 2-ethoxy-3-(4-{3-[3'-(1-hydroxy-ethyl)-biphenyl-4-yl]- but-2-enyloxy}-phenyl)-propionic acid (434 mg, 100%) as a colourless gum. 1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 1.55 (3H, d), 2.17 (3H, d), 2.96 (1 H, dd), 3.09 (1 H, dd), 3.41-3.53 (1 H, m), 3.54-3.66 (1 H, m), 4.06 (1 H, dd), 4.75 (2H, d), 4.98 (1H, q), 6.12 (1 H, tm), 6.90 (2H, dm), 7.17 (2H, dm), 7.32-7.46 (2H, m), 7.47-7.63 (6H, m), carboxylic acid proton not observed.
EXAMPLE 117
Figure imgf000147_0001
(£)-(S)-Ethyl 3-{4-[3-(3,5-Dibromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a)
Sodium (0.49 g, 21.3 mmol) was added to ethanol (50 ml) at room temperature and the mixture stirred until the metal had fully reacted. Triethyl phosphonoacetate (5.49 g, 24.5 mmol) was added, the solution stirred for 15 min, then an ethanol (100 ml) solution of 3,5- dibromoacetophenone (4.60 g, 16.6 mol) was added and the reaction mixture heated to 80°C under reflux for 72 h. The solution was cooled, the ethanol evaporated and the resulting orange residue partitioned between 1 N HCl (150 ml) and ethyl acetate (150 ml). The aqueous layer was collected and further extracted with ethyl acetate (2 x 100 ml). The organic layers were combined, washed with brine, dried (MgSO4) and evaporated to an orange/yellow gum, which was purified by column chromatography on silica gel (3% diethyl ether in n-heptane eluent) to give the product, (£)-ethyl 3-(3,5-dibromophenyl)-but-2-enoate, as a colourless wax; 4.06 g (70%).
1H NMR (300 MHz, CDCI3) δ: 1.32 (3H, t), 2.51 (3H, d), 4.22 (2H, q), 6.09 (1 H, m), 7.52 (2H, d), 7.64 (1H, t). MS: 350/348/346 (M+), 304/302/300 (M-EtOH), 115 (100%). Microanalysis Calculated % C: 41.41 , H: 3.48, Br: 45.92. Found % C: 41.75, H: 3.52, Br: 45.62. b)
(£)-Ethyl 3-(3,5-dibromophenyl)-but-2-enoate was reduced with DIBAL-H by a procedure analogous to that described in example 50b, to give the colourless oil (£)-3-(3,5-dibromo- phenyl)-but-2-en-1 -ol. 1H NMR (300 MHz, CDCI3) δ: 1.64 (1 H, br s), 2.01 (3H, d), 4.36 (2H, d), 5.96 (1 H, tm), 7.46 (2H, d), 7.54 (1H, t). MS: 308/306/304 (M+), 293/291/289 (M-Me), 266/264/262, 227/225/223, 131, 128, 115 (100%), 102.
c) The title compound (851 mg, 81%) was prepared from (£)-3-(3,5-dibromo-phenyl)-but-2-en- 1-ol (612 mg, 2.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (500 mg, 2.10 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.09 (3H, d), 2.96 (2H, d), 3.30-3.42 (1H, m), 3.54-3.66 (1H, m), 3.98 (1H, t), 4.17 (2H, q), 4.69 (2H, d), 6.04 (1H, tm), 6.85 (2H, dm), 7.16 (2H, dm), 7.48 (2H, d), 7.57 (1H, t). LCMS: 551/549/547 (100%, M+Na), 546/544/542 (M+NH4), 483/481/479 (M+H-EtOH).
EXAMPLE 118
Figure imgf000148_0001
(£)-(S)-3-{4-[3-(3,5-Dibromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(3,5-dibromophenyI)-but-2- enyloxy]-phenyl}-2-ethoxy-propionate (example 117) (840 mg, 1.60 mmol) and sodium hydroxide (1M, 16 ml, 16 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-3-{4-[3-(3,5-dibromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid (781 mg, 98%) as a colourless gum. 1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 2.08 (3H, d), 2.96 (1 H, dd), 3.09 (1H, dd), 3.41- 3.53 (1H, m), 3.55-3.67 (1H, m), 4.07 (1 H, dd), 4.70 (2H, d), 6.04 (I H, tm), 6.87 (2H, dm), 7.17 (2H, dm), 7.48 (2H, d), 7.58 (1 H, t), carboxylic acid proton not observed. LCMS: 523/521/519 (100%, M+Na), 518/516/514 (M+NH4), 455/453/451 (M+H-EtOH), 291/289/287.
EXAMPLE 119
Figure imgf000149_0001
(£)-(S)-Ethyl 3-{4-[3-(3,5-Dibromophenyl)-allyloxy]-phenyl}-2-ethoxy-propionate
a)
(£)-Ethyl 3-(3,5-dibromophenyl)-acrylate (example109a) was reduced with DIBAL-H by a procedure analogous to that described in example 50b, to give the colourless solid (£)-3-
(3,5-dibromophenyl)-prop-2-en-1-ol.
1H NMR (300 MHz, CDCI3) δ: 1.52 (1H, t, OH), 4.35 (2H, ddd), 6.36 (1H, dt), 6.50 (1H, dm),
7.44 (2H, d), 7.53 (1H, t). LCMS: 277/275/273 (100%, M+H-H2O), 196/194 (M+H-H2O-Br),
100.
b)
The title compound (780 mg, 78%) was prepared from (£)-3-(3,5-dibromophenyl)-prop-2-en-
1-ol (584 mg, 2.0 mmol) and (S)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (500 mg,
2.10 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 2.96 (2H, d), 3.30-3.42 (1H, m), 3.55-
3.67 (1H, m), 3.97 (1 H, t), 4.17 (2H, q), 4.68 (2H, dd), 6.41 (1H, dt), 6.59 (1H, dm), 6.86 (2H, dm), 7.17 (2H, dm), 7.46 (2H, d), 7,53 (1H, t). EXAMPLE 120
Figure imgf000150_0001
(£)-(S)-3-{4-[3-(3,5-Dibromophenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(3,5-dibromophenyl)-allyloxy]~ phenyI}-2-ethoxy-propionate (example 119) (512 mg, 1.0 mmol) and sodium hydroxide (1 M, 10 ml, 10 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)- 3-{4-[3-(3,5-dibromophenyl)-alIyloxy]-phenyl}-2-ethoxy-propionic acid (96 mg, 20%) as a colourless gum.
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 2.97 (1H, dd), 3.09 (1 H, dd), 3.40-3.66 (2H, m), 4.06 (1H, dd), 4.68 (2H, dd), 6.42 (1 H, dt), 6.59 (1H, dm), 6.88 (2H, dm), 7.18 (2H, dm), 7.46 (2H, d), 7.58 (1H, t), carboxylic acid proton not observed. LCMS: 509/507/505 (M+Na), 504/502/500 (100%, M+NH4), 441/439/437 (M+H-EtOH), 277/275/273.
EXAMPLE 121
Figure imgf000150_0002
(£)-(S)-Ethyl 3-{4-[3-(4,4"-Di-fe/τ-butyl-[1 ,1 ';3',1 "]terphenyl-5'-yl)-allyloxy]-phenyl}-2-ethoxy- propionate a)
The colourless glass, (£)-ethyl 3-(4,4"-di-tert-butyl-[1 ,1';3',1"]terphenyl-5'-yl)-acrylate was prepared from (£)-ethyl 3-(3,5-dibromophenyI)-acrylate (example 109a) and 4-tert- butylphenylboronic acid by a procedure analogous to that described in example 52a. 1H NMR (300 MHz, CDCI3) δ: 1.36 (3H, t), 1.38 (18H, s), 4.29 (2H, q), 6.55 (1H, d), 7.43-7.52 (4H, m), 7.52-7.61 (4H, m), 7.70 (2H, d), 7.81 (1H, t), 7.82 (1 H, d). MS: 440 (M+), 425 (100%, M-Me), 205.
b) The colourless gum (£)-3-(4,4"-di-.eAt-butyl-[1 ,1';3',1"]terphenyl-5'-yl)-prop-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(4,4"-di-fert-butyI-[1 ,1';3',1"]terphenyl-5'-yl)- acrylate by a procedure analogous to that described for example 52b. 1H NMR (300 MHz, CDCI3) δ: 1.37 (18H, s), 1.48 (1H, br t), 4.37 (2H, m), 6.49 (1H, dt), 6.75 (1 H, dm), 7.45-7.52 (4H, m), 7.54-7.61 (6H, m), 7.68 (1 H, t). LCMS: 779 (M+381), 761 (779- H2O), 437, 421 (M+Na), 399 (M+H, 381 (100%, M+H-H2O).
c)
The title compound (368 mg, 79%) was prepared from (£)-3-(4,4"-di-fe/τ-butyl-
[1 ,1';3',1"]terphenyl-5'-yl)-prop-2-en-1-ol (300 mg, 0.75 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyI)-propionate (188 mg, 0.79 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 1.37 (18H, s), 2.96 (2H, d), 3.30-3.43 (1H, m), 3.54-3.67 (1H, m), 3.98 (1H, t), 4.16 (2H, q), 4.72 (2H, d), 6.52 (1H, dt), 6.85 (1H, d), 6.90 (2H, dm), 7.18 (2H, dm), 7.44-7.52 (4H, m), 7.54-7.63 (6H, m), 7.69 (1 H, m). LCMS: 641 (100%, M+Na), 636 (M+NH4), 381.
EXAMPLE 122
Figure imgf000152_0001
(£)-(S)-3-{4-[3-(4,4"-Di-terf-butyl-[1 ,1 ';3',1 "]terphenyl-5'-yl)-allyloxy]-phenyl}-2-ethoxy- propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(4,4"-di-terf-butyl- [1 ,1';3',1"]terphenyl-5'-yl)-allyloxy]-phenyI}-2-ethoxy-propionate (example 121) (345 mg, 0.56 mmol) and sodium hydroxide (1M, 1.1 ml, 1.1 mmol) by a procedure analogous to that de- ■„ scribed in example 51 , yielding (£)-(S)-3-{4-[3-(4,4"-di-terf-butyl-[1 ,1';3',1"]terphenyl-5'-yl)- allyloxy]-phenyl}-2-ethoxy-propionic acid (284 mg, 86%) as a colourless foam. 1H NMR (300 MHz, CDCI3) δ: 1.18 (3H, t), 1.38 (18H, s), 2.97 (1 H, dd), 3.10 (1H, dd), 3.41- 3.65 (2H, m), 4.07 (1 H, dd), 4.72 (2H, dm), 6.52 (1H, dt), 6.85 (1H, d), 6.92 (2H, dm), 7.17 (2H, dm), 7.44-7.52 (4H, m), 7.55-7.62 (6H, m), 7.69 (1H, m), carboxylic acid proton not observed.
EXAMPLE 123
Figure imgf000152_0002
(£)-(S)-EthyI 3-{4-[3-(3',5'-Dibromo-biphenyI-4-yl)-but-2-enyIoxy]-phenyl}-2-ethoxy-propionate a)
The colourless gum (£)-ethyl 3-(3',5'-dibromo-biphenyl-4-yl)-but-2-enoate was prepared from (£)-ethyl 3-(4-iodophenyl)-but-2-enoate (example 91a) and 3,5-dibromobenzene boronic acid by a procedure analogous to that described in example 52a.
1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 2.61 (3H, d), 4.22 (2H, q), 6.20 (1 H, m), 7.44-7.80 (7H, m). LCMS: 427/425/423 (100%, M+H), 381/379/377 (M+H-EtOH).
b) The colourless gum (£)-3-(3',5'-dibromo-biphenyl-4-yl)-but-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(3',5'-dibromo-biphenyl-4-yl)-but-2-enoate as described for example 52b, with the purification of the product being carried out by preparative HPLC. 1H NMR (300 MHz, CDCI3) δ: 1.45 (1H, br s), 2.12 (3H, d), 4.41 (2H, d), 6.05 (1 H, tm), 7.45- 7.54 (4H, m), 7.62 (1 H, t), 7.66 (2H, d). LCMS: 367/365/363 (100%, M+H-H2O), 286/284.
c)
The title compound (177 mg, 83%) was prepared as a colourless gum from (£)-3-(3',5'- dibromo-biphenyl-4-yl)-but-2-en-1-ol (135 mg, 0.35 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (90 mg, 0.38 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.16 (3H, d), 2.96 (2H, d), 3.31-3.43 (1 H, m), 3.55-3.67 (1H, m), 3.98 (1H, t), 4.17 (2H, q), 4.74 (2H, d), 6.13 (1H, tm), 6.88 (2H, dm), 7.17 (2H, dm), 7.45-7.56 (4H, m), 7.63 (1H, t), 7.66 (2H, d). LCMS: 627/625/623 (100%, M+Na), 365.
EXAMPLE 124
Figure imgf000153_0001
(£)-(S)-3-{4-[3-(3',5'-Dibromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(3',5'-dibromo-biphenyl-4-yI)-but- 2-enyloxy]-phenyl}-2-ethoxy-propionate (example 123) (110 g, 0.18 mmol) and sodium hy- droxide (1 M, 1.0 ml, 1.0 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-3-{4-[3-(3',5'-dibromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid (90 mg, 86%) as a colourless gum.
1H NMR (300 MHz, CDCI3) δ: 1.20 (3H, t), 2.18 (3H, d), 2.99 (1H, dd), 3.12 (1H, dd), 3.43- 3.68 (2H, m), 4.08 (1H, dd), 4.75 (2H, d), 6.13 (1H, tm), 6.91 (2H, dm), 7.19 (2H, dm), 7.45- 7.60 (4H, m), 7.60-7.74 (3H, m), carboxylic acid proton not observed. LCMS: 599/597/595 (100%, M+Na), 365.
EXAMPLE 125
Figure imgf000154_0001
(£)-(S)-Ethyl 3-{4-[3-(3',5'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate
a)
The colourless solid (£)-ethyI 3-(3',5'-dichloro-biphenyl-4-yl)-but-2-enoate was prepared from
(£)-ethyl 3-(4-iodophenyl)-but-2-enoate (example 91a) and 3,5-dichlorobenzene boronic acid by a procedure analogous to that described in example 52a.
Mpt. 96.3-97.3°C. 1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 2.61 (3H, d), 4.23 (2H, q), 6.19 (1H, m), 7.35 (1H, t), 7.47 (2H, d), 7.51-7.61 (4H, m). LCMS: 335/337/339 (100%, M+H),
289/291/293 (M+H-EtOH). Microanalysis Calculated % C: 64.49, H: 4.81, Cl: 21.15; found C:
64.41, H: 4.80, Cl: 20.80.
b) The colourless oil (£)-3-(3',5'-dichloro-biphenyl-4-yI)-but-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(3',5'-dichloro-biphenyl-4-yl)-but-2-enoate as described for example 52b.
1H NMR (300 MHz, CDCI3) δ: 1.39 (1H, br s), 2.12 (3H, d), 4.40 (2H, d), 6.05 (1 H, tm), 7.33 (1 H, t), 7.46 (2H, d), 7.45-7.65 (4H, m). MS: 296/294/292 (100%, M+), 281/279/277 (M-Me), 278/276/274 (M-H2O), 253/251/249.
c)
The title compound (794 mg, 77%) was prepared as a colourless gum from (£)-3-(3',5'- dichloro-biphenyl-4-yl)-but-2-en-1-ol (586 mg, 2.0 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (500 mg, 2.10 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.17 (3H, d), 2.96 (2H, d), 3.30-3.42
(1 H, m), 3.55-3.67 (1 H, m), 3.98 (1 H, t), 4.17 (2H, q), 4.74 (2H, d), 6.13 (1H, tm), 6.88 (2H, dm), 7.18 (2H, dm), 7.33 (1H, t), 7.46 (2H, d), 7.48-7.54 (4H, m). LCMS: 539/537/535 (100%,
M+Na), 534/532/530 (M+NH4), 279/277/275.
EXAMPLE 126
Figure imgf000155_0001
(£)-(S)-3-{4-[3-(3',5'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(3',5'-dichloro-biphenyl-4-yl)-but- 2-enyloxy]-phenyl}-2-ethoxy-propionate (example 125) (513 mg, 1.0 mmol) and sodium hydroxide (1 M, 5.0 ml, 5.0 mmol) by a procedure analogous to that described in example 51, yielding (£)-(S)-3-{4-[3-(3',5'-dichloro-biphenyI-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid (422 mg, 87%) as a colourless glass. 1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 2.16 (3H, d), 2.97 (1 H, dd), 3.09 (1H, dd), 3.40- 3.54 (H, m), 3.54-3.67 (1H, m), 4.07 (1H, dd), 4.74 (2H, d), 6.12 (1 H, tm), 6.90 (2H, dm), 7.18 (2H, dm), 7.32 (1H, t), 7.46 (2H, d), 7.48-7.55 (4H, m), carboxylic acid proton not observed. LCMS: 511/509/507 (100%, M+Na), 279/277/275.
EXAMPLE 127
Figure imgf000156_0001
(£)-(S)-Ethyl 3-{4-[3-(3',5'-Dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionate
a)
The colourless solid (£)-ethyl 3-(3',5'-dichloro-biphenyl-4-yl)-acrylate was prepared from (£)- ethyl 3-(4-bromo-phenyl)-acrylate (example 71a) and 3,5-dichlorobenzene boronic acid by a procedure analogous to that described in example 52a.
Mpt. 70-78°C. 1H NMR (300 MHz, CDCI3) δ: 1.35 (3H, t), 4.29 (2H, q), 6.49 (1H, d), 7.36 (1 H, t), 7.47 (2H, d), 7.53-7.64 (4H, m), 7.71 (1H, d). LCMS: 325/323/321 (100%, M+H). Micro- analysis Calculated % C: 63.57, H: 4.39; found C: 63.37, H: 4.43.
b)
The colourless gum (£)-3-(3',5'-dichloro-biphenyl-4-yl)-prop-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(3',5'-dichloro-biphenyl-4-yl)-acrylate as described for example 52b. 1H NMR (300 MHz, CDCI3) δ: 1.47 (1 H, br t), 4.36 (2H, ddd), 6.43 (1 H, dt), 6.65 (1 H, dm), 7.33 (1 H, t), 7.37-7.55 (6H, m). MS: 282/280/278 (100%, M+), 239/237/235, 226/224/222.
c)
The title compound (732 mg, 70%) was prepared as a yellow gum, (containing 0.25 molar equivalents of ethyl acetate) from (£)-3-(3',5'-dichloro-biphenyl-4-yl)-prop-2-en-1-ol (559 mg, 2.0 mmol) and (S -ethyl 2-ethoxy-3-(4-hydroxyphenyl)-propionate (500 mg, 2.10 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 1.25 (0.75H, t, AcOEt), 2.04 (0.75H, s, AcOEt), 2.97 (2H, d), 3.30-3.41 (1H, m), 3.53-3.67 (1H, m), 3.98 (1H, t), 4.12 (0.5H, q, AcOEt), 4.17 (2H, q), 4.71 (2H, dd), 6.47 (1H, dt), 6.76 (1H, dm), 6.89 (2H, dm), 7.17 (2H, dm), 7.33 (1H, t), 7.43-7.55 (6H, m). LCMS: 525/523/521 (100%, M+Na), 265/263/261.
EXAMPLE 128
Figure imgf000157_0001
(£)-(S)-3-{4-[3-(3',5'-Dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(3',5'-dichIoro-biphenyl-4-yl)- . allyloxy]-phenyl}-2-ethoxy-propionate (example 127) (522 mg, 1.0 mmol) and sodium hydroxide (1M, 10.0 ml, 10.0 mmol) by a procedure analogous to that described in example 51, yielding (£)-(S)-3-{4-[3-(3',5'-dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid (325 mg, 67%) as a colourless wax, which contained 0.167 molar equivalents of AcOEt.. 1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 1.26 (0.5H, t, AcOEt), 2.04 (0.5H, s, AcOEt), 2.97 (1H, dd), 3.09 (1 H, dd), 3.41-3.53 (1H, m), 3.53-3.68 (1H, m), 4.07 (1 H, dd), 4.12 (0.33H, q, AcOEt), 4.71 (2H, dd), 6.48 (1H, dt), 6.76 (1 H, dm), 6.91 (2H, dm), 7.18 (2H, dm), 7.33 (1H, t), 7.40-7.60 (6H, m), carboxylic acid proton not observed. LCMS: 497/495/493 (100%, M+Na), 492/490/488 (M+NH4), 265/263/261. EXAMPLE 129
Figure imgf000158_0001
(£)-(S)-Ethyl 3-{4-[3-(3',5'-di-tert-butyl-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionate
a)
The colourless solid (£)-3-(4-bromo-phenyl)-prop-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(4-bromo-phenyl)-acrylate (example 71a) as described for example 52b. Mpt. 65.5-67.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.50 (1 H, br s), 4.33 (2H, d), 6.35 (1H, dt), 6.55 (1 H, d), 7.23 (2H, dm), 7.43 (2H, dm). MS: 214/212 (M+), 171/169, 158/156, 133 (M-Br, 100%), 115, 91 , 77.
b) fe/f-Butyl chlorodimethylsilane (1.33 g, 19.5 mmol) was added to a stirred solution of (£)-3- (4-bromo-phenyl)-prop-2-en-1-ol (3.20 g, 15.0 mmol), and imidazole (2.72 g, 18.0 mmol) in dry dichloromethane (75 ml) and the resulting mixture stirred at room temperature for 18 h, a colourless precipitate being formed. The mixture was diluted with dichloromethane (100 ml) and 1N hydrochloric acid (100 ml). The aqueous layer was separated, further extracted with dichloromethane (2 x 100ml) and the combined organic layers washed with brine, dried
(MgSO4) and evaporated. The product was purified by column chromatography on silica gel (1 % diethyl ether in n-heptane eluent) to give the colourless solid, (£)-[3-(4-bromo-phenyl)- allyloxyHerf-butyldimethylsilane (4.39 g, 89%). Mpt. 46.5-48°C. 1H NMR (300 MHz, CDCI3) δ: 0.11 (6H, s), 0.94 (9H, s), 4.34 (2H, dd), 6.27 (1 H, dt), 6.54 (1 H, dt), 7.24 (2H, dm), 7.42 (2H, dm), 7.71 (1 H, d). Microanalysis Calculated % C: 55.04, H: 7.08, Br: 24.41 ; found C: 54.81 , H: 7.22, Br: 24.51.
c)fetf-Butyllithium (1.7M in pentane, 3.5 ml, 6.0 mmol) was added dropwise, at -78°C to a stirred THF (10 ml) solution of (£)-[3-(4-bromo-phenyl)-allyloxy]-førf-butyldimethylsilane (982 mg, 3.0 mmol) and the resulting solution stirred for 45 min. Tri methyl borate (0.51 ml, 4.50 mmol) was added, the solution allowed to warm to room temperature over 2h, and the solvents evaporated to give the crude boronate ester as a yellow gum, which was dissolved in DME (10 ml). Tetrakis(triphenylphosphine)palladium(0) (69 mg, 0.06 mmol), was added to a stirred DME (20 ml) solution of 1-bromo-3,5-di-fe/f-butylbenzene (538 mg, 2.0 mmol), the so- lution stirred for 10 min, aqueous sodium carbonate (2M, 9 ml, 18.0 mmol) added, and stirring continued for a further 10 min. The boronate ester solution was added and the mixture heated to 80°C, under reflux, for 24h. The resulting mixture was diluted with 1N HCl (50 ml), the products extracted into ethyl acetate (3 x 50 ml), and the combined extracts washed with brine, dried (MgSO4), and evaporated. The resulting yellow gum was dissolved in dry THF (20 ml), tetra- ?-butyl ammonium fluoride (1.26 g, 4.0 mmol) added and the solution stirred at room temperature for 18h. The resulting mixture was diluted with 1N HCl (50 ml), and the products extracted into ethyl acetate (2 x 50 ml). The combined organic phases were washed with brine, dried (MgSO4), and evaporated to give the colourless glass, (£)-3-(3',5'-di-fe/f- butyI-biphenyl-4-yI)-prop-2-en-1-ol (127 mg, 20%). 1H NMR (300 MHz, CDCI3) δ: 1.38 (18H, s), 1.45 (1 H, br t), 4.35 (2H, br t), 6.41 (1 H, dt), 6.66 (1 H, br dm), 7.40-7.49 (5H, m), 7.53-7.58 (2H, m). MS: 322 (M+), 307 (100%, M-Me), 57.
d)
The title compound (110 mg, 51%) was prepared as a colourless gum from (£)-3-(3',5'-di- ferf-butyl-biphenyl-4-yl)-prop-2-en-1-ol (127 mg, 0.39 mmol) and (S)-eihyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (99 mg, 0.41 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 1.38 (18H, s), 2.97 (2H, d), 3.29-3.42
(1H, m), 3.53-3.67 (1H, m), 3.98 (1H, t), 4.17 (2H, q), 4.70 (2H, dd), 6.45 (1H, dt), 6.77 (1H, dm), 6.90 (2H, dm), 7.18 (2H, dm), 7.40-7.60 (7H, m).
EXAMPLE 130
Figure imgf000159_0001
(£)-(S)-3-{4-[3-(3',5'-Di-tert-butyl-biphenyl-4-yl)-alIyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(3',5'-di-ferf-butyI-biphenyl-4-yl)- allyloxy]-phenyl}-2-ethoxy-propionate (example 129) (110 mg, 0.20 mmol) and sodium hydroxide (1M, 0.8 ml, 0.8 mmol) by a procedure analogous to that described in example 51, yielding ((£)-(S)-3-{4-[3-(3',5'-di-terf-butyl-biphenyl-4-yI)-aIIyloxy]-phenyl}-2-ethoxy-propionic acid (92 mg, 88%) as a colourless solid.
1H NMR (300 MHz, CDCI3) δ: 1.20 (3H, t), 1.38 (18H, s), 2.97 (1 H, dd), 3.10 (1 H, dd), 3.40- 3.65 (2H, m), 4.07 (1H, dd), 4.70 (2H, dd), 6.45 (1H, dt), 6.77 (1 H, dm), 6.90 (2H, dm), 7.18 (2H, dm), 7.38-7.60 (7H, m), carboxylic acid proton not observed.
EXAMPLE 131
Figure imgf000160_0001
(£)-(S)-Ethyl 3-{4-[3-(3',5'-Di-fe/τ-butyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate
a)
The colourless oil, (£)-[3-(4-bromophenyl)-but-2-enyloxy]-terf-butyl-dimethylsilane was prepared from (£)-3-(4-bromophenyl)-but-2-en-1-ol (example 50b), imidazole and fe/tf-butyl chlorodimethylsilane by a procedure analogous to that described in example 129b. 1H NMR (300 MHz, CDCI3) δ: 0.10 (6H, s), 0.92 (9H, s), 4.37 (2H, d), 5.88 (1H, tm), 7.25 (2H, dm), 7.42 (2H, dm). MS: 342/340 (M+), 327/325 (M-Me), 285/283 (M-Bu), 130, 75 (100%).
b) The colourless wax, (£)-3-(3',5'-di-fert-butyl-biphenyl-4-yl)-but-2-en-1-ol was prepared via a metallation, boronation, cross coupling and deprotection sequence analogous to that described for example 129c.
1H NMR (300 MHz, CDCI3) δ: 1.26 (1H, br m), 1.38 (18H, s), 2.12 (3H, d), 4.40 (2H, br t), 6.05 (1H, dt), 7.40-7.42 (3H, m), 7.43-7.59 (4H, m). LCMS: 331 (M+H), 319 (100%, M+H- H2O).
c)
The title compound (429 mg, 74%) was prepared as a colourless gum from (£)-3-(3',5'-di- te/f-butyl-biphenyl-4-yl)-but-2-en-1-ol (350 mg, 1.04 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (260 mg, 1.09 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 1.22 (3H, t), 1.38 (18H, s), 2.17 (3H, d), 2.96 (2H, d), 3.30-3.43 (1 H, m), 3.55-3.68 (1H, m), 3.98 (1 H, t), 4.17 (2H, q), 4.75 (2H, d), 6.11 (1 H, tm), 6.89 (2H, dm), 7.17 (2H, dm), 7.40-7.45 (3H, m), 7.46-7.60 (4H, m). LCMS: 579 (100%,
M+Na), 574 (M+NH4), 511 (M+H-EtOH).
EXAMPLE 132
Figure imgf000161_0001
(£)-(S)-3-{4-[3-(3',5'-Di-tert-butyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-ethyl 3-{4-[3-(3',5'-di-fe/f-butyl-biphenyl-4-yl)- but-2-enyloxy]-phenyl}-2-ethoxy-propionate (example 131) (400 mg, 0.72 mmol) and sodium hydroxide (1M, 2.9 ml, 2.9 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S)-3-{4-[3-(3',5'-di-tert-butyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid (315 mg, 83%) as a colourless gum.
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 1.39 (18H, s), 2.18 (3H, d), 2.97 (1H, dd), 3.10 (1 H, dd), 3.40-3.67 (2H, m), 4.07 (1 H, dd), 4.70 (2H, d), 6.11 (1 H, tm), 6.90 (2H, dm), 7.18 (2H, dm), 7.40-7.45 (3H, m), 7.46-7.60 (4H, m), carboxylic acid proton not observed. LCMS: 847 (M+319), 551 (M+Na), 319 (100%).
EXAMPLE 133
Figure imgf000162_0001
(£)-(S )-EthyI 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-isopropoxy-propionate
a)
(SZ )-Ethyl 2-(diethoxyphosphoryl)-2-isopropoxy-acetate was prepared as a pale green oil by the rhodium(ll) acetate dimer catalysed reaction of ethyl diazo-(diethoxyphosphoryl)-acetate with isopropyl alcohol, according to the method described by OJ. Moody et al (Tetrahedron, 1992, 48, 3991-4004). 1H NMR (300 MHz, CDCI3) δ: 1.21 (3H, d), 1.23 (3H, d), 1.28-1.39 (9H, m), 3.74 (1 H, septet), 4.15-4.35 (6H, m), 4.39 (1H, d, JHP = 19.9 Hz). LCMS: 283 (M+H), 241 (100%), 213.
b)
A THF (20 ml) solution of (SZ )-ethyl 2-(diethoxyphosphoryl)-2-isopropoxy-acetate (6.40 g, 22.7 mmol) was added dropwise, at 0°C, to a stirred suspension of sodium hydride (60% dispersion in mineral oil, 0.92 g, 23.0 mmol) in THF (20 ml), and the resulting mixture stirred for 30 min. A THF (20 ml) solution of 4-benzyloxybenzaldehyde (3.21 g, 15.1 mmol) was added, the resulting solution allowed to warm to room temperature, and stirring continued for 72 h. The mixture was carefully diluted with 1 N HCl (150 ml), the products extracted into ethyl ace- tate (3 x 100 ml), and the combined organic phases washed with brine, dried (MgSO4) and (MgSO4) and evaporated to give a yellow gum, which was purified by column chromatography on silica gel (10% ethyl acetate in n-heptane eluent) to give the intermediate, (£ Z)-ethyl 3-(4-benzyloxyphenyl)-2-isopropoxy-acrylate as a colourless gum. The (£ Z)-ethyl 3-(4-benzyloxyphenyl)-2-isopropoxy-acrylate was dissolved in ethanol (100 ml), palladium on activated charcoal (10 wt. %, 0.80 g, 0.75 mmol) added and the mixture hydrogenated at 30 lb/in2 H2 pressure for 18 h. The catalyst was removed by filtration through celite and the solvent evaporated to give (SZ )-ethyl 3-(4-hydroxyphenyl)-2-isopropoxy- propionate (3.44 g, 90%) as a pale orange gum.
1H NMR (300 MHz, CDCI3) δ: 0.98 (3H, d), 1.15 (3H, d), 1.24 (3H, t), 2.82-2.98 (2H, m), 3.51 (1 H, septet), 4.02 (1H, dd), 4.17 (2H, q), 5.49 (1 H, br s), 6.75 (2H, dm), 7.09 (2H, dm). LCMS: 275 (M+Na), 253 (M+H), 235, 211, 193, 151, 137 (100%).
c)
The title compound (324 mg, 70%) was prepared as a colourless solid from (S R)-ethyl 3-(4- hydroxyphenyl)-2-isopropoxy-propionate (280 mg, 1.11 mmol) and (£)-3-biphenyl-4-yl-but-2- en-1-ol (225 mg, 1.0 mmol) by a procedure analogous to that described in example 52c. Mpt. 79-81 °C. 1H NMR (300 MHz, CDCI3) δ: 0.97 (3H, d), 1.16 (3H, d), 1.24 (3H, t), 2.17 (3H, d), 2.85-3.02 (2H, m), 3.51 (1H, septet), 4.01 (1H, dd), 4.08-4.25 (2H, m), 4.75 (2H, d), 6.11 (1 H, tm), 6.88 (2H, dm), 7.17 (2H, dm), 7.30-7.38 (1H, m), 7.40-7.65 (8H, m). LCMS: 665 (M+207), 481 (M+Na), 476 (M+NH4), 207 (100%).
EXAMPLE 134
Figure imgf000163_0001
(£)-(S )-3-[4-(3-BiphenyI-4-yl-but-2-enyloxy)-phenyl]-2-isopropoxy-propionic acid
The title compound was prepared from (£)-(S )-ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)- phenyrj-2-isopropoxy-propionate (example 133) (230 mg, 0.50 mmol) and sodium hydroxide (1M, 1.5 ml, 1.5 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S/j )-3-[4-(3-biphenyl-4-yl-but-2-enyIoxy)-phenyl]-2-isopropoxy-propionic acid (190 mg, 88%) as a colourless solid.
Mpt. 125-127.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.03 (3H, d), 1.16 (3H, d), 2.17 (3H, d), 2.90 (1H, dd), 3.08 (1H, dd), 3.55 (1H, septet), 4.10 (1H, dd), 4.75 (2H, d), 6.12 (1H, tm), 6.90 (2H, dm), 7.17 (2H, dm), 7.30-7.38 (1H, m), 7.40-7.65 (8H, m), carboxylic acid proton not observed. LCMS: 637 (M+207), 453 (M+Na), 448 (M+NH4), 207 (100%).
EXAMPLE 135
Figure imgf000164_0001
(£)-(S R)-Ethyl 3-[4-(3-Biphenyl-4-yI-but-2-enyloxy)-phenyl]-2-butoxy-propionate
a)
Butyl di-butoxy acetate (23.75 g, 91.2 mmol) was mixed with acetyl chloride (15.5 ml, 218 mmol) and iodine (0.2 g, 0.79 mmol) and the resulting brown solution heated to 60°C, under reflux, for 6 h. The product was then fractionally distilled, under reduced pressure, yielding (S )-butyl 2-butoxy-2-chloro-acetate (17.58 g, 79%) as an orange coloured oil.
Bpt. 130-135°C/approx. 15 mmHg. 1H NMR (300 MHz, CDCI3) δ: 0.89-0.99 (6H, m), 1.41 (4H, sextet), 1.60-1.75 (4H, m), 3.60 (1 H, dt), 3.98 (1H, dt), 4.25 (2H, t), 5.81 (1H, s).
b) A mixture of triethylphosphite (13.05 ml, 75.0 mmol) and (S R)-butyl 2-butoxy-2-chIoro- acetate (16.70 g, 75.0 mmol) was heated to 140°C, under reflux, for 6h. The resulting oil was fractionally distilled under reduced pressure to give the product, (S/R)-butyl 2-butoxy-2- (diethoxyphosphoryl)-acetate (20.42 g, 84%) as a colourless oil. Bpt. 170-175°C/1-5 immHg. 1H NMR (300 MHz, CDCI3) δ: 0.87-0.99 (6H, m), 1.30-1.49 (10H, m), 1.57-1.73 (4H, m), 3.52 (1 H, dt), 3.66 (1 H, dt), 4.15-4.30 (6H, m), 4.30 (1 H, d, JHP = 19 Hz). LCMS: 325 (100%, M+H), 269, 167.
c)
A THF (40 ml) solution of (S/R)-butyl 2-butoxy-2-(diethoxyphosphoryl)-acetate (14.60 g, 45.0 mmol) was added dropwise, at 0°C, to a stirred suspension of sodium hydride (55% dispersion in mineral oil, 2.61 g, 59.8 mmol) in THF (50 ml), and the resulting mixture stirred for 30 min. A THF (50 ml) solution of 4-benzyloxybenzaldehyde (6.37 g, 30.0 mmol) was added, the resulting solution allowed to warm to room temperature, and stirring continued for 48 h. The mixture was carefully diluted with 1N HCl (200 ml), the products extracted into ethyl acetate (4 x 100 ml), and the combined organic phases washed with brine, dried (MgSO4) and evaporated to give a yellow gum, which was purified by column chromatography on silica gel (10%) ethyl acetate in n-heptane eluent) to give the intermediate, (£ Z)-butyl 3-(4- benzyloxyphenyl)-2-butoxy-acrylate as a colourless gum.
The (£ Z)-butyl 3-(4-benzyloxyphenyI)-2-butoxy-acrylate was dissolved in ethanol (200 ml), palladium on activated charcoal (10 wt. %, 1.60 g, 1.5 mmol) added and the mixture hydrogenated at 30 lb/in2 H2 pressure for 18 h. The catalyst was removed by filtration through celite and the solvent evaporated to give an orange gum, which contained both (S F?)-butyl 3- (4-hydroxyphenyl)-2-butoxy-propionate and the trans-esterification product, (SZR)-ethyl 3-(4- hydroxyphenyl)-2-butoxy-propionate. These were separated by column chromatography on silica gel (15% ethyl acetate in n-heptane eluent) to give, in respective order of elution, (S/R)- butyl 3-(4-hydroxyphenyl)-2-butoxy-propionate (6.74 g, 76%) and (SZR)-ethyl 3-(4- hydroxyphenyl)-2-butoxy-propionate (0.40 g, 5%) as colourless oils.
(SZR)-butyl 3-(4-hydroxyphenyl)-2-butoxy-propionate: 1H NMR (300 MHz, CDCI3) δ: 0.85 (3H, t), 0.91 (3H, t), 1.22-1.43 (4H, m), 1.43-1.65 (4H, m), 2.89-2.98 (2H, m), 3.28 (1 H, dt), 3.54 (1H, dt), 3.97 (1H, dd), 4.11 (2H, t), 5.56 (1 H, br s), 6.74 (2H, dm), 7.08 (2H, dm). LCMS: 317 (M+Na), 295 (M+H), 221 (100%, M+H-BuOH), 193, 179, 165, 137.
(SZR)-ethyl 3-(4-hydroxyphenyI)-2-butoxy-propionate: 1H NMR (300 MHz, CDCI3) δ: 0.85 (3H, t), 1.23 (3H, t), 1.21-1.39 (2H, m), 1.43-1.60 (2H, m), 2.89-2.99 (2H, m), 3.28 (1H, dt), 3.55 (1H, dt), 3.97 (1H, dd), 4.17 (2H, q), 5.63 (1 H, br s), 6.74 (2H, dm), 7.08 (2H, dm). LCMS: 289 (M+Na), 267 (M+H), 193 (100%, M+H-BuOH), 151 , 137. d)
The title compound (420 mg, 71 %) was prepared as a colourless solid from (S )-ethyl 3-(4- hydroxyphenyl)-2-butoxy-propionate (385 mg, 1.45 mmol) and (£)-3-biphenyl-4-yl-but-2-en- 1-ol (280 mg, 1.25 mmol) by a procedure analogous to that described in example 52c. Mpt. 62-63.5°C. 1H NMR (300 MHz, CDCI3) δ: 0.85 (3H, t), 1.23 (3H, t), 1.20-1.40 (2H, m), 2.17 (3H, d), 2.90-3.00 (2H, m), 3.27 (1H, dt), 3.55 (1 H, dt), 3.95 (1 H, dd), 4.10-4.23 (2H, m), 4.74 (2H, d), 6.11 (1 H, tm), 6.88 (2H, dm), 7.17 (2H, dm), 7.30-7.38 (1 H, m), 7.40-7.63 (8H, m). LCMS: 679 (M+207), 495 (M+Na), 490 (M+NH4), 207 (100%).
EXAMPLE 136
Figure imgf000166_0001
(£)-(S/?)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-butoxy-propionic acid
The title compound was prepared from (£)-(S )-ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)- phenyl]-2-butoxy-propionate (example 135) (331 mg, 0.70 mmol) and sodium hydroxide (1M, 2.1 ml, 2.1 mmol) by a procedure analogous to that described in example 51 , yielding (£)-
(S )-3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenylj-2-butoxy-propionic acid (42 mg, 13%) as a colourless solid.
1H NMR (300 MHz, CDCI3) δ: 0.87 (3H, t), 1.21-1.38 (2H, m), 1.47-1.60 (2H, m), 2.17 (3H, br s), 2.96 (1H, dd), 3.09 (1H, dd), 3.33-3.44 (1H, m), 3.47-3.60 (1H, m), 4.04 (1H, dd), 4.75 (2H, d), 6.12 (1 H, br t), 6.90 (2H, dm), 7.17 (2H, dm), 7.30-7.38 (1 H, m), 7.38-7.65 (8H, m), carboxylic acid proton not observed. LCMS: 651 (M+207), 467 (100%, M+Na), 207. EXAMPLE 137
Figure imgf000167_0001
(£)-(S/ )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-hexyloxy-propionate
a)
(S )-Ethyl 2-(diethoxyphosphoryl)-2-hexyloxy-acetate was prepared as a pale green oil by the rhodium(ll) acetate dimer catalysed reaction of ethyl diazo-(diethoxyphosphoryI)-acetate with 1-hexanol, by a method analogous to that described for example 133a.
1H NMR (300 MHz, CDCI3) δ: 0.88 (3H, t), 1.23-1.44 (15H, m), 1.57-1.69 (2H, m), 3.51 (1H, dt), 3.65 (1H, dt), 4.15-4.38 (7H, m). LCMS: 671 (2M+Na), 649 (2M+H), 325 (100%, M+H), 297, 241.
b)
Sodium hydride (60% dispersion in mineral oil, 1.0 g, 25.0 mmol) was added at 0°C, in small portions, to a stirred THF (50 ml) solution of (SZ )-ethyl 2-(diethoxyphosphoryl)-2-hexyloxy- acetate (8.12 g, 25.0 mmol), and the resulting suspension stirred for 30 min. A THF (50 ml) solution of 4-benzyloxybenzaldehyde (4.25 g, 20.0 mmol) was added, the resulting solution allowed to warm to room temperature, and stirring continued for 4 h. The mixture was carefully diluted with 0.5N HCl (150 ml), the products extracted into ethyl acetate (4 x 75 ml), and the combined organic phases washed with brine, dried (MgSO4) and evaporated to give an orange coloured gum, which was purified by column chromatography on silica gel (15% ethyl acetate in n-heptane eluent) to give the intermediate, (£ Z)-ethyl 3-(4-benzyloxyphenyl)-2- hexyloxy-acrylate as a pale yellow oil.
The (£ Z)-ethyl 3-(4-benzyloxyphenyl)-2-hexyloxy-acrylate was dissolved in ethanol (150 ml), palladium on activated charcoal (10 wt. %, 1.40 g, 1.32 mmol) added and the mixture hydrogenated at 30 lb/in2 H2 pressure for 18 h. The catalyst was removed by filtration through celite and the solvent evaporated to give a colourless gum, which was purified by column chromatography on silica gel (10% ethyl acetate in n-heptane eluent) to give (S R)-ethyl 3-(4- hydroxyphenyl)-2-hexyloxy-propionate (1.83 g, 30%) as a colourless gum. 1H NMR (300 MHz, CDCI3) δ: 0.85 (3H, t), 1.14-1.32 (9H, m), 1.45-1.60 (2H, m), 2.94 (2H, d), 3.28 (1H, dt), 3.54 (1 H, dt), 3.97 (1H, dd), 4.17 (2H, q), 5.95 (1 H, br s), 6.74 (2H, dm), 7.07 (2H, dm). MS: 294 (M+), 221 (M-COOEt), 192 (M-hexanol), 137, 107 (100%).
c)
The title compound (248 mg, 81%) was prepared as a waxy solid from (SZ )-ethyl 3-(4- hydroxyphenyl)-2-hexyloxy-propionate (215 mg, 0.72 mmol) and (£)-3-biphenyl-4-yl-but-2- en-1-ol (137 mg, 0.61 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 0.86 (3H, t), 1.13-1.35 (9H, m), 1.46-1.60 (2H, m), 2.17 (3H, br s), 2.88-3.00 (2H, m), 3.26 (1H, dt), 3.55 (1 H, dt), 3.95 (1 H, dd), 4.10-4.23 (2H, m), 4.74 (2H, d), 6.12 (1 H, tm), 6.88 (2H, dm), 7.17 (2H, dm), 7.30-7.37 (1H, m), 7.40-7.63 (8H, m).
EXAMPLE 138
Figure imgf000168_0001
(£)-(S )-3-[4-(3-Biphenyl-4-yI-but-2-enyloxy)-phenyl]-2-hexyloxy-propionic acid
The title compound was prepared from (£)-(S R)-ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)- phenyI]-2-hexyloxy-propionate (example 137) (172 mg, 0.34 mmol) and sodium hydroxide (1 M, 1.0 ml, 1.0 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S )-3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-hexyloxy-propionic acid (160 mg, 99%) as a colourless solid. Mpt. 117-119°C. 1H NMR (300 MHz, CDCI3) δ: 0.87 (3H, t), 1.13-1.38 (6H, m), 1.45-1.60 (2H, m), 2.17 (3H, d), 2.96 (1 H, dd), 3.10 (1 H, dd), 3.40 (1 H, dt), 3.53 (1H, dt), 4.05 (1H, dd), 4.75 (2H, d), 6.12 (1H, tm), 6.90 (2H, dm), 7.16 (2H, dm), 7.30-7.38 (1H, m), 7.40-7.63 (8H, m), carboxylic acid proton not observed. EXAMPLE 139
Figure imgf000169_0001
(£)-(S R)-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyI]-2-(3-phenyl-propoxy)-propionate
a)
(SZ )-Ethyl 2-(diethoxyphosphoryl)-2-(3-phenyl-propoxy)-acetate was prepared as a pale green oil by the rhodium(ll) acetate dimmer catalysed reaction of 3-phenyl-1-propanol with ethyl diazo-(diethoxyphosphoryl)-acetate, by a method analogous to that described for example 133a.
1H NMR (300 MHz, CDCI3) δ: 1.23-1.40 (9H, m), 1.98 (2H, quintet), 2.72 (2H, t), 3.52 (1H, dt), 3.67 (1 H, dt), 4.15-4.35 (7H, m), 7.12-7.22 (3H, m), 7.22-7.32 (2H, m).
b)
A THF (50 ml) solution of (SZ )-ethyl 2-(diethoxyphosphoryl)-2-(3-phenyl-propoxy)-acetate (14.2 g, 39.6 mmol) was added dropwise, at 0°C, to a stirred mixture of sodium hydride (60% dispersion in mineral oil, 2.35 g, 58.8 mmol) and 4-benzyloxybenzaldehyde (4.20 g, 19.8 mmol) in THF (50 ml), and the resulting mixture allowed to warm slowly to room temperature over 18 h. The mixture was carefully diluted with water (150 ml), the products extracted into ethyl acetate (2 x 150 ml), and the combined organic phases washed with brine, dried (MgSO4) and evaporated to give (£ Z)-ethyl 3-(4-benzyloxyphenyl)-2-(3~phenyl-propoxy)- acrylate as a yellow oil. The (£ Z)-ethyl 3-(4-benzyloxyphenyl)-2-(3-phenyl-propoxy)-acrylate was dissolved in etha- nol (50 ml), palladium on activated charcoal (10 wt. %, 1.0 g, 0.94 mmol) added and the mixture hydrogenated at 30 lb/in2 H2 pressure for 18 h. The catalyst was removed by filtration through celite and the solvent evaporated to give a colourless oil.
1H NMR (300 MHz, CDCI3) δ: 1.23 (3H, t), 1.72-1.97 (2H, m), 2.52-2.64 (2H, m), 2.87-3.02 (2H, m), 3.17-3.27 (1H, m), 3.53-3.63 (1H, m), 3.94 (1 H, dd), 4.17 (2H, q), 4.93 (1 H, s), 6.76 (2H, dm), 7.02-7.29 (7H, m). C)
The title compound (150 mg, 56%) was prepared as a waxy solid from (SZR)-ethyl 3-(4- hydroxyphenyl)-2-(3-phenyl-propoxy)-propionate (172 mg, 0.53 mmol) and (£)-3-biphenyl-4- yl-but-2-en-1-ol (112 mg, 0.50 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.23 (3H, t), 1.72-1.97 (2H, m), 2.16 (3H, br s), 2.51-2.65 (2H, m), 2.89-3.05 (2H, m), 3.17-3.27 (1 H, m), 3.59 (1 H, dt), 3.95 (1H, dd), 4.18 (2H, q), 4.74 (2H, d), 6.11 (1H, tm), 6.90 (2H, dm), 7.01-7.63 (16H, m). LCMS: 741 (M+207), 557 (100%,, M+Na), 552 (M+NH4), 207.
EXAMPLE 140
Figure imgf000170_0001
(£)-(S R)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-(3-phenyl-propoxy)-propionic acid
The title compound was prepared from (£)-(S )-ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)- phenyl]-2-(3-phenyl-propoxy)-propionate (example 139) (130 mg, 0.24 mmol) and sodium hydroxide (1 M, 0.73 ml, 0.73 mmol) by a procedure analogous to that described in example
51 , yielding (£)-(S )-3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-(3-phenyl-propoxy)- propionic acid (90 mg, 73%) as a colourless solid.
Mpt. 115-117°C. 1H NMR (300 MHz, CDCI3) δ: 1.75-1.98 (2H, m), 2.16 (3H, d), 2.52-2.68 (2H, m), 2.96 (1 H, dd), 3.10 (1 H, dd), 3.36 (1H, dt), 3.57 (1 H, dt), 4.03 (1 H, dd), 4.74 (2H, d),
6.11 (1H, tm), 6.91 (2H, dm), 7.06 (2H, dm), 7.12-7.63 (14H, m), carboxylic acid proton not observed. LCMS: 529 (M+Na), 525 (M+NH4), 207 (100%). EXAMPLE 141
Figure imgf000171_0001
(£)-(S )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyI]-2-(4-phenyl-butoxy)-propionate
a)
(SZ )-Ethyl 2-(diethoxyphosphoryl)-2-(4-phenyl-butoxy)-acetate was prepared as a pale green oil by the rhodium(ll) acetate Dimmer catalysed reaction of 4-phenyl-1-butanol with ethyl diazo-(diethoxyphosphoryl)-acetate, by a method analogous to that described for example 133a.
1H NMR (300 MHz, CDCI3) δ: 1.25-1.40 (9H, m), 1.60-1.78 (4H, m), 2.63 (2H, t), 3.47-3.56 (1H, m), 3.61-3.70 (1H, m), 4.12-4.35 (7H, m), 7.12-7.21 (3H, m), 7.21-7.31 (2H, m). LCMS: 745 (2M+H), 373 (100%, M+H), 241.
b)
A THF (30 ml) solution of (SZ )-ethyl 2-(diethoxyphosphoryl)-2-(4-phenyl-butoxy)-acetate (15.64 g, 42.0 mmol) was added dropwise, at 0°C, to a stirred suspension of sodium hydride (60% dispersion in mineral oil, 2.52 g, 63.0 mmol) in THF (30 ml), and the resulting mixture stirred for 20 min. A THF (50 ml) solution of 4-benzyloxybenzaldehyde (4.46 g, 21.0 mmol) was added, and the mixture warmed, resulting in a vigorous reaction. The mixture was cooled, carefully diluted with 0.5N HCl (150 ml), the products extracted into ethyl acetate (2x 150 ml), and the combined organic phases washed with brine, dried (MgSO4) and evaporated to give (£XZ)-ethyl 3-(4-benzyloxyphenyl)-2-(4-phenyl-butoxy)-acrylate as a yellow oil. The (£ Z)-ethyl 3-(4-benzyloxyphenyl)-2-(4-phenyl-butoxy)-acrylate was dissolved in ethanol (175 ml), palladium on activated charcoal (10 wt. %, 0.50 g, 0.47 mmol) added and the mixture hydrogenated at 30 lb/in2 H2 pressure for 18 h. The catalyst was removed by filtration through celite and the solvent evaporated to give a colourless gum, which was purified by column chromatography on silica gel to give (S R)-ethyl 3-(4-hydroxyphenyl)-2-(4-phenyl- butoxy)-propionate (1.73 g, 24%) as a colourless oil. 1H NMR (300 MHz, CDCI3) δ: 1.22 (3H, t), 1.50-1.67 (4H, m), 2.50-2.60 (2H, m), 2.85-3.0 (2H, m), 3.21-3.31 (1 H, m), 3.53-3.63 (1 H, m), 3.94 (1H, dd), 4.16 (2H, q), 6.72 (2H, dm), 7.06-7.31 (7H, m), phenol proton not observed.
c)
The title compound (245 mg, 80%) was prepared as a yellow, waxy solid from (SZ )-ethyl 3- (4-hydroxyphenyl)-2-(4-phenyl-butoxy)-propionate (200 mg, 0.58 mmol) and (£)-3-biphenyl- 4-yl-but-2-en-1-ol (125 mg, 0.56 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 1.22 (3H, t), 1.50-1.68 (4H, m), 2.16 (3H, d), 2.50-2.60 (2H, m), 2.88-3.02 (2H, m), 3.21-3.33 (1H, m), 3.52-3.64 (1H, m), 3.95 (1H, dd), 4.1 (2H, q), 4.72 (2H, d), 6.11 (1H, tm), 6.87 (2H, dm), 7.06-7.63 (16H, m).
EXAMPLE 142
Figure imgf000172_0001
(£)-(S )-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyI]-2-(4-phenyl-butoxy)-propionic acid
The title compound was prepared from (£)-(S/j )-ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)- phenyl]-2-(4-phenyl-butoxy)-propionate (example 141) (225 mg, 0.41 mmol) and sodium hydroxide (1M, 1.64 ml, 1.64 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S R)-3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-(4-phenyl-butoxy)-propionic acid (210 mg, 99%) as a pale yellow solid.
1H NMR (300 MHz, CDCI3) δ: 1.50-1.70 (4H, m), 2.17 (3H, d), 2.53-2.61 (2H, m), 2.95 (1 H, dd), 3.09 (1H, dd), 3.34-3.44 (1H, m), 3.50-3.60 (1 H, m), 4.04 (1H, dd), 4.72 (2H, d), 6.11 (1 H, tm), 6.88 (2H, dm), 7.06-7.63 (16H, m), carboxylic acid proton not observed. EXAMPLE 143
Figure imgf000173_0001
(£)-(S/?)-Propyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-propoxy-propionate
a)
Morpholinium dimorpholinoacetate was prepared according to the method described by
Bourguignon and Wermuth (Bourguignon, J.J.; Wermuth, C.G. J. Org. Chem. 1981, 46, 4889-4894): an ethanol (100 ml) solution of morpholine (310 ml, 3.55 mol) was added, at 0°C, to a stirred ethanol (500 ml) solution of glyoxylic acid monohydrate (92.06 g, 1.0 mol) and the resulting mixture refrigerated for 60 h, a colourless precipitate being formed. The solid was collected by filtration, washed with diethyl ether (2 x 300 ml) and vacuum dried at 30°C to give morphilinium dimorhpholinoacetate (298 g, 94%) as a colourless solid, which contained a small amount of water.
Mpt. 139-139.5°C. 1H NMR (300 MHz, CDCI3) δ: 2.83 (12H, br m), 3.26 (1H, s); 3.78 (12H, br m), 7.78 (2H, br s). Microanalysis Calculated % C: 52.93, H: 8.58, N: 13.24, water: 0.1%; found C: 52.84, H: 8.84, N: 13.15, water: 0.1%.
b)
Using a method based on that described by Kerfanto and Jegou, (Kerfanto, M.; Jegou, D. Compt. Rendus. 1965, 261 (11), 2232-2233) morphilinium dimorpholinoacetate (127 g, 0.40 mol) was added to a stirred solution of hydrochloric acid (94.3 g, 6.5 mol) in 1-propanol (600 ml) and the resulting mixture heated to 80°C, under reflux, for 2 h. The resulting colourless suspension was filtered to remove morphiline hydrochloride, and the filtrate fractionally distilled, under reduced pressure, to give excess 1-propanol and the colourless oil, propyl 2,2- dipropoxyacetate (57.14 g, 65%). H NMR (300 MHz, CDCI3) δ: 0.86-1.05 (9H, m), 1.55-1.78 (6H, m), 3.47-3.65 (4H, m), 4.15 (2H, t), 4.89 (1H, s). C)
A mixture of propyl 2,2-dipropoxyacetate (43.66 g, 0.20 mol), acetyl chloride (28 ml, 0.394 mol) and iodine (0.25 g, 1.0 mmol) was heated to 55°C, under reflux, for 16 h. Since GC analysis showed that some propyl 2,2-dipropoxyacetate starting material was still present, second portions of acetyl chloride (14 ml, 0.197 mol) and iodine (0.25 g, 1.0 mmol) were added, and heating continued for a further 6 h. The product was then purified by fractional distillation under reduced pressure to give (SZ )-propyl 2-chloro-2-propoxyacetate (32.67 g, 84%) as a pale orange oil (trace of iodine present).
Bpt. 116-119.5°C/approx. 10 mmHg. 1H NMR (300 MHz, CDCI3) δ: 0.97 (3H, t), 0.98 (3H, t), 1.63-1.82 (4H, m), 3.58 (1H, dt), 3.93 (1H, dt), 4.13-4.26 (2H, m), 5.83 (1H, s).
d)
Triethylphosphite (27 ml, 0.155 mol) was added to (S )-propyl 2-chloro-2-propoxyacetate
(29.21 g, 0.15 mol), resulting in an immediate decolourisation of the pale orange acetate, and the resulting mixture heated to 140°C, under reflux, for 6 h, a colourless gas being evolved. The mixture was then fractionally distilled under reduced pressure to give the product, (S/R)- propyl 2-(diethoxyphosphoryI)-2-propoxyacetate (35.78 g, 80%) as a colourless oil. Bpt. 155-160°C/approx. 3 mmHg. 1H NMR (300 MHz, CDCI3) δ: 0.95 (3H, t), 0.98 (3H, t), 1.31-1.39 (6H, m), 1.60-1.76 (4H, m), 3.49 (1H, dt), 3.62 (1H, dt), 4.12-4.30 (6H, m), 4.31 (1 H, d, JHp = 19 Hz).
e)
A THF (50 ml) solution of (SZ )-propyl 2-(diethoxyphosphoryl)-2-propoxyacetate (18.52 g,
62.5 mmol) was added dropwise, at 0°C, to a stirred suspension of sodium hydride (60%> dis- persion in mineral oil, 2.50 g, 62.5 mmol) in THF (50 ml), and the resulting mixture stirred for 30 min. A THF (100 ml) solution of 4-benzyloxybenzaldehyde (10.62 g, 50.0 mmol) was added, the resulting solution allowed to warm to room temperature, and stirring continued for 24 h. TLC showed a considerable amount of unreacted 4-benzyloxybenzaldehyde was still present so a further portion of sodium hydride (60% dispersion in mineral oil, 1.0 g, 25.0 mmol) was added and stirring continued for a further 18 h. The mixture was carefully diluted with 0.5N HCl (400 ml), the products extracted into ethyl acetate (3 x 200 ml), and the combined organic phases washed with brine, dried (MgSO4) and evaporated to give a yellow gum, which was purified by column chromatography on silica gel (10% ethyl acetate in n- heptane eluent) to give the intermediate, (£XZ)-propyl 3-(4-benzyloxyphenyl)-2-propoxy- acrylate as a colourless gum.
The (£ Z)-propyl 3-(4-benzyloxyphenyl)-2-propoxy-acryIate was dissolved in ethanol (200, ml), palladium on activated charcoal (10 wt. %, 2.18 g, 2.05 mmol) added and the mixture hydrogenated at 30 lb/in2 H2 pressure for 20 h. The catalyst was removed by filtration through celite and the solvent evaporated to give an orange gum, which contained both the propyl and the ethyl (formed by trans-esterification) esters of (S )-3-(4-hydroxyphenyl)-2-propoxy- propionic acid. These were separated by column chromatography on silica gel (15% ethyl acetate in n-heptane eluent) to give, in respective order of elution, (SZ )-propyl 3-(4- hydroxyphenyl)-2-propoxy-propionate (4.52 g, 41%) and a mixture of both (S )-propyl and (S/R)-ethyl 3-(4-hydroxyphenyl)-2-propoxy-propionates (4.98 g, approx. 45%) as colourless oils.
(SZR)-propyl 3-(4-hydroxyphenyl)-2-propoxy-propionate: 1H NMR (300 MHz, CDCl3) δ: 0.84 (3H, t), 0.90 (3H, t), 1.48-1.69 (4H, m), 2.95 (2H, d), 3.25 (1H, dt), 3.52 (1H, dt), 4.00 (1H, t), 4.07 (2H, t), 6.43 (1 H, br s), 6.74 (2H, dm), 7.07 (2H, dm). 13C NMR (75 MHz, CDCI3) δ: 10.2 (q), 10.3 (q), 21.8 (t), 22.7 (t), 38.4 (t), 66.6 (t), 72.5 (t), 80.6 (d), 115.2 (d), 128.5 (s), 130.4 (d), 154.7 (s), 173.2 (s). MS: 266 (M+), 206 (M-PrOH), 179, 164, 137, 107 (100%).
f) ' The title compound (350 mg, 74%) was prepared as a colourless gum from (SZ )-propyl 3-(4- hydroxyphenyl)-2-propoxy-propionate (280 mg, 1.05 mmol) and (£)-3-biphenyl-4-yl-but-2-en- 1-ol (224 mg, 1.0 mmol) by a procedure analogous to that described in example 52c. 1H NMR (300 MHz, CDCI3) δ: 0.85 (3H, t), 0.90 (3H, t), 1.49-1.69 (4H, m), 2.17 (3H, d), 3.91- 3.02 (2H, m), 3.23 (1H, dt), 3.52 (1H, dt), 3.97 (1H, dd), 4.07 (2H, t), 4.74 (2H, d), 6.11 (1 H, tm), 6.88 (2H, dm), 7.17 (2H, dm), 7.30-7.38 (1H, m), 7.40-7.63 (8H, m). LCMS: 679 (M+207), 495 (100%,, M+Na), 490 (M+NH4), 207.
EXAMPLE 144
Figure imgf000176_0001
(£)-(S/R)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-propoxy-propionic acid
The title compound was prepared from (£)-(S/R)-propyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)- phenyl]-2-propoxy-propionate (example 143) (330 mg, 0.70 mmol) and sodium hydroxide (1 M, 1.4 ml, 1.4 mmol) by a procedure analogous to that described in example 51 , yielding (£)-(S ?)-3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyI]-2-propoxy-propionic acid (300 mg, 100%) as a colourless gum.
1H NMR (300 MHz, CDCI3) δ: 0.88 (3H, t), 1.58 (2H, sextet), 2.17 (3H, s), 2.96 (1H, dd), 3.10 (1H, dd), 3.37 (1H, dt), 3.50 (1H, dt), 4.06 (1H, dd), 4.75 (2H, d), 6.11 (1H, t), 6.90 (2H, dm), 7.17 (2H, dm), 7.30-7.38 (1H, m), 7.40-7.63 (8H, m), carboxylic acid proton not observed. LCMS: 637 (M+207), 453 (100%, M+Na), 207.
EXAMPLE 145
Figure imgf000176_0002
(£)-(S)-3-{4-[3-(3,5-Diethoxyoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 3,5-dihydroxybenzaldehyde (3.0 g, 22.0 mmol) and ethyl iodide (17.2 g, 110 mmol) by a sequence analogous to that described in example 75. 1H NMR (300 MHz, CDCI3) δ: 1.15 (t, 3H), 1.20 (t, 3H), 1.38 (t, 6H), 2.95 (d, 2H), 3.30-3.40 (m, 1 H), 3.53-3.65 (m, 1 H), 3.98 (q, 4H), 4.15 (q, 2H), 4.63 (d, 2H), 6.28-6.40 (m, 2H), 6.53 (d, 2H), 6.60 (d, 1H), 6.87 (d, 2H), 7.15 (d, 2H).
EXAMPLE 146
Figure imgf000177_0001
(£)-(S)-3-{4-[3-(3,5-Diethoxyoxy-phenyl)-aIlyloxy]-phenyl}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-{4-[3-(3,5-diethoxyoxy-phenyl)-allyloxy]- phenyl}-2-ethoxy-propionic acid ethyl ester (730 mg, 1.6 mmol) by a procedure analogous to that described in example 26.
1H NMR (300 MHz, CDCI3) δ: 1.15 (t, 3H), 1.22 (t, 3H), 1.38 (t, 6H), 2.95 (d, 2H), 3.28-3.38 (m, 1 H), 3.53-3.65 (m, 1 H), 3.98 (q, 4H), 4.15 (q, 2H), 4.63 (d, 2H), 6.28-6.40 (m, 2H), 6.53 (d, 2H), 6.60 (d, 1 H), 6.85 (d, 2H), 7.15 (d, 2H).
EXAMPLE 147
Figure imgf000177_0002
(£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 3,5-bis(trifluoromethyI)benzaldehyde (5.0 g, 20.7 mmol) by a sequence analogous to that described in example 23. The title compound was purified on HPLC, using ethyl acetate/heptane (20:80) as eluent.
1H NMR (300 MHz, CDCI3) δ: 1.15 (t, 3H), 1.22 (t, 3H), 2.97 (d, 2H), 3.30-3.42 (m, 1H), 3.55- 3.67 (m, 1H), 3.98 (t, 1H), 4.18 (q, 2H), 4.72 (d, 2H), 6.55 (dt, 1H), 6.80 (d, 1H), 6.89 (d, 2H), 7.18 (d, 2H), 7.75 (bs, 1H), 7.82 (bs, 2H).
EXAMPLE 148
Figure imgf000178_0001
(£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-allyloxy]-phenyI}-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-{4-[3-(3,5-bis-trifluoromethyl-phenyl)- allyIoxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (0.58 g, 1.2 mmol) by a procedure analogous to that described in example 26.
1H NMR (300 MHz, CDCI3) δ: 1.18 (t, 3H), 2.98 (dd, 1H), 3.08 (dd, 1H), 3.36-3.48 (m, 1H), 3.58-3.71 (m, 1H), 4.05 (dd, 1H), 4.72 (d, 2H), 6.55 (dt, 1H), 6.80 (d, 1H), 6.89 (d, 2H), 7.20 (d, 2H), 7.75 (bs, 1H), 7.82 (bs, 2H). EXAMPLE 149
Figure imgf000179_0001
(£)-(R,S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester
The title compound was prepared from 3-biphenyl-4-yl- prop-2-en-1-ol (0.25 g, 0.001 mol) by a procedure analogous to that described in example 3c yielding 0.050 g of (E)-(R, S)-3-[4-(3- biphenyI-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester. 1H NMR (200 MHz, CDCI3) δ: 1.1-1.26 (6H, m), 2.97 (2H, d), 3.3-3.4 (1H, m), 3.52-3.7 (1H, m), 4.0 (1 H, t), 4.15 (2H, q), 4.75 (2H, dd), 6.35-6.5 (1 H, dt), 6.75 (1 H, d), 6.87 (2H, d), 7.15 (2H, d), 7.4-7.7 (9H, m).
EXAMPLE 150
Figure imgf000179_0002
(£)-( ?,S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid
The title compound was prepared from (£)-(S)-3-[4-(3-biphenyl-4-yl-allyIoxy)-phenyl]-2- ethoxy-propionic acid ethyl ester (example 149) (0.040 g) by a procedure analogous to that described in example 2 yielding 0.0045 g of (£)-(R,S)-3-[4-(3-biphenyl-4-yl-allyloxy)-phenylJ- 2-ethoxy-propionic acid. 1H NMR (300 MHz, CDCI3) δ: 1.14 (3H, t), 2.85 (1 H, dd), 3.1 (1H, dd) 3.42-3.57 (2H, m), 3.84-3.96 (2H, m), 4.1 (1H, dd), 4.7 (2H, d), 6.3-6.5 (1 H, dt), 6.78 (1 H, d), 6.88 (2H, d), 7.15 (2H, d) 7.4-7.6 (9H, m).
EXAMPLE 151
Figure imgf000180_0001
(£)-(S)- 4-(3-{3-[4-(2-Ethoxy-2-ethoxycarbonyl-ethyl)-phenoxy]-propenyl}-phenoxymethyl)- benzoic acid methyl ester
a) (£)-3-(3-Hydroxy-propenyl)-phenol was prepared from 3-hydroxybenzaldehyde (6.0 g, 0.049 mol) by a procedure analogous to that described in example 1a-b yielding 1.5 g 1H NMR (300 MHz, CDCI3) δ: 1.4 (1H, t), 4.27 (2H, m), 4.88 (1 H, s), 6.35 (1H, dt), 6.57 (1 H, d), 6.68 (1H, dd), 6.87 (1 H, s), 6.96 (1 H, d), 7.19 (1H, dd).
b)
A mixture of (£)-3-(3-Hydroxy-propenyl)-phenol (0.5 g, 3.33 mmol), methyl 4-(bromomethyl) benzoate (763 mg, 3.33 mmol) and potassium carbonate (1.8 g, 13.3 mmol) in acetone (40 ml) was stirred at roomtemperature over night. The reaction mixtyre was added water (30ml) and acidified with 1 N HCl and extracted with ethyl acetate (90 ml). The organic phase was washed with water, brine and dried with sodium sulphate and evaporated and dried in vacuo yielding 954 mg (96%) (£)- 4-[3-(3-Hydroxy-propenyl)-phenoxymethyl]-benzoic acid methyl ester.
1H NMR (300MHz, CDCI3) δ: 3.8 (3H, s), 4.24 (2H, d), 5.15 (2H, s), 6.3 (1H, dt), 6.57 (1 H, d), 7.0 (2H, d), 7.2 (1 H, d), 7.51 (2H, d), 8.08 (2H, d).
c)
The title compound was prepared from (£)- 4-[3-(3-Hydroxy-propenyl)-phenoxymethyl]- benzoic acid methyl ester (0.298 g, 1.0 mmol) by a procedure analogous to that described in example 3c yielding 0.184 g (35%) of (£)-(S)- 4-(3-{3-[4-(2-Ethoxy-2-ethoxycarbonyl-ethyl)- phenoxy]-propenyl}-phenoxymethyl)-benzoic acid methyl ester.
1H NMR (300 MHz, CDCI3) δ: 1.15-1.35 (6H, m), 2.9 (2H, d) 3.3-3.45 (1H, m), 3.53-3.68 (,1H, m), 3.89 (3H, s), 3.97 (1 H, t), 4.13 (2H, q), 4.68 (2H, dd), 5.15 (2H, s), 6.35 (1H, dt), 6.62 (1H, d), 6.87 (3H, d), 7.05 (2H, d), 7.13-7.3 (3H, m), 7.5 (2H, d), 8.10 (2H, d).
EXAMPLE 152
Figure imgf000181_0001
(£)-(S)- 4-(3-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propenyl}-phenoxymethyI)-benzoic acid
The title compound was prepared from (£)-(S)- 4-(3-{3-[4-(2-ethoxy-2-ethoxycarbonyl-ethyl)- phenoxy]-propenyl}-phenoxymethyl)-benzoic acid methyl ester (example 151) (0.220 g) by a procedure analogous to that described in example 2 yielding 0.160 g (77%) (£)-(S)-4-(3-{3- [4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propenyl}-phenoxymethyl)-benzoic acid. 1H NMR (300 MHz, CDCI3) δ: δ: 1.17 (3H, t), 2.9-3.15 (2H, m) 3.3-3.68 (2H, m), 4.1 (2H, q), 4.67 (2H, d), 5.17 (2H, s), 6.35 (1H, dt), 6.68 (1 H, d), 6.86 (3H, d), 7.05 (2H, d), 7.12-7.32 (3H, m), 7.52 (2H, d), 8.12 (2H, d).
EXAMPLE 153
Figure imgf000182_0001
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4'-fluoro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate
a)
The colourless solid (£)-ethyl 3-(4'-fluoro-biphenyl-4-yl)-but-2-enoate was prepared from (£)- ethyl 3-(4-iodophenyl)-but-2-enoate (example 91a) and 4-fluorobenzene boronic acid by a procedure analogous to that described in example 52a.
Mpt. 63.5-64.5°C. 1H NMR (300 MHz, CDCI3) δ: 1.33 (3H, t), 2.61 (3H, d), 4.23 (2H, q), 6.20 (1H, m), 7.14 (2H, dd), 7.52-7.62 (6H, m). MS: 284 (100%, M+), 255, 239, 212, 196. Micro- analysis Calculated % C: 76.04, H: 6.03; found C: 76.10, H: 6.17.
b)
The colourless solid (£)-3-(4'-fluoro-biphenyl-4-yI)-but-2-en-1-ol was prepared by DIBAL-H reduction of (£)-ethyl 3-(4'-fluoro-biphenyl-4-yl)-but-2-enoate as described for example 52b. Mpt. 120.5-122°C (n-heptane). 1H NMR (300 MHz, CDCI3) δ: 1.39 (1 H, br s), 2.12 (3H, d), 4.40 (2H, d), 6.05 (1 H, tm), 7.12 (2H, dd), 7.42-7.60 (6H, m). MS: 242 (100%, M+), 227 (M- Me), 224 (M-H2O), 203, 199. Microanalysis Calculated % C: 79.32, H: 6.24; found C: 79.34, H: 6.37.
c) The title compound (849mg, 89%) was prepared as a colourless gum from (£)-3-(4'-fluoro- biphenyl-4-yl)-but-2-en-1-ol (500 mg, 2.06 mmol) and (S)-ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (516 mg, 2.17 mmol) by a procedure analogous to that described in example 52c.
1H NMR (200 MHz, CDCI3) δ: 1.17 (3H, t), 1.23 (3H, t), 2.17 (3H, d), 2.97 (2H, d), 3.27-3.44 (1H, m), 3.52-3.69 (1H, m), 3.98 (1H, t), 4.17 (2H, q), 4.75 (2H, d), 6.12 (1H, tm), 6.88 (2H, dm), 7.05-7.22 (4H, m), 7.44-7.62 (6H, m). LCMS: 687 (M+225), 641 (687-EtOH), 485 (M+Na), 480 (M+NH4), 225 (100%).
EXAMPLE 154
Figure imgf000183_0001
(£)-(S)-2-Ethoxy-3-{4-[3-(4'-fluoro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid
The title compound was prepared from (£)-(S)-ethyl 2-ethoxy-3-{4-[3-(4'-fluoro-biphenyl-4-yl)- but-2-enyloxy]-phenyl}-propionate (example 153) (463 mg, 1.0 mmol) and sodium hydroxide (1M, 1.5 ml, 1.5 mmol) by a procedure analogous to that described in example 51, yielding (£)-(S)-2-ethoxy-3-{4-[3-(4'-fluoro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid (229 mg, 53%) as a colourless solid containing a trace of water.
1H NMR (300 MHz, CDCI3) δ: 1.19 (3H, t), 2.16 (3H, d), 2.97 (1H, dd), 3.09 (1H, dd), 3.42- 3.65 (2H, m), 4.07 (1H, dd), 4.75 (2H, d), 6.11 (1H, tm), 6.90 (2H, dm), 7.07-7.20 (4H, m), 7.45-7.60 (6H, m), carboxylic acid proton not observed. LCMS: 457 (M+Na), 225 (100%,). Mi- croanalysis for C27H27FO4 »0.05H2O Calculated % C: 74.48, H: 6.27, H2O: 0.21; found C: 74.25, H: 6.39, H2O: 0.21. EXAMPLE 155
Figure imgf000184_0001
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4-lodophenyl)-but-2-enyloxy]-phenyl}-propionate
The title compound (398 mg, 80%) was prepared as a colourless gum, from (£)-3-(4- iodophenyl)-but-2-en-1-oI (example 107a) (275 mg, 1.0 mmol) and (S -ethyl 2-ethoxy-3-(4- hydroxyphenyl)-propionate (256 mg, 1.07 mmol) by a procedure analogous to that described in example 52c.
1H NMR (300 MHz, CDCI3) δ: 1.17 (3H, t), 2.10 (3H, d), 2.96 (2H, d), 3.30-3.40 (1H, m), 3.55- 3.65 (1H, m), 3.97 (1H, t), 4.16 (2H, q), 4.70 (2H, d), 6.04 (1H, tm), 6.86 (2H, dm), 7.13-7.20 (4H, m), 7.64 (2H, dm). LCMS: 751 (M+257), 705 (751-EtOH), 517 (100%, M+Na), 512 (M+NH4), 449 (M+H-EtOH), 257, 130.

Claims

CLAIMS:
1. A compound of formula (I)
Figure imgf000185_0001
wherein A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from hydroxy, halogen, perhalomethyl, perhalomethoxy, acyl, cyano, amino, C1-6-alkylamino, C1-6-dialkylamino, methylenedioxy, aralkenyl, aralkynyl, heteroary- loxy, heteroaralkoxy, aralkyl, heteroaralkyl, arylamino, or
A is optionally substituted with C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl each of which is optionally substituted with one or more substituents selected from C1-6-alkoxycarbonyl or carboxy, or A is optionally substituted with C1-6-alkoxy, C1-6-alkylthio or C2-6-alkenyloxy each of which is optionally substituted with one or more halogens, or
A is optionally substituted with aryloxy, arylthio or aralkoxy each of which is optionally substituted with one or more substituents selected from C1-6-alkoxy, nitro, carboxy or C^e- alkoxycarbonyl; and Xi and X2 independently are hydrogen, aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C1-6-alkoxy, C1-6- alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino, C1-6-aIkylamino, C1-6-dialkyIamino, arylamino or methylenedioxy, or aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from Cι-6-alkyl, C2-6-alkenyl or C2-6-alkynyl each of which is optionally substituted with hydroxy; or
A is selected from the ring systems consisting of
Figure imgf000186_0001
Figure 1
wherein the attachment point of A to the remaining part of the structure of formula (I) is as indicated on the chemical structures in Figure 1 , and wherein A is optionally substituted with one or more substituents selected from d-e-alkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6- dialkylamino, arylamino or methylenedioxy; and wherein Xi and X2 are hydrogen; and
R5 is hydrogen or C1-6-alkyl; and Y is hydrogen, or
Y is C1-12-alkyl, C2-ι2-alkenyl, C2-ι2-alkynyl, C -12-alkenynyl, aralkyl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, C1-6- alkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
Z is hydrogen, halogen, hydroxy, or
Z is C1-6-alkyl or Cι-6-alkoxy each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C1-6-alkoxy; and
Q is O, S or NR6, wherein R6 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C^-alkenynyl, aralkyl, heteroaralkyl and wherein R6 is optionally substituted with one or more substituents selected from halogen, hydroxy, C1-6-alkoxy, amino or carboxy; and
Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C1-6-aIkyl, aryl or C1-6-alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
Ri is hydrogen, hydroxy or halogen; or R forms a bond together with R2; and
R2 is hydrogen or C1-6-alkyl; or R2 forms a bond together with R^ and
R3 is hydrogen, or
R3 is C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl, aryl, aralkyl, C^-alkoxyC^alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
R is hydrogen, C1-6-aIkyl, C2-6-alkenyl, C2-6-alkynyI, C^-alkenynyl or aryl; and
n is an integer ranging from 0 to 3; and
m is an integer ranging from 0 to 1 ; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric. forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs.
2. A compound according to claim 1 of formula (I)
Figure imgf000188_0001
wherein A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from hydroxy, halogen, perhalomethyl, perhalomethoxy, acyl, cyano, amino, C1-6-alkylamino, C1-6-dialkylamino, methylenedioxy, aralkenyl, aralkynyl, heteroaryloxy, heteroaralkoxy, aralkyl, heteroaralkyl, arylamino, or
A is optionally substituted with C1-6-alkyl, C2.6-alkenyl or C2-6-aIkynyl each of which is optionally substituted with one or more substituents selected from C1-6-alkoxycarbonyl or carboxy, or A is optionally substituted with C1-6-alkoxy, Cι-6-alkylthio or C2-6-alkenyloxy each of which is optionally substituted with one or more halogens, or
A is optionally substituted with aryloxy, arylthio or aralkoxy each of which is optionally substituted with one or more substituents selected from C1-6-alkoxy, nitro, carboxy or C1-6- alkoxycarbonyl; and Xi and X2 independently are hydrogen, aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C1-6-alkoxy, C1-6- alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino, Cι-6-aIkylamino, C1-6-diaIkylamino, arylamino or methylenedioxy, or aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from C1-6-alkyl, C2-6-alkenyl or C2-6-alkynyl each of which is optionally substituted with hydroxy; or
A is selected from the ring systems consisting of
Figure imgf000189_0001
Figure 1
wherein the attachment point of A to the remaining part of the structure of formula (I) is as indicated on the chemical structures in Figure 1 , and wherein A is optionally substituted with one or more substituents selected from C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6- dialkylamino, arylamino or methylenedioxy; and wherein Xi and X2 are hydrogen; and
R5 is hydrogen or C1-6-alkyl; and Y is hydrogen, or
Y is Ci-12-alkyl, C2-ι2-alkenyl, C2-ι2-alkynyI, C4-ι2-alkenynyl, aralkyl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, C1-6- alkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
Z is hydrogen, halogen, hydroxy, or
Z is C1-6-alkyl or C1-6-alkoxy each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C1-6-alkoxy; and
Q is O, S or NR6, wherein R6 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl, aralkyl, heteroaralkyl and wherein R6 is optionally substituted with one or more substituents , selected from halogen, hydroxy, d-e-alkoxy, amino or carboxy; and
Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C^-alky!, aryl or C1-6-alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
R is hydrogen, hydroxy or halogen; or R forms a bond together with R2; and
R2 is hydrogen or C1-6-alkyl; or R2 forms a bond together with R^ and
R3 is hydrogen, or
R3 is C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C^-alkenynyl, aryl, aralkyl, C1-6-alkoxyC1-6alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl each of which is optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
R is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C^e-alkenynyl or aryl; and
n is an integer ranging from 1 to 3; and
m is 1; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs.
3. A compound according to claim 1 of formula (I)
Figure imgf000191_0001
wherein A is aryl or heteroaryl and wherein A is optionally substituted with one or more sub- stituents selected from C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6- dialkylamino, arylamino or methylenedioxy; and
X^ and X2 independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from Cι-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino, Cι-6-alkylamino, d-e-dialkylamino, arylamino or methylenedioxy; or
wherein A is selected from the ring systems consisting of
Figure imgf000192_0001
Figure imgf000192_0002
Figure imgf000192_0003
Figure 1
wherein the attachment point of A to the remaining part of the structure of formula (I) is as indicated on the chemical structures in Figure 1 , and wherein A is optionally substituted with one or more substituents selected from C1-6-alkyl, C2- 6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6-dialkylamino, arylamino or methylenedioxy, and wherein X^ and X2 are hydrogen; and
R5 is hydrogen or C1-6-alkyl; and
Y is hydrogen, C1-12-alkyl, C2-i2-alkenyl, C2-i2-alkynyl, C^-alkenynyl, aralkyl or heteroaralkyl optionally substituted with one or more substituents selected from halogen, C -6-aIkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
Z is hydrogen, halogen, hydroxy, C1-6-alkyl or C1-6-alkoxy optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or d-6-alkoxy; and Q is O, S or NR6, wherein R6 is hydrogen, C1-6-aIkyl, C2.6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl, aralkyl, heteroaralkyl and wherein R6 is optionally substituted with one or more substituents selected from halogen, hydroxy, d-6-alkoxy, amino or carboxy; and
Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C1-6-alkyl, aryl or C1-6-alkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
Ri is hydrogen, hydroxy or halogen; or R1 forms a bond together with R2; and
R2 is hydrogen or C1-6-aIkyl; or R2 forms a bond together with R^ and
Rs is hydrogen, C1-6-alkyl, C2-6-aIkenyl, C2-6-alkynyl, C4-6-alkenynyl, aryl, aralkyl, C1-6- alkoxyC1-6alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
R* is hydrogen, C1-6-aIkyl, C2-6-alkenyl, C2-6-alkynyl, C4-6-aIkenynyl or aryl; and
n is an integer ranging from 0 to 3; and
m is an integer ranging from 0 to 1 ;
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a race- mic mixture, or polymorphs.
4. A compound according to any one of the preceding claims of formula (I)
Figure imgf000194_0001
wherein A is aryl or heteroaryl and wherein A is optionally substituted with one or more substituents selected from C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6- dialkylamino, arylamino or methylenedioxy; or
provided Xi and X2 is hydrogen, A is selected from the ring systems consisting of
Figure imgf000195_0001
Figure imgf000195_0003
Figure imgf000195_0002
wherein A is optionally substituted with one or more substituents selected from C1-6-alkyl, C2- 6-alkenyl, C2-6-alkynyl, hydroxy, aryloxy, arylthio, aralkoxy, d-6-alkoxy, C1-6-alkylthio, heteroaryloxy, heteroaralkoxy, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6-dialkylamino, arylamino or methylenedioxy; and
R5 is hydrogen or C1-6-alkyl; and
Xi and X2 independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from d-6-alkyl, C2-6-alkenyl, C2-6-aIkynyl, hydroxy, aryloxy, arylthio, aralkoxy, heteroaryloxy, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, halogen, perhalomethyl, perhalomethoxy, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, amino, C1-6-alkylamino, C1-6-dialkylamino, arylamino or methylenedioxy; and
Y is hydrogen, C1-12-alkyl, C2-12-alkenyl, C2-12-alkynyl, C -12-alkenynyl, aralkyl or heteroaralkyl optionally substituted with one or more substituents selected from halogen, C1-6-alkyl, perhalomethyl, hydroxy, aryl, heteroaryl, carboxy or amino; and
Z is hydrogen, halogen, hydroxy, d-6-alkyl or C1-6-alkoxy optionally substituted with one or more substituents selected from halogen, hydroxy, carboxy, amino, cyano or C1-6-alkoxy; and Q is O, S or NR6, wherein R6 is hydrogen, C1-6-aIkyl, C2-6-alkenyl, C2-6-alkynyl, C4-6-alkenynyl, aralkyl, heteroaralkyl and wherein R6 is optionally substituted with one or more substituents selected from halogen, hydroxy, d-6-alkoxy, amino or carboxy; and
Ar is arylene, heteroarylene or a divalent heterocyclic group each of which can be optionally substituted with one or more substituents selected from C1-6-alkyl, aryl or C1-6-aIkoxy each of which can be optionally substituted with halogen, hydroxy, carboxy, cyano or heterocyclyl; and
Ri is hydrogen, hydroxy or halogen; or Ri forms a bond together with R2; and
R2 is hydrogen or C1-6-alkyl; or R2 forms a bond together with R^ and
R3 is hydrogen, C1-6-alkyI, C2-6-alkenyl, C2-6-aIkynyl, C -6-aIkenynyl, aryl, aralkyl, C1-6- alkoxyC1-6alkyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups optionally substituted with one or more substituents selected from halogen, perhalomethyl, hydroxy or cyano; and
R4 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2.6-aIkynyl, C4-6-alkenynyl or aryl; and
n is an integer ranging from 0 to 3; and
m is an integer ranging from 0 to 1 ;
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a race- mic mixture, or polymorphs.
5. A compound according to any one of the preceding claims wherein A is aryl or heteroaryl optionally substituted with one or more substituents selected from from C1-6-alkyl, C2-6-aIkenyl each of which is optionally substituted with one or more substituents selected from C1-6-aIkoxycarbonyl or carboxy, or
A is optionally substituted with aryloxy optionally substituted with one or more C1-6-alkoxy, or A is optionally substituted with aralkoxy optionally substituted with one or more substituents selected from C1-6-alkoxy, nitro, carboxy or C1-6-alkoxycarbonyI, or A is optionally substituted with C1-6-aIkoxy optionally substituted with one or more halogens, or
A is optionally substituted with aralkenyl, C2-6-alkenyloxy, aralkynyl, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl or methylenedioxy.
6. A compound according to any one of the preceding claims wherein A is aryl, heteroaryl or
Figure imgf000197_0001
optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
7. A compound according to any one of the preceding claims wherein A is aryl optionally sub- stituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, C1-6-alkoxy,
C1-6-alkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
8. A compound according to any one of the preceding claims wherein A is aryl optionally substituted with one or more substituents selected from from C1-6-alkyl, C2-6-alkenyl each of which is optionally substituted with one or more substituents selected from d-6- alkoxycarbonyl or carboxy, or
A is optionally substituted with aryloxy optionally substituted with one or more C1-6-alkoxy, or
A is optionally substituted with aralkoxy optionally substituted with one or more substituents selected from C -6-alkoxy, nitro, carboxy or C1-6-aIkoxycarbonyl, or A is optionally substituted with C1-6-alkoxy optionally substituted with one or more halogens, or
A is optionally substituted with aralkenyl, C2-6-alkenyloxy, aralkynyl, halogen, perhalomethyl, perhalomethoxy, acyl, aralkyl or methylenedioxy.
9. A compound according to any one of the preceding claims wherein A is aryl optionally substituted with one or more substituents selected from from C1-6-alkyl, or A is optionally substituted with aryloxy optionally substituted with one or more C1-6-alkoxy, A is optionally substituted with aralkoxy optionally substituted with one or more substituents selected from C -6-alkoxy, or
A is optionally substituted with d-6-alkoxy optionally substituted with one or more halogens, or
A is optionally substituted with aralkenyl, aralkynyl, halogen, perhalomethyl, perhalomethoxy or aralkyl.
10. A compound according to any one of the preceding claims wherein A is heteroaryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, C1-6- alkoxy, C1-6-alkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
11. A compound according to any one of the preceding claims wherein A is heteroaryl.
12. A compound according to any one of the preceding claims wherein A is
Figure imgf000198_0001
optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, C1-6-alkoxy, C1-6-alkylthio, halogen, perhalomethyl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
13. A compound according to any one of the preceding claims wherein A is
Figure imgf000198_0002
optionally substituted with one or more substituents selected from C1-6-alkyl, and wherein R5 is hydrogen or C1-6-aIkyl.
14. A compound according to any one of the preceding claims wherein Xi and X2 independently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents se- lected from aryloxy, arylthio, aralkoxy, halogen, perhalomethyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
15. A compound according to any one of the preceding claims wherein X^ and X2 independ- ently are hydrogen, aryl or heteroaryl optionally substituted with one or more substituents selected from halogen, acyl, aryl, or aryl or heteroaryl optionally substituted with one or more substituents selected from C1-6- alkyl, C2-6-alkynyl each of which is optionally substituted with hydroxy.
16. A compound according to any one of the preceding claims wherein X^ and X2 independently are hydrogen, or aryl optionally substituted with one or more substituents selected from halogen.
17. A compound according to any one of the preceding claims wherein X^ and X2 independently are hydrogen or aryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, halogen, perhalomethyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
18. A compound according to any one of the preceding claims wherein X^ and X2 independently are hydrogen, aryl optionally substituted with one or more substituents selected from halogen, acyl, aryl, or aryl optionally substituted with one or more substituents selected from C1-6-alkyl, C2-6-alkynyl each of which is optionally substituted with hydroxy.
19. A compound according to any one of the preceding claims wherein Xi and X2 independ- ently are hydrogen, or phenyl optionally substituted with one or more substituents selected from halogen.
20. A compound according to any one of the preceding claims wherein Xi and X2 independently are hydrogen or heteroaryl optionally substituted with one or more substituents selected from aryloxy, arylthio, aralkoxy, halogen, perhalomethyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heteroaryloxy or heteroaralkoxy.
21. A compound according to any one of the preceding claims wherein Xi and X2 independently are hydrogen or heteroaryl.
22. A compound according to any one of the preceding claims wherein Xi and X2 is hydrogen.
23. A compound according to any one of the preceding claims wherein Y is hydrogen or C1-12- alkyl.
24. A compound according to any one of the preceding claims wherein Y is hydrogen or methyl.
25. A compound according to any one of the preceding claims wherein Z is hydrogen or C1-6- alkoxy.
26. A compound according to any one of the preceding claims wherein Z is hydrogen or C1-6- alkyl.
27. A compound according to any one of the preceding claims wherein Z is hydrogen.
28. A compound according to any one of the preceding claims wherein Q is O.
29. A compound according to any one of the preceding claims wherein Ar is arylene optionally substituted with one or more substituents selected from C1-6-alkyl or d-6-alkoxy each of which can be optionally substituted with carboxy.
30. A compound according to any one of the preceding claims wherein Ar is arylene.
31. A compound according to any one of the preceding claims wherein Ri is hydrogen or R-i forms a bond together with R2.
32. A compound according to any one of the preceding claims wherein Ri is hydrogen.
33. A compound according to any one of the preceding claims wherein R2 is hydrogen or R2 forms a bond together with R^
34. A compound according to any one of the preceding claims wherein R2 is hydrogen.
35. A compound according to any one of the preceding claims wherein R3 is C1-6-alkyl or aralkyl.
36. A compound according to any one of the preceding claims wherein R3 is C -6-alkyl.
37. A compound according to any one of the preceding claims wherein * is hydrogen, C1-3- alkyl.
38. A compound according to any one of the preceding claims wherein R4 is hydrogen.
39. A compound according to any one of the preceding claims wherein n is 1.
40. A compound according to any one of the preceding claims wherein m is 1.
41. A compound according to any one of the preceding claims wherein alkyl is methyl, ethyl, n-propyl, iso-propyl, butyl, tert-butyl, pentyl, hexyl, cyclopropyl or cyclopentyl.
42. A compound according to any one of the preceding claims wherein alkenyl is vinyl or 1- propenyl.
43. A compound according to any one of the preceding claims wherein alkynyl is ethynyl, 1- propynyl and 2-propynyl.
44. A compound according to any one of the preceding claims wherein alkoxy is methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, isopropoxy or cyclopentyloxy.
45. A compound according to any one of the preceding claims wherein alkylthio is methylthio, ethylthio, propylthio or cyclopentylthio.
46. A compound according to any one of the preceding claims wherein aryl is phenyl optionally substituted with halogen.
47. A compound according to any one of the preceding claims wherein arylene is phenylene optionally substituted with halogen.
48. A compound according to any one of the preceding claims wherein halogen is fluorine or chlorine.
49. A compound according to any one of the preceding claims wherein perhalomethyl is trifluoromethyl.
50. A compound according to any one of the preceding claims wherein acyl is acetyl.
51. A compound according to any one of the preceding claims wherein heteroaryl is furan, thiophene, pyrrole, imidazole, pyrazole, pyridine, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole or benzofuran.
52. A compound according to any one of the preceding claims wherein heteroaryl is furan, pyrrole, indole or benzofuran.
53. A compound according to any one of the preceding claims wherein heteroarylene is furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine or pyridazine.
54. A compound according to any one of the preceding claims wherein aralkyl is benzyl or phenethyl.
55. A compound according to any one of the preceding claims wherein aryloxy is phenoxy.
56. A compound according to any one of the preceding claims wherein aralkoxy is benzyloxy.
57. A compound according to any one of the preceding claims wherein n is an integer ranging from 1 to 3 and m is 1.
58. A compound according to any of the preceding claims wherein the substituents Z and Y are arranged in a trans-configuration.
59. A compound according to any of the preceding claims wherein the substituents Z and Y are arranged in a cis-configuration.
60. The compound according to claim 1 , 2 or 3 which is:
(£)-(S)-Ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-ethoxy-propionate,
(£)-(S)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyI]-2-ethoxy-propionic acid, (E)-(S)-3-{4-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyIoxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£)-(S)-3-{4-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester, £J-(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl}-propionic acid,
(£)-(S)-2-Ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy}-phenyl)-propionic acid ethyl ester,
(£)-(S)-2-Ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyI]-but-2-enyloxy}-phenyl)-propionic acid, (£)-(S)-2-Ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester,
(£)-(S)-2-Ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid,
(£)-(S)-3-{4-[3-(3,4-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£)-(S)-3-{4-[3-(3,4-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-but-2-enyIoxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyI-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£ (S)-3-[4-(3-BiphenyI-4-yl-alIyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-[4-(3-Biphenyl-4-yl-alIyloxy)-phenyl]-2-ethoxy-propionic acid, (£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-but-2-enyloxy)-phenyl]-propionic acid, (£)-(S)-2-Ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid, (£)-(S 3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-allyloxy)-phenyI]-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-[4-(3-naphthaIen-2-yl-allyloxy)-phenyl]-propionic acid, (£)-(S)-2-Ethoxy-3-{4-[3-(3-phenoxy-phenyl)-allyloxy]-phenyl}-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-{4-[3-(3-phenoxy-phenyl)-aIIyloxy]-phenyl}-propionic acid, (S)-3-[4-(2-Benzofuran-3-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (S)-3-[4-(2-Benzofuran-3-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid;
or a pharmaceutically acceptable salt thereof.
61. The compound according to claim 4 which is:
(£)-(S)-Ethyl 3-[4-(3-biphenyl-4-yl-but-2-enyloxy)-phenyI]-2-ethoxy-propionate, (£)-(S)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-ethoxy-propionic acid, (E)-(S)-3-{4-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(4'-Bromo-biphenyI-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester, £J-(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenyl)-but-2-enyloxy]-phenyl}-propionic acid, (£)-(S)-2-Ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy}-phenyI)-propionic acid ethyl ester,
(£)-(S)-2-Ethoxy-3-(4-{3-[4-(4-methoxy-phenoxy)-phenyl]-but-2-enyloxy}-phenyl)-propionic acid,
(£)-(S)-2-Ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2-enyIoxy]-phenyl}-propionic acid ethyl ester,
(£)-(S)-2-Ethoxy-3-{4-[3-(9H-fluoren-2-yl)-but-2-enyloxy]-phenyI}-propionic acid, (£)-(S)-3-{4-[3-(3,4-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£)-(S)-3-{4-[3-(3,4-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£ -(S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester,
(£)-(S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-but-2-enyloxy)-phenyl]-propionic acid, (£)-(S)-2-Ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-[4-(3-pyridin-2-yl-but-2-enyloxy)-phenyl]-propionic acid, (£J-(SJ-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yI-allyloxy)-phenyl]-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-[4-(3-naphthalen-2-yl-allyloxy)-phenyl]-propionic acid, (£)-(S)-2-Ethoxy-3-{4-[3-(3-phenoxy-phenyI)-allyloxy]-phenyl}-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-{4-[3-(3-phenoxy-phenyl)-allyloxy]-phenyl}-propionic acid, (S)-3-[4-(2-Benzofuran-3-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (S)-3-[4-(2-Benzofuran-3-yI-allyloxy)-phenyl]-2-ethoxy-propionic acid;
or a pharmaceutically acceptable salt thereof.
62. The compound according to claim 1 , 2 or 3 which is:
(£)-(S)-3-{4-[3-(4-Benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (E)-(S)-3-{4-[3-(4-Benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-3-[4-(3-Benzo[1 ,3]dioxol-5-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-[4-(3-Benzo[1,3]dioxol-5-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (£)-(S)-3-{4-[3-(4-Allyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(4-Allyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-3-[4-(3-Benzofuran-7-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-[4-(3-Benzofuran-7-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (S)-3-[4-(3-Benzo[1 ,3]dioxol-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (S)-3-[4-(3-Benzo[1,3]dioxol-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (£)-(S)-2-Ethoxy-3-(4-[3-(9H-fluoren-2-yl)-allyloxy]-phenyl)-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-(4-[3-(9H-fluoren-2-yI)-allyloxy]-phenyl)-propionic acid, (S)-2-Ethoxy-3-[4-(3-quinolin-2-yl-allyloxy)-phenyl]-propionic acid ethyl ester, (S)-2-Ethoxy-3-[4-(3-quinolin-2-yl-allyloxy)-phenyl]-propionic acid,
(£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyI)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-3-{4-[3-(3,5-Dimethoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Dimethoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-2-Ethoxy-3-[4-(3-phenanthren-9-yl-allyloxy)-phenyl]-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-{4-[3-(2-methoxy-naphthalen-1 -yl)-a!lyloxy]-phenyl}-propionic acid ethyl ester,
(£)-(S)-2-Ethoxy-3-{4-[3-(2-methoxy-naphthalen-1-yI)-allyIoxy]-phenyl}-propionic acid, (£)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-3-{4-[3-(4-Bromophenyl)-but-2-enyIoxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-Ethyl 3-{4-[3-(4'-Chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-3-{4-[3-(4'-Chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yI)-but-2-enyloxy]-phenyl}- propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}- propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(5'-chIoro-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}- propionate,
(£)-(S)-3-{4-[3-(5'-ChIoro-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid, (£)-(S)-Ethyl 3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(2,,6'-Dimethoxy-biphenyI-4-yl)-but-2-enyloxy]-phenyI}-2-ethoxy- propionate, (£)-(S)-3-{4-[3-(2,,6'-Dimethoxy-biphenyl-4-yI)-but-2-enyIoxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (Z)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (Z)-(S)-3-{4-[3-(4-BromophenyI)-2-methyl-but-2-enyloxy]-phenyI}-2-ethoxy-propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-[4-(3-[1 ,1 ';3',1 "]terphenyl-4"-yl-but-2-enyloxy)-phenyl]-propionate, (£)-(S)-2-Ethoxy-3-[4-(3-[1 ,1,;3,,1"]terphenyl-4"-yl-but-2-enyloxy)-phenyl]-propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(3'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate, (£)-(S)-2-Ethoxy-3-{4-[3-(3'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyI}-propionic acid, (£)-(S)-3-{4-[3-(3'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-allyloxy]-phenyl}-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-allyloxy]-phenyl}-propionic acid,
(£)-(S)-3-{4-[3-(3,5-Distyryl-phenyl)-allyloxy]-phenyI}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Distyryl-phenyl)-allyloxy]-phenyI}-2-ethoxy-propionic acid;
or a pharmaceutically acceptable salt thereof.
63. The compound according to claim 4 which is:
(£)-(S)-3-{4-[3-(4-Benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(4-Benzyloxy-phenyl)-allyloxy]-phenyI}-2-ethoxy-propionic acid, (£)-(S)-3-[4-(3-Benzo[1 ,3]dioxol-5-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-[4-(3-Benzo[1 ,3]dioxol-5-yl-aIlyloxy)-phenyl]-2-ethoxy-propionic acid, (£)-(S)-3-{4-[3-(4-Allyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(4-Allyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-3-[4-(3-Benzofuran-7-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-[4-(3-Benzofuran-7-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid,
(S)-3-[4-(3-Benzo[1 ,3]dioxol-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (S)-3-[4-(3-Benzo[1 ,3]dioxol-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (£)-(S)-2-Ethoxy-3-(4-[3-(9H-fluoren-2-yl)-allyloxy]-phenyl)-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-(4-[3-(9H-fluoren-2-yl)-allyloxy]-phenyl)-propionic acid, (S)-2-Ethoxy-3-[4-(3-quinolin-2-yl-allyloxy)-phenyl]-propionic acid ethyl ester, (S)-2-Ethoxy-3-[4-(3-quinolin-2-yl-allyloxy)-phenyl]-propionic acid,
(£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyI)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Bis-benzyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-3-{4-[3-(3,5-Dimethoxy-phenyl)-allyloxy]-phenyI}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Dimethoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-2-Ethoxy-3-[4-(3-phenanthren-9-yl-allyloxy)-phenyl]-propionic acid ethyl ester, (£)-(S)-2-Ethoxy-3-{4-[3-(2-methoxy-naphthalen-1 -yl)-allyloxy]-phenyl}-propionic acid ethyl ester,
(£)-(S)-2-Ethoxy-3-{4-[3-(2-methoxy-naphthalen-1-yl)-allyloxy]-phenyl}-propionic acid, (£)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-but-2-enyIoxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-3-{4-[3-(4-Bromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-Ethyl 3-{4-[3-(4'-Chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-3-{4-[3-(4'-Chloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(5'-isopropyl-2,-methoxy-biphenyl-4-yl)-but-2-enyIoxy]-phenyl}- propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yI)-but-2-enyloxy]-phenyl}- propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(5'-chloro-2'-methoxy-biphenyl-4-yI)-but-2-enyloxy]-phenyl}- propionate,
(£)-(S)-3-{4-[3-(5'-Chloro-2'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- . propionic acid, (£)-(S)-Ethyl 3-{4-[3-(2',3'-Dichioro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(2,,3'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-Ethyl 3-{4-[3-(2',6'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate, (£)-(S)-3-{4-[3-(2',6'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate, (£)-(S)-3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (Z)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyIoxy]-phenyl}-2-ethoxy-propionate, (Z)-(S)-3-{4-[3-(4-Bromophenyl)-2-methyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-[4-(3-[1 , 1 ';3', 1 "]terphenyl-4"-yl-but-2-enyloxy)-phenyl]-propionate, (£)-(S)-2-Ethoxy-3-[4-(3-[1 ,1';3,,1"]terphenyl-4"-yl-but-2-enyIoxy)-phenyl]-propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(3'-methyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate, (£)-(S)-2-Ethoxy-3-{4-[3-(3'-methyl-biphenyI-4-yl)-but-2-enyloxy]-phenyl}-propionic acid, (£)-(S)-3-{4-[3-(3'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-allyloxy]-phenyl}-propionic acid ethyl ester,
(£)-(S)-2-Ethoxy-3-{4-[3-(5'-isopropyl-2'-methoxy-biphenyl-4-yl)-allyloxy]-phenyl}-propionic acid, (£)-(S)-3-{4-[3-(3,5-DistyryI-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-DistyryI-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid;
or a pharmaceutically acceptable salt thereof.
64. The compound according to claim 1 , 2, 3 or 4 which is:
(E)-(S)-3-{4-[3-(3,5-Diisopropoxy-phenyl)-allyIoxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(3,5-Diisopropoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(S)-3-{4-[3-(3-Bromo-5-styryl-phenyI)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(S)-3-{4-[3-(3-Bromo-5-styryl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(E)-(S)-2-Ethoxy-3-[4-(3-phenyl-allyloxy)-phenyI]-propionic acid ethyl ester,
(E)-(S)-2-Ethoxy-3-[4-(3-phenyl-allyloxy)-phenyl]-propionic acid,
(E)-(S)-3-{4-[3-(2',3,-DichIoro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(2',3'-Dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (E)-(S)-3-{4-[3-(3,5-Bis-phenylethynyl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(3,5-Bis-phenylethynyI-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(E)-(S)-3-{4-[3-(3,5-Diphenethyl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(3,5-Diphenethyl-phenyl)-allyloxy]-phenyI}-2-ethoxy-propionic acid,
3-{4-[3-(3,5-Bis-cycIopentyloxy-phenyl)-alIyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-{4-[3-(3,5-Bis-cyclopentyloxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(E)-(S)-3-(4-{3-[3,5-Bis-(2,2,2-trifluoro-ethoxy)-phenyl]-allyloxy}-phenyl)-2-ethoxy-propionic acid ethyl ester,
(E)-(S)-3-(4-{3-[3,5-Bis-(2,2,2-trifluoro-ethoxy)-phenyl]-allyloxy}-phenyl)-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-but-2-enyloxy]-phenyl}-propionate,
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(2'-methyl-biphenyl-4-yI)-but-2-enyloxy]-phenyl}-propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(2'-methyl-biphenyI-4-yl)-but-2-enyloxy]-phenyl}-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(2',5'-Dimethoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(2',5'-Dimethoxy-biphenyl-4-yl)-but-2-enyIoxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid, (Z)-(S)-Ethyl 3-{4-[3-(4-Bromophenyl)-2-ethyl-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(Z)-(S)-3-{4-[3-(4-BromophenyI)-2-ethyI-but-2-enyIoxy]-phenyI}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(4'-fen'-Butyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-Ethyl 3-{4-[3-(3',5,-Bis-trifluoromethyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(3',5'-Bis-trifluoromethyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionic acid,
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4'-isopropyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(4'-isopropyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(E)-(S)- 3-{4-[3-(3,5-Dimethoxy-phenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£)-(S)-Ethyl 3-{4-[3-(4'-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-3-{4-[3-(4"-Acetyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ,
(£)-(S)-Ethyl 2-Ethoxy-3-[4-(3-[1 ,1 ';3',1 "]terphenyl-5"-yl-allyloxy)-phenyl]-propionate,
(£)-(S)-2-Ethoxy-3-[4-(3-[1 ,1';3',1"]terphenyl-5,-yl-allyloxy)-phenyl]-propionic acid,
(£,£)-(S)-Ethyl 3-(4'-{3-[4-(2-Ethoxy-2-ethoxycarbonyl-ethyl)-phenoxy]-1-methyl-propenyl}- biphenyl-3-yl)-but-2-enoate, (£,£)-(S)- 3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-1-methyl-propenyl}-biphenyl-3-y|)- but-2-enoic acid,
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(3'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate,
(£)-(S)-2-Ethoxy-3-{4-[3-(3'-methoxy-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid,
(E)-(S, S/R)-Ethy\ 2-Ethoxy-3-(4-{3-[3'-(1 -hydroxy-ethyi)-biphenyl-4-yl]-but-2-enyloxy}-phenyl)- propionate,
(£)-(S,S/r?)-2-Ethoxy-3-(4-{3-[3'-(1-hydroxy-ethyl)-biphenyl-4-yl]-but-2-enyloxy}-phenyl)- propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3,5-Dibromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-3-{4-[3-(3,5-Dibromophenyl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3,5-Dibromophenyl)-allyloxy]-phenyl}-2-ethoxy-propionate,
(£)-(S)-3-{4-[3-(3,5-Dibromophenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(4,4"-Di-terf-butyl-[1 ,1 ';Z λ "jterphenyl-δ'-y -allyloxyj-phenylJ^-ethoxy- propionate,
(£)-(S)-3-{4-[3-(4,4,,-Di-te/t-butyl-[1 ,1 ';3M "]terphenyl-5'-yl)-allyloxy]-phenyl}-2-ethoxy- propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3',5'-Dibromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
(£)-(S)-3-{4-[3-(3',5'-Dibromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
(£)-(S)-Ethyl 3-{4-[3-(3',5'-Dichloro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate, £)-(S)-3-{4-[3-(3',5,-Dichloro-biphenyl-4-yl)-but-2-enyIoxy]-phenyl}-2-ethoxy-propionic acid,
£)-(S)-Ethyl 3-{4-[3-(3',5'-Dichloro-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionate,
£)-(S)-3-{4-[3-(3',5'-Dichloro-biphenyl-4-yl)-allyIoxy]-phenyl}-2-ethoxy-propionic acid,
£)-(S)-Ethyl 3-{4-[3-(3,,5,-di--er -butyl-biphenyl-4-yl)-alIyloxy]-phenyl}-2-ethoxy-propionate,
£)-(S)-3-{4-[3-(3,,5'-Di-ten'-butyl-biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
£)-(S)-Ethyl 3-{4-[3-(3',5,-Di-tert-butyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy- propionate,
£)-(S)-3-{4-[3-(3',5'-Di-tert-butyl-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid,
£)-(S/j )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-isopropoxy-propionate,
£)-(S )-3-[4-(3-Biphenyl-4-yI-but-2-enyloxy)-phenyl]-2-isopropoxy-propionic acid,
£)-(S )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-butoxy-propionate,
£)-(S F?)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-butoxy-propionic acid,
£)-(S )-Ethyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-hexyloxy-propionate,
£)-(S R)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-hexyloxy-propionic acid,
£)-(S )-EthyI 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyI]-2-(3-phenyl-propoxy)-propionate,
£)-(S ?)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-(3-phenyl-propoxy)-propionic acid,
£)-(S/ )-Ethyl 3-[4-(3-BiphenyI-4-yl-but-2-enyloxy)-phenyl]-2-(4-phenyl-butoxy)-propionate, (£)-(S/R)-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-(4-phenyl-butoxy)-propionic acid,
(£)-(S )-Propyl 3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-propoxy-propionate,
(£)-(S )-3-[4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl]-2-propoxy-propionic acid,
(£)-(S)-3-{4-[3-(3,5-Diethoxyoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (£)-(S)-3-{4-[3-(3,5-Diethoxyoxy-phenyl)-alIyloxy]-phenyl}-2-ethoxy-propionic acid, (£)-(S)-3-{4-[3-(3,5-Bis-trif luoromethyl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£)-(S)-3-{4-[3-(3,5-Bis-trifluoromethyl-phenyl)-allyIoxy]-phenyl}-2-ethoxy-propionic acid, (£ -( S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£)-( S)-3-[4-(3-Biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (£)-(S)- 4-(3-{3-[4-(2-Ethoxy-2-ethoxycarbonyl-ethyI)-phenoxy]-propenyl}-phenoxymethyl)- benzoic acid methyl ester,
(£)-(S)- 4-(3-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propenyl}-phenoxymethyl)-benzoic acid;
or a pharmaceutically acceptable salt thereof.
65. The compound according to claim 1 , 2, 3 or 4 which is:
(£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4'-fluoro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionate, (£)-(S)-2-Ethoxy-3-{4-[3-(4'-fluoro-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-propionic acid, (£)-(S)-Ethyl 2-Ethoxy-3-{4-[3-(4-lodophenyl)-but-2-enyloxy]-phenyl}-propionate;
or a pharmaceutically acceptable salt thereof.
66. A pharmaceutical composition comprising, as an active ingredient, a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
67. A composition according to claim 66 in unit dosage form, comprising from about 0.05 to about 100 mg, preferably from about 0.1 to about 50 mg of the compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof.
68. A pharmaceutical composition useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the composition comprising, as an active ingredient, a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
69. A pharmaceutical composition useful in the treatment and/or prevention of diabetes and/or obesity, the composition comprising, as an active ingredient, a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
70. A pharmaceutical composition according to any one of the claims 66-69 for oral, nasal, transdermal, pulmonal, or parenteral administration.
71. A method for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof, or of a composition according to any one of the preceding claims 66-70.
72. A method for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof, or of a composition according to any one of the preceding claims 66-70.
73. A method for the treatment and/or prevention of diabetes and/or obesity, the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof, or of a composition according to any one of the preceding claims 66-70.
74. The method according to claims 71 , 72 or 73, wherein the effective amount of the compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt or ester thereof is in the range of from about 0.05 to about 100 mg per day, preferably from about 0.1 to about 50 mg per day.
75. Use of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament.
76. Use of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
77. Use of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treatment and/or prevention of diabetes and/or obesity.
78. A pharmaceutical composition suitable for treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising a compound according to any of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an ACE (angiotensin converting enzyme) inhibitor.
79. The use of a compound according to any one of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an ACE (angiotensin converting enzyme) inhibitor for the preparation of a medicament suitable for the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity.
80. A method of treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising administering to a subject in need thereof an effective amount of a compound according to any of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an ACE (angiotensin converting enzyme) inhibitor to said subject.
81. A pharmaceutical composition suitable for treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising a compound according to any of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an agent stimulating insulin release from β cells such as a meglitinide, like repaglinide or senaglinide.
82. The use of a compound according to any one of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and an agent stimulating insulin release from β cells such as a meglitinide, like repaglinide or senaglinide, for the preparation of a medicament suitable for the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity.
83. A method of treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising administering to a subject in need thereof an effective amount of a compound according to any of the claims 1 to 65 and an agent stimulating insulin release from β cells such as a meglitinide, like repaglinide or senaglinide, to said subject.
84. A pharmaceutical composition suitable for treating type I diabetes, type II diabetes, im- paired glucose tolerance, insulin resistance or obesity comprising a compound according to any of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and a biguanide like metformin.
85. The use of a compound according to any one of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and a biguanide, like metformin, for the preparation of a medicament suitable for the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity.
86. A method of treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising administering to a subject in need thereof an effective amount of a compound according to any of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and a biguanide, like metformin, to said subject.
87. A pharmaceutical composition suitable for treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising a compound according to any of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and a HMG CoA inhibitor.
88. The use of a compound according to any one of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and a HMG CoA inhibitor for the preparation of a medicament suitable for the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity.
89. A method of treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising administering to a subject in need thereof an effective amount of a compound according to any of the claims 1 to 65 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs together with one or more pharmaceutically acceptable carriers or diluents and a HMG CoA inhibitor to said subject.
PCT/DK2001/000058 2000-01-28 2001-01-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity WO2001055085A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PL01357010A PL357010A1 (en) 2000-01-28 2001-01-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity
BR0107901-8A BR0107901A (en) 2000-01-28 2001-01-26 Compound, pharmaceutical composition, method for treating illness, for treating and / or preventing conditions mediated by nuclear receptors, and for the treatment and / or prevention of diabetes and / or obesity, use of a compound, and, method for treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance or obesity
HU0204574A HUP0204574A3 (en) 2000-01-28 2001-01-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity, pharmaceutical compositions containing them and their preparation
MXPA02007286A MXPA02007286A (en) 2000-01-28 2001-01-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity.
AU28319/01A AU2831901A (en) 2000-01-28 2001-01-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity
IL15026001A IL150260A0 (en) 2000-01-28 2001-01-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity
EP01946844A EP1254101A1 (en) 2000-01-28 2001-01-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity
KR1020027009463A KR20020070508A (en) 2000-01-28 2001-01-26 Propionic acid der1vatives and their use in the treatment of diabetes and obesity
CA002395298A CA2395298A1 (en) 2000-01-28 2001-01-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity
JP2001555028A JP2003520838A (en) 2000-01-28 2001-01-26 New compounds, their manufacture and use.
NO20023566A NO20023566L (en) 2000-01-28 2002-07-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200000136 2000-01-28
DKPA200000136 2000-01-28
DKPA200001071 2000-07-07
DKPA200001071 2000-07-07
DKPA200001594 2000-10-25
DKPA200001594 2000-10-25

Publications (1)

Publication Number Publication Date
WO2001055085A1 true WO2001055085A1 (en) 2001-08-02

Family

ID=27222336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000058 WO2001055085A1 (en) 2000-01-28 2001-01-26 Propionic acid derivatives and their use in the treatment of diabetes and obesity

Country Status (13)

Country Link
EP (1) EP1254101A1 (en)
JP (1) JP2003520838A (en)
KR (1) KR20020070508A (en)
CN (1) CN1396903A (en)
AU (1) AU2831901A (en)
BR (1) BR0107901A (en)
CA (1) CA2395298A1 (en)
HU (1) HUP0204574A3 (en)
IL (1) IL150260A0 (en)
MX (1) MXPA02007286A (en)
NO (1) NO20023566L (en)
PL (1) PL357010A1 (en)
WO (1) WO2001055085A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100812A1 (en) * 2001-04-20 2002-12-19 Eisai Co., Ltd. Carboxylic acid derivative and salt thereof
WO2003011807A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
WO2003033453A1 (en) * 2001-10-17 2003-04-24 Novo Nordisk A/S Dicarboxylic acid derivatives, their preparation and therapeutical use
WO2004022533A1 (en) * 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
WO2004037775A1 (en) 2002-10-28 2004-05-06 Novo Nordisk A/S Novel compounds useful in treating ppar mediated diseases
WO2004048333A1 (en) * 2002-11-26 2004-06-10 Shenzhen Chipscreen Biosciences Ltd. Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity
WO2004113266A1 (en) * 2003-06-20 2004-12-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derivatives of phenylalkyl and phenoxyalkyl acids for the treatment of the hyperglycaemia and hypertriglyceridaemia and type 2 diabetes and process for preparing them
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
US7192970B2 (en) 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
JP2007523064A (en) * 2004-01-23 2007-08-16 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Surface-amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and their use
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
US7378427B2 (en) 2004-06-18 2008-05-27 Wyeth Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
US7524975B2 (en) 2001-10-11 2009-04-28 Kaneka Corporation Peroxisome proliferator activated receptor ligand and process for producing the same
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
US7709528B2 (en) 2002-10-28 2010-05-04 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
US8008525B2 (en) 2003-11-26 2011-08-30 Takeda Pharmaceutical Company Limited Receptor function regulating agent
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8236800B2 (en) 2003-03-17 2012-08-07 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
US8889163B2 (en) 2001-03-08 2014-11-18 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers as anti-infective agents
US11267795B2 (en) 2020-07-22 2022-03-08 Reneo Pharmaceuticals, Inc. Crystalline PPAR-delta agonist
US11931365B2 (en) 2022-01-25 2024-03-19 Reneo Pharmaceuticals, Inc. Use of PPAR-delta agonists in the treatment of disease

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403148D0 (en) * 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
KR20070026503A (en) * 2004-05-14 2007-03-08 아이알엠 엘엘씨 Compounds and compositions as ppar modulators
KR100788454B1 (en) * 2006-06-15 2007-12-24 대원제약주식회사 Rapid-acting fomulation containing nateglinide as an active ingredient
KR101497577B1 (en) * 2012-07-31 2015-03-02 서울대학교산학협력단 Pharmaceutical composition or pharmaceutically acceptable salt thereof for the prevention or treatment of Circadian clock related diseases containing 2-ethoxypropionic acid derivative as an active ingredient
CN114349723B (en) * 2021-12-23 2024-02-02 中山大学 Polyene alkyne compound as well as preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP0903343A1 (en) * 1997-09-19 1999-03-24 SSP Co., Ltd. Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
WO1999016758A1 (en) * 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1999038850A1 (en) * 1998-01-29 1999-08-05 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2000063153A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903343A1 (en) * 1997-09-19 1999-03-24 SSP Co., Ltd. Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
WO1999016758A1 (en) * 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999038850A1 (en) * 1998-01-29 1999-08-05 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO2000063153A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 65, no. 3, 1 August 1966, Columbus, Ohio, US; abstract no. 3781, ELZBIETA WYRZYKIEWICZ ET AL: "Optically active stilbene derivatives" XP002901748 *
ZESZYTY NAUK. UNIW. POZNANIU MAT., FIS., CHEM, no. 9, 1965, pages 29 - 45 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889163B2 (en) 2001-03-08 2014-11-18 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers as anti-infective agents
US7544835B2 (en) 2001-04-20 2009-06-09 Eisai R&D Management Co., Ltd. Carboxylic acid derivative and salt thereof
WO2002100812A1 (en) * 2001-04-20 2002-12-19 Eisai Co., Ltd. Carboxylic acid derivative and salt thereof
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
WO2003011807A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
US7888388B2 (en) 2001-10-11 2011-02-15 Kaneka Corporation Peroxisome proliferator activated receptor ligand and process for producing the same
US7524975B2 (en) 2001-10-11 2009-04-28 Kaneka Corporation Peroxisome proliferator activated receptor ligand and process for producing the same
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
WO2003033453A1 (en) * 2001-10-17 2003-04-24 Novo Nordisk A/S Dicarboxylic acid derivatives, their preparation and therapeutical use
US7091245B2 (en) 2002-09-05 2006-08-15 Novo Novdisk A/S Compounds, their preparation and use
WO2004022533A1 (en) * 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
WO2004037775A1 (en) 2002-10-28 2004-05-06 Novo Nordisk A/S Novel compounds useful in treating ppar mediated diseases
US7709528B2 (en) 2002-10-28 2010-05-04 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
US7192970B2 (en) 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
WO2004048333A1 (en) * 2002-11-26 2004-06-10 Shenzhen Chipscreen Biosciences Ltd. Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity
US7268157B2 (en) 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
US8236800B2 (en) 2003-03-17 2012-08-07 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
US9241917B2 (en) 2003-03-17 2016-01-26 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
US8455490B2 (en) 2003-03-17 2013-06-04 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
WO2004113266A1 (en) * 2003-06-20 2004-12-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derivatives of phenylalkyl and phenoxyalkyl acids for the treatment of the hyperglycaemia and hypertriglyceridaemia and type 2 diabetes and process for preparing them
US8008525B2 (en) 2003-11-26 2011-08-30 Takeda Pharmaceutical Company Limited Receptor function regulating agent
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
US8716530B2 (en) 2004-01-23 2014-05-06 The Trustess Of The University Of Pennsylvania Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
US8222456B2 (en) 2004-01-23 2012-07-17 The Trustees Of The University Of Pennsylvania Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
JP2007523064A (en) * 2004-01-23 2007-08-16 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Surface-amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and their use
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7378427B2 (en) 2004-06-18 2008-05-27 Wyeth Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8551993B2 (en) 2005-12-22 2013-10-08 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
US8362016B2 (en) 2005-12-22 2013-01-29 High Point Pharmaceuticals, Llc Phenyl propionic acids as PPAR delta activators
US9663481B2 (en) 2005-12-22 2017-05-30 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists
US9855274B2 (en) 2005-12-22 2018-01-02 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US10471066B2 (en) 2005-12-22 2019-11-12 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US10947180B2 (en) 2005-12-22 2021-03-16 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US11420929B2 (en) 2005-12-22 2022-08-23 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US11267795B2 (en) 2020-07-22 2022-03-08 Reneo Pharmaceuticals, Inc. Crystalline PPAR-delta agonist
US11713301B2 (en) 2020-07-22 2023-08-01 Reneo Pharmaceuticals, Inc. Crystalline PPARδ agonist
US11931365B2 (en) 2022-01-25 2024-03-19 Reneo Pharmaceuticals, Inc. Use of PPAR-delta agonists in the treatment of disease

Also Published As

Publication number Publication date
JP2003520838A (en) 2003-07-08
PL357010A1 (en) 2004-07-12
NO20023566L (en) 2002-09-25
CA2395298A1 (en) 2001-08-02
NO20023566D0 (en) 2002-07-26
HUP0204574A3 (en) 2003-08-28
AU2831901A (en) 2001-08-07
IL150260A0 (en) 2002-12-01
KR20020070508A (en) 2002-09-09
EP1254101A1 (en) 2002-11-06
CN1396903A (en) 2003-02-12
HUP0204574A2 (en) 2003-05-28
MXPA02007286A (en) 2002-11-29
BR0107901A (en) 2002-11-05

Similar Documents

Publication Publication Date Title
EP1254101A1 (en) Propionic acid derivatives and their use in the treatment of diabetes and obesity
US6569901B2 (en) Alkynyl-substituted propionic acid derivatives, their preparation and use
EP1438283A1 (en) Dicarboxylic acid derivatives, their preparation and therapeutic use
WO2003011807A1 (en) Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
US6555577B1 (en) Compounds, their preparation and use
EP1745014B1 (en) Novel compounds, their preparation and use
WO2001055086A1 (en) Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity
EP1578716A1 (en) Dicarboxylic acid derivatives as ppar-agonists
US6869967B2 (en) Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
EP1414785A1 (en) Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
EP1763511B1 (en) Phenoxyacetic acid derivatives as ppar agonists
US7067530B2 (en) Compounds, their preparation and use
US6972294B1 (en) Compounds, their preparation and use
US7220877B2 (en) Compounds, their preparation and use
WO2003011834A1 (en) Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
US20040259950A1 (en) Novel compounds, their preparation and use
US20030055076A1 (en) Novel compounds, their preparation and use
AU2002316815A1 (en) Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 150260

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2395298

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001946844

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2002-2481

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 28319/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020027009463

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/1137/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 018042414

Country of ref document: CN

Ref document number: PA/a/2002/007286

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 555028

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2002 2002123049

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027009463

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001946844

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-2481

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: PV2002-2481

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001946844

Country of ref document: EP